



RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY 2019

(with international participation)

RSC for professionals and patients –
from primary care to advanced technologies

PROGRAMME

SEPTEMBER 24–26th, 2019 | EKATERINBURG, RUSSIA

EKATERINBURG-EXPO, INTERNATIONAL EXHIBITION CENTER
(EXPO BOULEVARD, 2)



www.scardio.ru



DEAR COLLEAGUES AND FRIENDS!

I am delighted to welcome the participants of the Russian National Congress of Cardiology 2019!

The wide platform of the Congress traditionally unites doctors and researchers, teachers and clinicians in cardiology and related fields, will open new the prospects for improving medical care based on innovative medical technologies, and will be the step forward to the development of the national project “Healthcare”.

You belong to the category of people who tirelessly raise professional level and amaze others with determination and efficiency. All your energy, talent, ability to work, set and solve complex problems serve as an example that inspires and makes your students and colleagues to believe in their own strengths.

The main theme of the upcoming Congress is “Russian Society of Cardiology for professionals and patients – from primary care to the latest technologies”; it reflects the desire to face and effectively solve the problems existing in professional cardiological community. Specialists should exchange clinical experience, research results to achieve our main goal – to increase the duration and improve the quality of life.

I am sure that the Congress that brings together specialists in CVD will facilitate a fruitful exchange of ideas and experience between researchers for people’s health enhancement.

I wish all participants of the Russian National Congress of Cardiology successful work, good health, peace and all the best!

Minister V.I. Skvortsova



DEAR FRIENDS!

I welcome the organizers, participants and guests of the Russian National Congress of Cardiology 2019 and express my confidence that such a representative and authoritative forum in the Ural region will make a significant contribution to the solution of the most important task – multiplying human capital and saving the health of the nation.

Sverdlovsk region is one of the Russian leaders in high-tech medical care delivery. I consider it logical that Ekaterinburg is becoming the point of attraction for the best cardiologists of the country for the second time, a professional platform for sharing best practices on the most modern problems of prevention, diagnostics and treatment of cardiovascular diseases, and effective rehabilitation of patients.

Implementing the goals set by the President of Russia, we are actively involved in the national projects, the regional program “Five-Year Plan for the Development of the Sverdlovsk Region”.

We intend to turn our region into a territory of health including the territory of healthy hearts. To do this, we are systematically developing a system for assisting patients with cardiovascular diseases and implementing unique innovative projects. Among the priority areas are increasing the accessibility of cardiological care to the Urals, creating a modern system of patient rehabilitation, improving the system of medical personnel training.

Dear participants of the Congress!

I wish you productive work, breakthrough ideas and solutions for Russian healthcare development. I wish you success, prosperity and all the best!

Governor Sverdlovsk region
E.V. Kuyvashev



DEAR COLLEAGUES, DEAR FRIENDS!

On behalf of the Presidium of the Russian Society of Cardiology, I am honoured and delighted to welcome the participants of the Russian National Congress of Cardiology!

This largest scientific, practical and educational event aimed at the exchange of experience on the topical issues of prevention, diagnosis and treatment of cardiovascular diseases offers us new questions for discussion each year, it becomes more and more attractive for Russian and foreign colleagues.

The aim to discuss this topic with the participation of specialists from all regions of Russia is prescribed not only by the high social significance and widespread prevalence of circulatory system diseases, but also by new perspectives of the National project “Healthcare”.

Our state budget significant funds for health protection and its effectiveness is mainly determined by the level of medical personnel training, their willingness to realize the achievements of scientific and technological progress and fundamental biomedical research.

It is in this context that the Congress program should demonstrate to the Congress participants and guests all the latest achievements in the field of medical care for cardiac patients at all stages – from improving primary care to introducing the latest technologies in every day practice.

I wish you all success and the most fruitful work at the Congress!

President of the Russian Society of Cardiology
Professor Evgeny Shlyakhto

The Congress is supported by the Government of the Sverdlovsk Region.

PROGRAMME COMMITTEE OF THE RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY

Chairman of the Programme Committee – President of the Russian Society of Cardiology, RAS Academician, Prof. **E.V. Shlyakhto** (Saint-Petersburg)

Congress Executive Secretary – Board Member of the Russian Society of Cardiology, Corresponding member of RAS, Prof. **G.P. Arutyunov** (Moscow)

Co-chairmen of the Program Committee Working Groups:

Abugov S.A. (Moscow)	Zaklyazminskaya E.V. (Moscow)
Averkov O.V. (Moscow)	Zateischikov D.A. (Moscow)
Ageev F.T. (Moscow)	Zemtsovsky E.V. (Saint-Petersburg)
Akchurin R.S. (Moscow)	Zyryanov S.K. (Moscow)
Alekyan B.G. (Moscow)	Imaev T.E. (Moscow)
Arutyunov G.P. (Moscow)	Kavteladze Z.A. (Moscow)
Baranova E.I. (Saint-Petersburg)	Kapustina A.V. (Moscow)
Barbarash O.L. (Kemerovo)	Karaskov A.M. (Novosibirsk)
Belenkov Y.N. (Moscow)	Karpov R.S. (Tomsk)
Bogachev-Prokofiev A.V. (Novosibirsk)	Karpov Y.A. (Moscow)
Boytsov S.A. (Moscow)	Koziolova N.A. (Permian)
Bokeria L.A. (Moscow)	Kozlov B.N. (Tomsk)
Boldueva S.A. (Saint-Petersburg)	Kontsevaya A.V. (Moscow)
Vasyuk Y.A. (Moscow)	Kosmacheva E.D. (Krasnodar)
Villevalde S.V. (Saint-Petersburg)	Kostareva A.A. (Saint-Petersburg)
Galagudza M.M. (Saint-Petersburg)	Kotovskaya Yu.V. (Moscow)
Galyavich A.S. (Kazan)	Kuznetsov V.A. (Tyumen)
Gapon L.I. (Tyumen)	Kuharchuk V.V. (Moscow)
Gafarov V.V. (Novosibirsk)	Lebedev D.S. (Saint-Petersburg)
Gendlin G.E. (Moscow)	Libis R.A. (Orenburg)
Glezer M.G. (Moscow)	Lishmanov Yu.B. (Tomsk)
Golitsyn S.P. (Moscow)	Lopatim Yu..M. (Volgograd)
Golukhova E.Z. (Moscow)	Mareev V.Yu. (Moscow)
Gordeev M.L. (Saint-Petersburg)	Matskeplishvili S.T. (Moscow)
Greenstein Yu.I. (Krasnoyarsk)	Miller O.N. (Novosibirsk)
Demin A.A. (Novosibirsk)	Mitrofanova L.B. (Saint-Petersburg)
Dzemeshkevich S.L. (Moscow)	Mikhailov E.N. (Saint-Petersburg)
Drapkina O.M. (Moscow)	Mikhin V.P. (Kursk)
Duplyakov D.V. (Samara)	Moiseeva O.M. (Saint-Petersburg)
Ezhov M.V. (Moscow)	Nebieridze D.V. (Moscow)

Nedogoda S.V. (Volgograd)	Tarlovskaia E.I. (Nizhny Novgorod)
Nikulina S.Yu. (Krasnoyarsk)	Tereshchenko S.N. (Moscow)
Oganov R.G. (Moscow)	Ternovoy S.K. (Moscow)
Orlova J.A. (Moscow)	Tkachuk V.A. (Moscow)
Pavlyukova E.N. (Tomsk)	Trufanov G.E. (Saint-Petersburg)
Paleev F.N. (Moscow)	Fokin V.A. (Saint-Petersburg)
Panchenko E.P. (Moscow)	Fomin I.V. (Nizhny Novgorod)
Pervunina T.M. (Saint-Petersburg)	Tsaregorodtsev D.A. (Moscow)
Pogosova N.V. (Moscow)	Chazova I.E. (Moscow)
Podzolkov V.I. (Moscow)	Charchyan E.R. (Moscow)
Pozdnyakov Yu.M. (Moscow)	Chernyavsky A.M. (Novosibirsk)
Popov S.V. (Tomsk)	Chesnikova A.I. (Rostov-on-Don)
Poteshkina N.G. (Moscow)	Chumakova G.A. (Barnaul)
Puzyrev V.P. (Tomsk)	Shalnova S.A. (Moscow)
Revishvili A.S. (Moscow)	Shkolnikova M.A. (Moscow)
Rotar O.P. (Saint-Petersburg)	Shlyk S.V. (Rostov-on-Don)
Ryzhkova D.V. (Saint-Petersburg)	Shulman V.A. (Krasnoyarsk)
Saidova M.A. (Moscow)	Shumakov D.V. (Moscow)
Samko A.N. (Moscow)	Yavelov I.S. (Moscow)
Skibitsky V.V. (Krasnodar)	Yakovlev A.N. (Saint-Petersburg)
Smolensky A.V. (Moscow)	Yakushin S.S. (Ryazan)

RUSSIAN SOCIETY OF CARDIOLOGY AWARD 2019 COMMITTEE

Chairman: Prof. **Evgeny Shlyakhto** (Saint-Petersburg)

Boytsov S.A. (Moscow), Galyavich A.S. (Kazan),
 Duplyakov D.V. (Samara), Karpov R.S. (Tomsk),
 Koziolova N.A. (Perm), Konradi A.O. (Saint-Petersburg)

YOUNG SCIENTISTS AWARD COMMITTEE

Villevalde S.V. (Saint-Petersburg), Grinshtein Yu.I. (Krasnoyarsk),
 Duplyakov D.V. (Samara), Kontsevaya A.V. (Moscow),
 Mayanskaya S.D. (Kazan), Melekhov A.V. (Moscow),
 Nikulina S.Yu. (Krasnoyarsk), Osipova I.V. (Barnaul),
 Sumin A.N. (Kemerovo), Khaisheva L.A. (Rostov-on-Don).

SECRETARIAT OF THE CONGRESS PROGRAMME COMMITTEE

Konradi A.O. (Saint-Petersburg), Nedoshivin A.O. (Saint-Petersburg),
 Ratova L.G. (Saint-Petersburg), Tanicheva A.A. (Saint-Petersburg),
 Chumak I.B. (Saint-Petersburg).

GENERAL INFORMATION

The Organizing Committee invites you to take part in the Russian National Congress of Cardiology to be held in Ekaterinburg on September 24–26, 2019.

CONGRESS VENUE

**Ekaterinburg-Expo, International Exhibition Center
(EXPO Boulevard, 2)**

HOW TO GET THERE

By bus from the Botanicheskaya metro station:

Special bus shuttles will go from the Botanicheskaya metro station to the Ekaterinburg-Expo Exhibition Center. The bus stop is opposite the park and ride lot, along the street of Academician Schwarz (metro exit to the Shopping Mall Dirizhabl).

By hotel shuttles:

Check the bus schedule with the official partner of the Congress — MIR INTERNATIONAL company (olga@mirint.ru +7 (812) 7670831).

By car:

The entrance is from the Koltsovsky tract. The direction of travel is from the city.

REGISTRATION

On-line registration of the participants at the official website of the Russian Society of Cardiology www.scardio.ru is possible up to September 15, 2019.

After September 15, 2019 – on-site registration only.

Admittance to all sessions and the exhibition is free of charge, admittance by name badges that are issued to the registered participants only.

On-site Registration Timetable

24 September — 07.30–17.00

25 September — 08.00–17.00

26 September — 08.00–13.30

All registered at the RSC website www.scardio.ru and all those who paid for the Congress materials can get a congress bag and a badge in the registration area.

CONGRESS MATERIALS:

From September 1, 2019 – 2,500 rubles (for RSC members – 2,000 rubles).

One can pay for the Congress materials (congress bag, book of scientific programme, abstract book, exhibition catalogue, participant's certificate) in the registration area on any day of the Congress.

Congress materials are free of charge for RSC Board members, all session chairs and Young Scientists Award winners.

All participants registered at www.scardio.ru can receive a name badge in the registration area.

ATTENTION! All Congress sessions and the exhibition are free to attend after the registration procedure. Registration is required of all participants. Each participant will receive a name badge, which will serve as a pass to all sessions and the exhibition.

POSTERS

Posters are to be presented on **September 24-26 in the exhibition area (4th floor) from 09.00 to 19.00.**

E-posters will be available all time throughout the Congress. The numbers for e-posters are indicated in the Congress program in blitz sessions.

All e-posters will be presented at the sessions of blitz reports in the form of short messages no more than 5 minutes (report for 3-4 minutes and questions & answers for 1-2 minutes).

OFFICIAL CONGRESS EVENTS

September 24th from 17.15 to 19.00

Opening of the Congress and Awarding Ceremony:
Russian Society of Cardiology Awards and Young Scientists Awards
Plenary Hall 1

September 25th from 19.15 to 20.30

General Assembly of the Russian Society of Cardiology
Plenary Hall 1

CONGRESS SESSIONS TIMETABLE

24 September — 09.00–19.00
25 September — 09.00–19.00
26 September — 09.00–19.00

Plenary Hall 1 is on the 1st and 2nd floors (entrance only at the 1st floor). Plenary Hall 2 (3.2) is on the 3rd floor. Hall 2.3 is on the 2nd floor. Halls 4.4–4.6 are on the 4th floor and the rest of the halls are on the 3rd floor of the Congress center.

EXHIBITION

Exhibition of medical, diagnostic and therapeutic equipment, modern information technology, and specialized medical publications will be presented daily on the 1st and 2nd floors of the Congress center.

Exhibition plan and participants' information be found in the Exhibition Catalogue.

24 September — 08.00–17.00
25 September — 08.00–19.00
26 September — 08.00–19.00

INFORMATION FOR SPEAKERS

Presentation specifications:

- File format .ppt or .pptx (MS Office 2003/2007/2010).
- Standard animation.
- Standard fonts (Windows).
- Multimedia files (audio and video) must be at the same folder with presentation file.
- Acceptable formats for video files avi, mp4, wmv.
- Maximum size for video file is 200 Mb, maximum video file resolution — 640x480 px. Higher resolution (full HD) is acceptable in accordance with advanced agreement.

According to the regulations of the Coordinate Council of the Continuous Medical and Pharmaceutical Education in Russia all speakers are obliged to disclose their conflict of interest in their presentations.

EQUIPMENT AND WORK WITH PRESENTATIONS

- All lecture halls are equipped with laptops connected to the projector and/or widescreen panels.
- Using speakers' equipment is not allowed.

- All the laptops are equipped with a presenter (the device to switch slides) which can be replaced by a presenter of the lecturer after the consultation with technical personnel.
- Internet access (for broadcasting, video conferences, etc.) using the presentation equipment is possible only after the consultation the technical personnel.
- Presentations must be downloaded in advance, in any case no later than 20 minutes before the session starts. Presentations must be given to the technical personnel in the lecture hall.
- Speakers are strictly forbidden to work independently with the presentation equipment.

SIMULTANEOUS TRANSLATION

The official language of the Congress is Russian. Simultaneous English/Russian translation will be provided during plenary sessions and symposia with participation of foreign speakers. Please, do not use mobile phones during the Congress sessions! Please mute your phones during the sessions.

PRESENTATIONS BY YOUNG SCIENTISTS AWARD WINNERS

will be held on September 24th in the Hall 4.6 (2nd floor) from 11.00 to 12.30.

INTERNET

Free Wi-Fi is provided in all zones of the Congress Center.

Login: **congress2019**

Password: **congress2019**

ORGANIZING COMMITTEE ROOM

Organizing Committee Room is located on the 3rd floor of the Congress Center (Meeting Rooms 5-6).

SPEAKERS SERVICE CENTER


Speakers Service Center is located on the 3rd floor of the Congress Center (opposite to the Hall 3.10).

SMOKING


The Russian Society of Cardiology actively promotes healthy lifestyle and considers smoking to be a serious risk factor of cardiovascular diseases. The Organizing Committee strongly recommends to all participants to refrain from smoking at the time of the Congress.

1st FLOOR


PLENARY HALL 1




2nd FLOOR



3rd FLOOR



4th FLOOR



Time	Plenary Hall №1	Plenary Hall №2 (3.2)	Hall 2.3	Hall 3.1	Hall 3.3	Hall 3.4	Hall 3.5	Hall 3.6	Hall 3.7	Hall 3.8	Hall 3.9	Hall 3.10	Hall 4.5	Hall 4.6
ONSITE REGISTRATION OF PARTICIPANTS OPENS AT 07.30 (MAIN ENTRANCE)														
09.00–10.30	Plenary Session Difficult patient in cardiovascular surgery <i>On-line broadcasting / Simultaneous translation</i>	Plenary Session CAD, lipids, atherosclerosis <i>On-line broadcasting / Simultaneous translation</i>	Symposium Multimorbid patient with cardiovascular and infectious diseases: what should the practitioner know?	Satellite symposium Myocardial infarction-2019 (in memory of Prof. M. Ruda) <i>(supported by Sanofi, CME points are not accrued)</i>	Symposium Cardiotoxicity of antitumor therapy: not only heart failure	Symposium Multimodality imaging in the stable coronary artery disease diagnostic	Symposium In search of health	Symposium Traditions and innovations – two poles of the world of education	Satellite symposium Master Class “Expert in cardiology” <i>(supported by KRKA, CME points are not accrued)</i>	Symposium Diagnosis of cardiovascular diseases in pregnancy, therapy opportunities	Satellite symposium Individual approach to the treatment of patients with arterial hypertension and excessive body weight <i>(supported by Abbott Laboratories, CME points are not accrued)</i>	Scientific session Heart failure/left ventricular dysfunction	Symposium Pediatric cardiology	
10.30–11.00 BREAK														
11.00–12.30	Satellite symposium 10 years of DOAC in stroke prevention: practical issues to revolutionary solutions <i>(supported by Boehringer Ingelheim, CME points are not accrued)</i> <i>On-line broadcasting / Simultaneous translation</i>	Multidisciplinary Satellite symposium What does every physician need to know? The rules of elderly AF patients' management <i>(supported by Bayer, CME points are not accrued)</i> <i>On-line broadcasting</i>	Satellite symposium From optimal drug therapy to patient-oriented treatment of stable CAD <i>(supported by Berlin Chemie, CME points are not accrued)</i>	Satellite symposium Making a menu for a family dinner <i>(supported by Servier, CME points are not accrued)</i> <i>Online broadcasting</i>	Satellite symposium Lifestyle and heart health: realities of hypersympathicotonia with arterial hypertension <i>(supported by Merck, CME points are not accrued)</i> <i>On-line broadcasting / Simultaneous translation</i>	Symposium of the National Society of Preventive Cardiology Breakthroughs in preventive cardiology	Symposium Cardiovascular complications in patients receiving renal replacement therapy	Training workshop Difficult cases of diagnostics and treatment in cardiology	Satellite symposium Multifaceted approach to therapy of hypertensive patients: why current guidelines are sagacious? Part 2. <i>(supported by KRKA, CME points are not accrued)</i>	Satellite symposium Rational aspirin therapy: new horizons <i>(supported by Takeda, CME points are not accrued)</i>	Satellite symposium Specific therapy of pulmonary arterial hypertension of new generation: focus on late outcomes <i>(supported by Actelion, a Janssen Pharmaceutical company of Johnson&Johnson, CME points are not accrued)</i> <i>On-line broadcasting / Simultaneous translation</i>	Scientific session Epidemiology, prevention and rehabilitation. Sports medicine	Presentations by winners of the Young Scientists Award	
12.40–13.20	Plenary lecture Atar D. (Norway). Moderator: Arutyunov G. (Moscow) <i>On-line broadcasting / Simultaneous translation</i>	Plenary lecture Galié N. (Italy). Moderator: Moiseeva O. (Saint-Petersburg) <i>On-line broadcasting / Simultaneous translation</i>												
12.30–13.30 BREAK														

09.00–17.00 / Hall 4.4

Rapid Fire Abstracts

Time	Plenary Hall №1	Plenary Hall №2 (3.2)	Hall 2.3	Hall 3.1	Hall 3.3	Hall 3.4	Hall 3.5	Hall 3.6	Hall 3.7	Hall 3.8	Hall 3.9	Hall 3.10	Hall 4.5	Hall 4.6
13.30–15.00	<p>Satellite symposium Anticoagulant therapy in elderly comorbid patient</p> <p>(supported by Pfizer, CME points are not accrued)</p> <p>On-line broadcasting / Simultaneous translation</p>	<p>Satellite symposium How to lower the risk of cardiovascular death? Innovations in CAD and peripheral artery disease patients' management</p> <p>(supported by Bayer, CME points are not accrued)</p> <p>On-line broadcasting</p>	<p>Satellite symposium A new era in lipid-lowering therapy for a comorbid patient</p> <p>(supported by Recordati, CME points are not accrued)</p>	<p>Satellite symposium Hypertension: three types of patients – three diagnoses – three solutions</p> <p>(supported by Servier, CME points are not accrued)</p>	<p>Satellite symposium A paradigm shift in the treatment of arterial hypertension-from optimal drug to optimal combinations</p> <p>(supported by Werteks, CME points are not accrued)</p>	<p>Joint symposium with the Russian Transplant Society Heart transplantation in Russia: status artis MMXIX</p>	<p>Satellite symposium Closed scientific discussion</p> <p>(supported by Boehringer Ingelheim, CME points are not accrued)</p>	<p>Symposium Paradoxes of nutrition in prevention of cardiovascular diseases</p>	<p>Symposium Anxiety and depression in cardiac practice: prevalence, prognostic significance and approaches to therapy</p>	<p>Satellite symposium Cardiac fair. Open dialogue. Variety of hypertensive patients and therapeutically decisions, so is it possible to put a point?</p> <p>(joint symposium of the RSC and Sanofi, CME points are not accrued)</p> <p>On-line broadcasting</p>	<p>Satellite symposium Truth is born in a dispute. Discussion club "Criteria for the selection of antihypertensive therapy"</p> <p>(supported by Gedeon Richter, CME points are not accrued)</p>	<p>Satellite symposium Optimal therapy approach in patients with MI and additional cardiovascular risk factors</p> <p>(supported by AstraZeneca, CME points are not accrued)</p> <p>On-line broadcasting</p>	<p>Scientific session Interdisciplinary issues of cardiology</p>	<p>Symposium Optimal navigation for patient with atrial fibrillation: how to set the right course?</p>
15.00–15.30 BREAK														
15.30–17.00	<p>Plenary Session Imaging diagnostics in cardiology: different clinical scenarios</p> <p>On-line broadcasting / Simultaneous translation</p>	<p>Satellite symposium Patient with arterial hypertension: is everything clear with the choice of therapy?</p> <p>(supported by Takeda, CME points are not accrued)</p> <p>On-line broadcasting</p>	<p>Symposium Intestinal microbiota – a new participant in the cardiovascular continuum</p>	<p>Satellite symposium Actual issues of emergency medical care in management of cardiovascular patients</p> <p>(supported by Boehringer Ingelheim, CME points are not accrued)</p>	<p>Satellite symposium Patients with venous thromboembolism in the interdisciplinary practice of cardiologist, oncologist and vascular surgeon</p> <p>(supported by Bayer, CME points are not accrued)</p>	<p>Satellite symposium Place of thrombolytic therapy in managing patients with acute cardiovascular catastrophes: state-of-the-art</p> <p>(supported by Generium, CME points are not accrued)</p>	<p>Symposium Lessons from the ESSE-RF study. Practical and scientific value</p>	<p>Symposium Do we know everything about aortic stenosis?</p>	<p>Satellite symposium Arrhythmias, hypertension, atherosclerosis – evolution of treatment approaches</p> <p>(supported by Sandoz, CME points are not accrued)</p>	<p>Satellite symposium Interchangeability of drugs in cardiology: the possibilities of generics</p> <p>(supported by Canonpharma production, CME points are not accrued)</p>	<p>Satellite symposium Towards the main goal</p> <p>(joint symposium of the Russian Society of Cardiology and Sanofi, CME points are not accrued)</p>	<p>Symposium Familial hypercholesterolemia is a target for reducing cardiovascular mortality in the Russian Federation</p>	<p>Satellite symposium Ideal sponsor of the clinical trial vs ideal trial site</p> <p>(supported by the Association of International Pharmaceutical Manufacturers, CME points are not accrued)</p>	<p>Symposium Typical errors in the diagnosis and treatment of cardiovascular diseases in multimorbid patients: 3D session</p>
17.00–17.15 BREAK														
17.15–19.00	<p>PLENARY SESSION / PLENARY HALL №1 OPENING CEREMONY</p> <p>AWARDING CEREMONY: RSC PRIZE 2019 AND YOUNG SCIENTISTS AWARDS</p> <p>On-line broadcasting / Simultaneous translation</p>						<p>PLENARY SESSION / PLENARY HALL №1 OPENING CEREMONY</p> <p>AWARDING CEREMONY: RSC PRIZE 2019 AND YOUNG SCIENTISTS AWARDS</p> <p>On-line broadcasting / Simultaneous translation</p>							
19.00 WELCOME COCKTAIL														

PLENARY HALL №1

09.00–10.30

PLENARY SESSION

Difficult patient in cardiovascular surgery

On-line broadcasting / Simultaneous translation

Chairpersons: Bockeria L. (Moscow), **Skopin I.** (Moscow),
Goluchova E. (Moscow)

- **Bockeria L.** (Moscow). Difficult patient in cardiac surgery.
- **Skopin I.** (Moscow). Difficult patient with acquired heart disease.
- **Muratov R.** (Moscow). Difficult patient with infective endocarditis.
- **Alshibaya M.** (Moscow). Difficult patient with coronary artery disease.
- **Arakelyan V.** (Moscow). Difficult patient with vascular pathologies.

PLENARY HALL №2 (3.2)

09.00–10.30

PLENARY SESSION

CAD, lipids, atherosclerosis

On-line broadcasting / Simultaneous translation

Chairpersons: Galyavich A. (Kazan), **Karpov Yu.** (Moscow)

- **Ezhov M.** (Moscow). Unsolved issues of the modern lipidology.
- **Galyavich A.** (Kazan). Chronic coronary syndrome: pathogenesis to diagnostics and treatment.
- **Karpov Yu.** (Moscow). Drug and interventional treatment of CAD: how to choose wisely?
- **Gabinskiy Ya.** (Ekaterinburg). Coronary passport – the right to live long.

HALL 2.3

09.00–10.30

SYMPOSIUM

Multimorbid patient with cardiovascular and infectious diseases: what should the practitioner know?

Chairperson: **Fomin I.** (Nizhny Novgorod)

- **Arutyunov A.** (Moscow). Cardiovascular patient, what can be really prevented by vaccinations?
- **Shalenkova M.** (Nizhny Novgorod), **Mikhailova Z.** (Nizhny Novgorod). Infective endocarditis: the course and treatment in special clinical situations.
- **Esayan A.** (Saint-Petersburg). Urinary tract infection in a patient with chronic heart failure. What the practitioner should know.

HALL 3.1

09.00–10.30

SATELLITE SYMPOSIUM

Myocardial infarction-2019 (in memory of Prof. M. Ruda) (supported by Sanofi, CME points are not accrued)

Chairperson: **Barbarash O.** (Kemerovo), **Staroverov I.I.** (Moscow)

- **Barbarash O.** (Kemerovo). NSTEMI.
- **Averkov O.** (Moscow). STEMI.
- **Yavelov I.** (Moscow). Opportunities for increasing adherence to treatment in patients with ACS.

HALL 3.3

09.00-10.30

SYMPOSIUM

Cardiotoxicity of antitumor therapy: not only heart failure

Chairperson: **Belenkov Yu.** (Moscow)

- **Vasyuk Yu.** (Moscow), **Yushchuk E.** (Moscow). Antitumor therapy and cardiotoxicity: a random combination or a characteristic regularity?
- **Gendlin G.** (Moscow), **Emelina E.** (Moscow), **Ibragimova A.** (Moscow). Comparative analysis of cardiac remodeling, the clinical manifestation and the course of severe cardiotoxicity.
- **Emelina E.** (Moscow). Arrhythmias and antithrombotic therapy in patients receiving antitumor treatment.
- **Poltavskaya M.** (Moscow). What should a cardiologist know about radiation therapy and its consequences?
- **Zateyshikov D.** (Moscow). Genetic aspects of cardiotoxicity of chemotherapy drugs in oncology.

HALL 3.4

09.00–10.30

SYMPOSIUM

Multimodality imaging in the stable coronary artery disease diagnostic

Chairpersons: **Zavadovsky K.** (Tomsk), **Karpov R.** (Tomsk), **Ryzhkova D.** (Saint-Petersburg)

- **Zavadovsky K.** (Tomsk), **Mochula A.** (Tomsk), **Saushkin V.** (Tomsk). Myocardial perfusion imaging in patients with stable coronary artery disease: state of the art.
- **Boschenko A.** (Tomsk), **Vrublevsky A.** (Tomsk), **Karpov R.** (Tomsk). Stress echocardiography as a method for non-invasive assessment of myocardial ischemia: renaissance or forgetfulness?
- **Arhipova I.** (Moscow). Cardiac imaging — coronary CTA: beyond the imaging?
- **Stukalova O.** (Moscow), **Ternovoy S.** (Moscow). The use of cardiac MRI in patients with coronary artery disease: clinical practice and perspectives.

- **Paleev F.** (Moscow). The role of CT coronarography in early diagnostics of coronary artery disease in stable patients.
- **Ryzhkova D.** (Saint-Petersburg), **Zverev D.** (Saint-Petersburg). Perfusion positron emission computed tomography in the assessment of coronary artery intermediate stenosis significance.

HALL 3.5

09.00–10.30

SYMPOSIUM

In search of health

Chairperson: **Shalnova S.** (Moscow)

- **Arutyunov G.** (Moscow). Coffee beans: Where reality ends, myths begin.
- **Karamnova N.** (Moscow). Two diets — South and North: a conflict of interest or friendship of nations?
- **Nedogoda S.** (Volgograd). How do we optimize activity to reduce cardiovascular risk?
- **Perepech N.** (Saint-Petersburg). Psychology of health after 65 years. Guidance for elderly patients.

HALL 3.6

09.00–10.30

SYMPOSIUM

Traditions and innovations – two poles of the world of education

Chairpersons: **Shlyakhto E.** (Saint-Petersburg), **Balkizov Z.** (Moscow), **Shlyk S.** (Rostov-on-Don), **Drobotya N.** (Rostov-on-Don)

- **Shlyakhto E.** (Saint-Petersburg). Training of new clinicians in demand of healthcare.
- **Balkizov Z.** (Moscow). Continuing professional education – new regulations.
- **Khaisheva L., Khorolets E., Glova S.** (Rostov-on-Don). The role of simulation training in cardiology education. Assessment of primary care physicians' awareness of early detection of cardiovascular diseases.

- **Shlyk S.** (Rostov-on-Don). Primary specialized accreditation of cardiologists: experience of Rostov State Medical University.
- **Drobotya N., Kaltykova V., Pirozenko A.** (Rostov-on-Don). Standard of cardiologist — how to meet it?

HALL 3.7 AND 3.8

09.30–10.30

SATELLITE SYMPOSIUM

Master Class “Expert in cardiology”

(supported by KRKA, CME points are not accrued)

- **Susekov A.V.** (Moscow). Hot issues in diagnosis and management of lipid disorders
- **Villevalde S.V.** (Saint-Petersburg). Patient with hypertension and nephropathy: goals of therapy and managing algorithm.
- **Arutyunov G.P.** (Moscow). Patient with hypertension and visceral obesity: diagnostic and therapeutic features.

HALL 3.9

09.00–10.30

SYMPOSIUM

Diagnosis of cardiovascular diseases in pregnancy, therapy opportunities

Chairpersons: **Moiseeva O.** (Saint-Petersburg),
Chesnikova A. (Rostov-on-Don)

- **Chulkov V.** (Chelyabinsk). Hypertension in pregnancy: what is new in the 2018 ESC and ISSHP Guidelines?
- **Dzhioeva O.** (Moscow). Echocardiography in pregnancy: who, when and how often?
- **Irtiyuga O.** (Saint-Petersburg). Anticoagulant therapy in pregnancy – pitfalls.
- **Karelkina E.** (Saint-Petersburg). Heart failure in pregnancy.

HALL 3.10

09.00–10.30

SATELLITE SYMPOSIUM

Individual approach to the treatment of patients with arterial hypertension and excessive body weight (supported by Abbott Laboratories, CME points are not accrued)

Chairpersons: **Nedogoda S.** (Volgograd), **Baranova E.** (Saint-Petersburg)

- **Nedogoda S.** (Volgograd). Choosing tactics for rational antihypertensive therapy based on clinical guidelines.
- **Valensi P.** (France). Hyperactivation of sympathetic nervous system as a component of Arterial Hypertension pathogenesis.
- **Schlaich M.** (Australia). Pharmacotherapeutic strategies for treating hypertension in overweight patients.
- **Baranova E.** (Saint-Petersburg). Individual approach to the treatment of patients with arterial hypertension and metabolic syndrome.

HALL 4.5

09.00–10.30

SCIENTIFIC SESSION

Heart failure/left ventricular dysfunction

Chairpersons: **Tereschenko S.** (Moscow), **Koziolova N.** (Perm)

- **Skorodumova E.G., Kostenko V., Skorodumova E.A., Siverina A., Rysev A., Fedorov A.** (Saint-Petersburg). Period of isovolumetric relaxation of the left ventricle as predictor of short-term and long-term poor prognosis in patients with acute decompensation of heart failure and mid-range EF.
- **Kvan V., Shevchenko A., Kachanova Yu., Koloskova N., Gotye S.** (Moscow). Efficacy of spironolactone in heart recipients: results of the prospective one-center study.
- **Shilov S., Popova A., Berezikova E.** (Novosibirsk), **Teplyakov A., Grekova E.** (Tomsk), **Neupokoeva M., Tuleutaev Sh.** (Novosibirsk). New opportunities for prognosis of anthracycline-induced cardiotoxicity development.

- **Berezikova E., Shilov S., Popova A.** (Novosibirsk), **Teplyakov A., Grakova E.** (Tomsk), **Yakovleva I., Molokov A.** (Novosibirsk). Impact of biphosphonate therapy on reducing the risk of cardiovascular complications in patients with chronic heart failure.
- **Solovyeva A., Bayarsaykhan M., Villevalde S., Kobalava Zh.** (Moscow). Combined increasing of liver density and liver markers in patients with heart failure decompensation: clinical and prognostic significance.
- **Ganenko O., Nazimova M., Demchenko E., Malysheva A., Kozlova A.** (Saint-Petersburg). Safety and efficacy of controlled gym workout in patients with terminal chronic heart failure.

HALL 4.6

09.00–10.30

SYMPOSIUM

Pediatric cardiology

Chairpersons: **Skorobogatova O., Sozonov A.** (Ekaterinburg)

- **Korkina T.** (Kurgan). State of the pediatric cardiology service in the Ural Federal District of Russia.
- **Skorobogatova O.** (Ekaterinburg). Features of the medical care provided to children with CVD in Sverdlovsk Region.
- **Velikanov I.** (Ekaterinburg). Neonatal cardiology in Regional Children's Clinical Hospital of Sverdlovsk Region.
- **Trunova Yu., Sozonov A., Andreeva D., Ryazanova T.** (Ekaterinburg). Hypertension in children. Clinical guidelines in real practice.
- **Lvova O.** (Ekaterinburg). Risk factors of developing ischaemic stroke in children with surgically operated congenital heart disorders.
- **Kazantsev K.** (Ekaterinburg). Critical congenital heart disorders in newborns. Diagnostic, treatment, outcomes on the basis of Sverdlovsk region.

PLENARY HALL №2 (3.2)

11.00–12.30

MULTIDISCIPLINARY SATELLITE SYMPOSIUM

What does every physician need to know? The rules of elderly AF patients' management

(supported by Bayer, CME points are not accrued)

On-line broadcasting

Chairperson: **Arutyunov G.** (Moscow)

- **Arutyunov G.** (Moscow). Physician's point of view: what are the important aspects to consider when choosing anticoagulant therapy for AF patients?
- **Fomin I.** (Nizhny Novgorod). Cardiologist's point of view: the rules of elderly AF patients' management.
- **Batyusin M.** (Rostov-on-Don). Nephrologist's point of view: why it is important to monitor kidney function in AF patients and which aspects are relevant?
- **Orlova Ya.** (Moscow). Gerontologist's point of view: how to increase safety of NOAC therapy in elderly and frail AF patients?
- **Gusev V.** (Ekaterinburg). Neurologist's point of view: how to prevent stroke in AF patients and what actions should be taken if a stroke has already occurred?

HALL 2.3

11.00–12.30

SATELLITE SYMPOSIUM

From optimal drug therapy to patient-oriented treatment of stable CAD

(supported by Berlin Chemie, CME points are not accrued)

Chairpersons: **Nedoshivin A.** (Saint-Petersburg), **Bubnova M.** (Moscow), **Sergienko I.** (Moscow)

- **Nedoshivin A.** (Saint-Petersburg). CAD: aiming at the latest clinical guidelines.
- **Sergienko I.** (Moscow). Diagnosis of CAD – how to live after?
- **Bubnova M.** (Moscow). Comorbid patient with CAD: modern treatment.

HALL 3.1

11.00–12.30

SATELLITE SYMPOSIUM

Making a menu for a family dinner

(supported by Servier, CME points are not accrued)

Online broadcasting

Chairpersons: **Karpov Yu.** (Moscow), **Nedogoda S.** (Volgograd)

- **Karpov Yu.** (Moscow). Anti-age appetizer.
- **Nedogoda S.** (Volgograd). First course: less salt more love.
- **Kobalava Zh.** (Moscow). Chief's special.

HALL 3.3

11.00–12.30

SATELLITE SYMPOSIUM

Lifestyle and heart health: realities of hypersympathicotonia with arterial hypertension

(supported by Merck, CME points are not accrued)

On-line broadcasting / Simultaneous translation

Chairpersons: **Boytsov S.** (Moscow), **Kjeldsen S.E.** (Norway)

- **Boytsov S.** (Moscow). Sympathetic overdrive in arterial hypertension. Should the patients be differentiated?
- **Kjeldsen S.E.** (Norway). Activation of sympathetic nervous system in patient with hypertension and CAD. How it impacts on the therapy choice?
- **Karpov Yu.** (Moscow). Hypersympathicotonia in patient with hypertension and metabolic disorders.

HALL 3.4

11.00–12.30

SYMPOSIUM OF THE NATIONAL SOCIETY OF PREVENTIVE CARDIOLOGY

Breakthroughs in preventive cardiology

Chairperson: Pogosova N. (Moscow)

- **Pogosova N.** (Moscow). New approaches in secondary prevention of CAD: evidence-based medicine data.
- **Osipova I.** (Barnaul). Possibilities of prevention of cardiovascular complications in elderly patients.
- **Barbarash O.** (Kemerovo). Peripheral atherosclerosis: can the prognosis be improved?
- **Yufereva Yu.** (Moscow). Reduction of cardiovascular mortality in patients with type 2 diabetes: the goal is the same, the approaches are new.

HALL 3.5

11.00–12.30

SYMPOSIUM

Cardiovascular complications in patients receiving renal replacement therapy

Chairpersons: **Arutyunov G.** (Moscow), **Koziolova N.** (Perm)

- **Gordeev I.** (Moscow), **Fedoseev A.** (Moscow), **Lapochkina N.** (Moscow), **Balkarova O.** (Moscow). All-Russian Registry of Atrial Fibrillation Patients Receiving Replacement Therapy with Programmed Hemodialysis and Peritoneal Dialysis under the auspices of the Eurasian Association of Physicians.
- **Gendlin G.** (Moscow), **Tomilina N.** (Moscow), **Shilo V.** (Moscow). Long-term survival of patients on chronic program hemodialysis, depending on the state of their cardiovascular system.
- **Korsakova L.** (Moscow), **Stolar A.** (Ekaterinburg). Thrombotic complications in patients receiving renal replacement therapy.
- **Lebedeva A.** (Moscow), **Malimon V.** (Moscow). Strategy and tactics of cardiovascular therapy in patients with CKD and stages.

- **Gordeev I.** (Moscow), **Luchinkina E.** (Moscow). Atrial fibrillation and CKD.
- **Benevskaia M.** (Moscow). Changes in intracardiac hemodynamics in patients receiving renal replacement therapy.

HALL 3.6

11.00–12.30

TRAINING WORKSHOP

Difficult cases of diagnostics and treatment in cardiology

Chairperson: **Galyavich A.** (Kazan)

- **Galyavich A.** (Kazan). General principles of diagnosis and treatment in cardiology.
- **Kamalov G.** (Kazan). Cardiomyopathy and myopathy.
- **Galeeva Z.** (Kazan). Unusual hypertrophic cardiomyopathy.
- **Baleeva L.** (Kazan). Chronic heart failure syndrome.

HALL 3.7 AND 3.8

11.00–12.30

SATELLITE SYMPOSIUM

Multifaceted approach to therapy of hypertensive patients: why current guidelines are sagacious? Part 2.

(supported by KRKA, CME points are not accrued)

Chairperson: **Nedoshivin A.** (Saint-Petersburg)

- **Konradi A.** (Saint-Petersburg). New hypertension guidelines: how daily practice of cardiologists will change?
- **Kobalava Zh.** (Moscow). Importance of multifaceted organ protection in management of hypertension.
- **Nedoshivin A.** (Saint-Petersburg). Complex therapy of CVD – pathway to prolonging vascular youth.

HALL 3.9

11.00–12.30

SATELLITE SYMPOSIUM

Rational aspirin therapy: new horizons

(supported by Takeda, CME points are not accrued)

Chairperson: **Ageev F.** (Moscow)

- **Ageev F.** (Moscow). Is it possible to assert with confidence today – who absolutely needs aspirin? Lessons from completed studies.
- **Belenkov Yu.** (Moscow). Dosage of ASA for primary and secondary prevention: long-awaited updates. Review of recent studies.
- **Lomakin N.** (Moscow). Not all aspirin drugs are equally useful. Results of the comparative study of the aspirin forms in Russia (SFAYROS TRIAL).

HALL 3.10

11.00–12.30

SATELLITE SYMPOSIUM

Specific therapy of pulmonary arterial hypertension of new generation: focus on late outcomes

(supported by Actelion, a Janssen Pharmaceutical company of Johnson&Johnson, CME points are not accrued)

On-line broadcasting / Simultaneous translation

Chairpersons: **Galiè N.** (Italy), **Avdeev S.** (Moscow)

- **Martynyuk T.** (Moscow). Diagnostics and treatment of PAH in Russia: can we be satisfied by the treatment outcomes?
- **Moiseeva O.** (Saint-Petersburg). Selexipag – the first and only agonist of prostacyclin IP-receptors in PAH treatment.
- **Galiè N.** (Italy). Evolution of PAH therapy: monotherapy to early combination therapy.
- **Panel discussion.** How can we improve late outcomes in PAH patients?

HALL 4.5

11.00–12.30

SCIENTIFIC SESSION

Epidemiology, prevention and rehabilitation. Sports medicine

Chairpersons: **Gafarov V.** (Novosibirsk), **Shalnova S.** (Moscow)

- **Gogolashvili N., Yaskevich R., Tuchkov A.** (Krasnoyarsk). Frequency of prescription of the oral anticoagulants in patients with atrial fibrillation in 2015–2018 based on the data of Krasnoyarsk atrial fibrillation registry.
- **Imaeva A., Shalnova S., Balanova Yu., Kapustina A.** (Moscow), **Shkolnikov V.** (Germany). Association between stress hormones and overall and cardiovascular mortality in citizens of Moscow 55 years old and older.
- **Kozlova A., Demchenko E., Ganenko O.** (Saint-Petersburg). Gym workouts of patients after sternotomy surgery during in-hospital rehabilitation.
- **Mamaeva O., Pavlova N., Podlesov A., Guseva O., Evsikova I., Strelyukhina S., Lebedeva S., Scherbak S.** (Saint-Petersburg). Results of comparing 2D, 3D echo and Speckle-tracking in quantity assessment of left ventricular systolic function in young sportsmen.
- **Balanova Yu., Imaeva A., Shalnova S., Kapustina A., Muromtseva G., Evstifeeva S., Tarasov V., Deev A.** (Moscow). Arterial hypertension dynamics in the Russian population.
- **Gorbunova E.** (Kemerovo). Decision support module “personalized choice of anticoagulant in atrial fibrillation”.

HALL 4.6

11.00–12.30

PRESENTATIONS BY WINNERS OF THE YOUNG SCIENTISTS AWARD

Jury: **Villevalde S.** (Saint-Petersburg), **Grinshtein Yu.** (Krasnoyarsk), **Duplyakov D.** (Samara), **Kontsevaya A.** (Moscow), **Mayanskaya S.** (Kazan), **Melekhov A.** (Moscow), **Nikulina S.** (Krasnoyarsk), **Osipova I.** (Barnaul), **Sumin A.** (Kemerovo), **Khaisheva L.** (Rostov-on-Don)

PLENARY HALL №1

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

- **Atar D.** (Norway). Double or triple antithrombotic therapy in patients with AF after an ACS?
- Pro Double: **Atar D.** (Norway).
- Pro Triple: **Arutyunov G.** (Moscow)

PLENARY HALL №2 (3.2)

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

- **Galié N.** (Italy). Modern view on diagnostics and treatment of pulmonary hypertension.
Moderator: **Moiseeva O.** (Saint-Petersburg)

PLENARY HALL №1

13.30–15.00

SATELLITE SYMPOSIUM

Anticoagulant therapy in elderly comorbid patient
(supported by Pfizer, CME points are not accrued)

On-line broadcasting / Simultaneous translation

Chairperson: **Shlyakhto E.** (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Opportunities and perspectives of anticoagulant therapy in patient with atrial fibrillation.
- **Arkhipov M.** (Ekaterinburg). SPAF – risk and benefit in daily doctor's practice.

- **Wehling M.** (Germany). FORTA system as clinical tool for pharmacotherapy optimization in older patients.
- **Wehling M.** (Germany). OAC-FORTA: anticoagulant therapy in elderly patients.
- **Kobalava Zh.** (Moscow). AF is not a verdict: longevity – active and positive.

PLENARY HALL №2 (3.2)

13.30–15.00

SATELLITE SYMPOSIUM

How to lower the risk of cardiovascular death?

Innovations in CAD and peripheral artery disease patients' management

(supported by Bayer, CME points are not accrued)

On-line broadcasting

Chairperson: **Arkhipov M.** (Ekaterinburg)

- **Panchenko E.** (Moscow). New Guidelines – new approaches in the treatment of patients with CAD.
- **Karpov Yu.** (Moscow). It's time to change our approach: rivaroxaban in the management of patients with CAD and peripheral artery disease.
- **Perepech N.** (Saint-Petersburg). Evaluation of the risk/benefit balance when prescribing combined antithrombotic therapy to patients with CAD or peripheral artery disease.

HALL 2.3

13.30–15.00

SATELLITE SYMPOSIUM

A new era in lipid-lowering therapy for a comorbid patient

(supported by Recordati, CME points are not accrued)

Chairpersons: **Aronov D.** (Moscow), **Kukharchuk V.** (Moscow)

- **Aronov D., Kukharchuk V.** (Moscow). Welcome.

- **Sergienko I.** (Moscow). New target levels of LDL-cholesterol for primary and secondary prevention.
- **Bubnova M.** (Moscow). Statins in different clinical states: effects, risks and real problems.
- **Ezhov M.** (Moscow). Pitavastatin like a stable base of effective and harmless therapy.
- **Q&A. Discussion.**

HALL 3.1

13.30–15.00

SATELLITE SYMPOSIUM

Hypertension: three types of patients – three diagnoses – three solutions

(supported by Servier, CME points are not accrued)

Chairperson: **Boytsov S.** (Moscow)

- **Konradi A.** (Saint-Petersburg). Hypertension and young patient: the right choice of the therapy from the beginning.
- **Kobalava Zh.** (Moscow). Hypertension and elderly patient: how to lower BP safely.
- **Privalova E.** (Moscow). Hypertension and other CVD: simple solutions for comorbid patient.

HALL 3.3

13.30–15.00

SATELLITE SYMPOSIUM

A paradigm shift in the treatment of arterial hypertension – from optimal drug to optimal combinations

(supported by Werteks, CME points are not accrued)

Chairperson: **Nedoshivin A.** (Saint-Petersburg)

- **Nedoshivin A.** (Saint-Petersburg). Composition of fixed combinations – what selection is based on?

- **Galyavich A.** (Kazan). Questions about arterial hypertension: simply about the complex.
- **Konradi A.** (Saint-Petersburg). Fixed combination in arterial hypertension treatment- history of rising.

HALL 3.4

13.30–15.00

JOINT SYMPOSIUM WITH THE RUSSIAN TRANSPLANT SOCIETY

Heart transplantation in Russia: status artis MMXIX

Chairpersons: **Gautier S.** (Moscow), **Klimusheva N.** (Ekaterinburg), **Shevchenko A.** (Moscow)

- **Gautier S.** (Moscow). Heart transplantation in Russian Federation: present and future.
- **Klimusheva N.** (Ekaterinburg). Organ donation and transplantation in Ekaterinburg.
- **Fedotov P., Sitnikova M., Gordeev M., Simonenko M., Karpenko M.** (Saint-Petersburg). Outpatient management of heart recipients: Almazov Centre experience.
- **Shevchenko A.** (Moscow). Updated national guidelines on the management of heart recipients 2019: new statements and take home messages.

HALL 3.5

13.30–15.00

SATELLITE SYMPOSIUM

Closed scientific discussion

(supported by Boehringer Ingelheim, CME points are not accrued)

HALL 3.6

13.30–15.00

SYMPOSIUM

Paradoxes of nutrition in prevention of cardiovascular diseases

Chairpersons: **Starodubova A.** (Moscow), **Kontsevaya A.** (Moscow)

- **Starodubova A.** (Moscow). Modern guidelines on rational nutrition for the prevention of cardiovascular diseases.
- **Kontsevaya A.** (Moscow). Results of PURE and other studies breaking the stereotypes of rational nutrition.
- **Serebryakova V.** (Tomsk). Recommendations and research results: clinician's comments.
- **Karamnova N.** (Moscow). Recommendations and findings: comments nutritionist.

HALL 3.7

13.30–15.00

SYMPOSIUM

Anxiety and depression in cardiac practice: prevalence, prognostic significance and approaches to therapy

Chairpersons: **Vasyuk Y.** (Moscow), **Ufereva Y.** (Moscow)

- **Pogosova N.** (Москва). Anxiety and depressive states in patients with hypertension and coronary heart disease in general medical practice in 30 cities of the Russian Federation: new data from the COMET study.
- **Begrambekova Yu.** (Moscow). Anxiety and depressive conditions in patients with heart failure: the effect on the prognosis and effectiveness of non-drug management methods.
- **Kursakov A.** (Moscow). Anxiety and depression in cardiology practice from the point of view of a psychiatrist.

HALL 3.8

13.30–15.00

SATELLITE SYMPOSIUM

Cardiac fair. Open dialogue. Variety of hypertensive patients and therapeutically decisions, so is it possible to put a point?

(joint symposium of the RSC and Sanofi, CME points are not accrued)

On-line broadcasting

Chairperson: **Kobalava Zh.** (Moscow), **Drapkina O.** (Moscow)

- **Kobalava Zh.** (Moscow). Welcome. From the beginning of hypertension treatment to the present state.
- **Kobalava Zh.** (Moscow). In an action film “The hypertension onset. How to help the patient?”.
- **Drapkina O.** (Moscow). In psychological thriller “The patient and doctor consciousness. Pledge of success therapy”.
- **Ostroumova O.** (Moscow). In catching blockbuster “Geriatric patient with hypertension, high cardiovascular risks”.

HALL 3.9

13.30–15.00

SATELLITE SYMPOSIUM

Truth is born in a dispute. Discussion club “Criteria for the selection of antihypertensive therapy”

(supported by Gedeon Richter, CME points are not accrued)

Chairperson **Arutyunov G.** (Moscow)

- **Nedogoda S.** (Volgograd). When « $1 + 1 = 3$ » or how to achieve the maximum effect of treatment of hypertension.
- **Konradi A.** (Saint-Petersburg). Therapy strategy for comorbid patients. Nothing is impossible.
- **Arutyunov G.** (Moscow). When total control is not just words.

HALL 3.10

13.30–15.00

SATELLITE SYMPOSIUM

Optimal therapy approach in patients with MI and additional cardiovascular risk factors

(supported by AstraZeneca, CME points are not accrued)

On-line broadcasting

Chairperson **Vasilieva E.** (Moscow)

- **Lebedeva A.** (Moscow). What do clinical guidelines say?
- **Skrypnik D.** (Moscow). Optimal choice of DAPT from the point of view of an intervention cardiologist.
- **Shogenov Z.** (Moscow). Questions of DAPT duration.

HALL 4.5

13.30–15.00

SCIENTIFIC SESSION

Interdisciplinary issues of cardiology

Chairpersons: **Orlova Ya.** (Moscow), **Rebrov A.** (Saratov), **Chesnikova A.** (Rostov-on-Don)

- **Mustafina S., Vinter D., Scherbakova L.** (Novosibirsk), **Bobak M.** (UK), **Gafarov V., Rymar O., Malyutina S.** (Novosibirsk). 13-year risk of developing myocardial infarction in patients with metabolically healthy obese phenotype.
- **Reznik E., Nguen T., Stepanova E., Nikitin I.** (Moscow). Chronic heart failure in patients with systemic amyloidosis.
- **Yusupova A., Zhbanov K., Popova L., Kondratieva T., Kozhevnikova M., Belenkov Yu.** (Moscow). Case of paradoxical embolism, cryptogenic stroke in patient with patent foramen ovale and congenital thrombophilia.
- **Chumakova S., Vins M., Urazova O., Mainagasheva E., Pogonchenkova D., Shipulin V., Pryakhin A., Novitskiy V.** (Tomsk). Impact of interleukin-10 on monocyte subpopulation in ischaemic cardiomyopathy.

- **Sokolova A.** (Moscow). Role of the level of cytokine in patients with sarcopenia, chronic heart failure and chronic kidney disease.
- **Dragunova D.** (Moscow). Prognostic role of bendopnea in patients with chronic heart failure, preserved ejection fraction and different level of sodium intake.

HALL 4.6

13.30–15.00

SYMPOSIUM

Optimal navigation for patient with atrial fibrillation: how to set the right course?

Chairpersons: **Duplyakov D.** (Samara), **Baranova E.** (Saint-Petersburg)

- **Duplyakov D.** (Samara). Atrial fibrillation is an «iceberg»? How to optimize diagnostics?
- **Baranova E.** (Saint-Petersburg), **Ionin V.** (Saint-Petersburg). «Underwater reefs» in the AF management. Cardiologist's point of view.
- **Yanishewsky S.** (Saint-Petersburg). «Storms and shoals» in the atrial fibrillation management. Neurologist's point of view.
- **Vorobieva N.** (Arkhangelsk). «Archipelago» of well-being — «safe haven» for patient and doctor... How to improve adherence to AF treatment?

PLENARY HALL №1

15.30–17.00

PLENARY SESSION

Imaging diagnostics in cardiology: different clinical scenarios

On-line broadcasting / Simultaneous translation

Chairpersons: **Vasyuk Yu.** (Moscow), **Golukhova E.** (Moscow),
Kuznetsov V. (Tyumen), **Lishmanov Yu.**, **Ternovoy S.** (Moscow).

- **Alekhin M.** (Moscow), **Vasyuk Yu.** (Moscow), **Golukhova E.** (Moscow), **Kuznetsov V.** (Tyumen), **Saidova M.** (Moscow). Myocardial infarction with nonobstructive coronary arteries. Echocardiography in diagnostics MINOCA.
- **Basek I.** (Saint-Petersburg), **Veselova T.** (Moscow), **Ternvoy S.** (Moscow). CT in urgent cardiology: opportunities and prospects.
- **Stukalova O.** (Moscow), **Trufanov G.** (Saint-Petersburg), **Usov V.** (Tomsk), **Fokin V.** (Saint-Petersburg). Place of cardiac MRI in diagnostics of acute coronary syndrome patients.
- **Aslanidi I.** (Moscow), **Zavadovsky K.** (Tomsk), **Ryzhkova D.** (Saint-Petersburg). Modern opportunities of radionuclide methods in urgent cardiology.

PLENARY HALL №2 (3.2)

15.30–17.00

SATELLITE SYMPOSIUM

Patient with arterial hypertension: is everything clear with the choice of therapy?

(supported by Takeda, CME points are not accrued)

On-line broadcasting

Chairpersons: **Kobalava Zh.** (Moscow), **Nedogoda S.** (Volgograd), **Karpov Yu.** (Moscow)

- **Karpov Yu.** (Moscow). Patient with grade 1 hypertension: mono- or combined therapy?
- **Nedogoda S.** (Volgograd). What is new in treatment of patients with diabetes mellitus, pre-diabetes and cardiovascular diseases? Antihypertensive drugs in the light of the correction of insulin resistance and leptin resistance.
- **Kobalava Zh.** (Moscow). Redefining diuretics use in hypertension.

HALL 2.3

15.30–17.00

SYMPOSIUM

Intestinal microbiota – a new participant in the cardiovascular continuum

Chairperson **Voevoda M.** (Novosibirsk)

- **Arutyunov A.** (Moscow). Theory of the role of intestinal microflora in the structure of cardiovascular diseases.
- **Starodubova A.** (Moscow). The relation of diet and intestinal microbiota.
- **Shrainer E.** (Novosibirsk). Methods of microbiome correction in patients with chronic inflammatory bowel disease.

HALL 3.1

15.30–17.00

SATELLITE SYMPOSIUM

Actual issues of emergency medical care in management of cardiovascular patients

(supported by Boehringer Ingelheim, CME points are not accrued)

Chairpersons: **Terschenko S.** (Moscow), **Zateyschikov D.** (Moscow)

- **Yavelov I.** (Moscow). Actual issues in pharmaco-invasive approach in patients with acute coronary syndrome.
- **Tereschenko S.** (Moscow). Prehospital thrombolysis in Acute Coronary Syndrome with ST elevation: clinical guidelines and Russian reality.
- **Yanischevsky S.** (Saint-Petersburg). Thrombolysis in patients with ischemic stroke who are receiving anticoagulation therapy. New opportunities for the physician and for patient.
- **Zateyschikov D.** (Moscow). Ensuring safety of patient with AF receiving combined antithrombotic therapy after coronary stenting.

HALL 3.3

15.30–17.00

SATELLITE SYMPOSIUM

Patients with venous thromboembolism in the interdisciplinary practice of cardiologist, oncologist and vascular surgeon

(supported by Bayer, CME points are not accrued)

Chairperson **Belenkov Yu.** (Moscow)

- **Zateyschikov D.** (Moscow). Practical aspects of antithrombotic therapy in special PE patient groups.
- **Matskeplishvili S.** (Moscow). Therapy of cancer associated thrombosis: a path from LMWH to DOACs.
- **Lobastov K.** (Moscow). Anticoagulant therapy continuum in VTE patients. An optimal treatment choice.

HALL 3.4

15.30–17.00

SATELLITE SYMPOSIUM

Place of thrombolytic therapy in managing patients with acute cardiovascular catastrophes: state-of-the-art

(supported by Generium, CME points are not accrued)

Chairpersons: **Kokorin V.** (Moscow), **Erlikh A.** (Moscow)

- **Poteryaev D.** (Moscow). Revelise® – the first Russian bioanalogue of alteplase.
- **Kokorin V.** (Moscow). Thrombolytic therapy in myocardial infarction: water under the bridge or life continues? Results of Revelise clinical trial.
- **Soldatov M.** (Moscow). Thrombolysis in therapy of acute ischaemic stroke: current view.
- **Erlikh A.** (Moscow). Thrombolytic therapy in PE.
- **Discussion**

HALL 3.5

15.30–17.00

SYMPOSIUM

Lessons from the ESSE-RF study. Practical and scientific value

Chairpersons: **Drapkina O.** (Moscow), **Shalnova S.** (Moscow)

- **Yakushin S., Filippov E., Nikulina N., Smirnova E., Dobrynina N.** (Ryazan). Continuum of epidemiological Studies in the Ryazan region — from prevention to... preventions.
- **Kaveshnikov V., Trubacheva I., Serebryakova V.** (Tomsk). Features of the early vascular aging in the Siberian urban population. Results from the population-based study ESSE-RF Tomsk.
- **Kontsevaya A.** (Moscow). Results of epidemiological studies as part of the planning and evaluation of the effectiveness of programmes for cardiovascular prevention: ESSE-RF.
- **Shalnova S., Balanova Yu.** (Moscow). Are research lessons always learned?

HALL 3.6

15.30–17.00

SYMPOSIUM

Do we know everything about aortic stenosis?

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Chernyavskiy A.** (Novosibirsk)

- **Dzhioeva O.** (Moscow). Patient with aortic stenosis: the purpose of echocardiography.
- **Murtazalieva P., Zhiduleva E., Irtyuga O., Ryzhkova D.** (Saint-Petersburg). Can we predict the development and progression of aortic stenosis?
- **Irtyuga O., Malev E., Sibagatullina Y.** (Saint-Petersburg). Treatment based on the pathogenesis of aortic stenosis: myth or reality?
- **Bogachev-Prokophiev A.** (Novosibirsk). Who and when should be referred to a cardiac surgeon?

HALL 3.7

15.30–17.00

SATELLITE SYMPOSIUM

Arrhythmias, hypertension, atherosclerosis – evolution of treatment approaches

(supported by Sandoz, CME points are not accrued)

Chairperson: **Shevchenko A.** (Moscow)

- **Adasheva T.** (Moscow). Antiarrhythmic therapy choice for a patient with atrial fibrillation – equation with multiple unknowns?!
- **Nebieridze D.** (Moscow). Latest arterial hypertension clinical guidelines review – focus on therapy choice.
- **Shevchenko A.** (Moscow). Managing patient with high CV risk – how to win a «steepchase»?

HALL 3.8

15.30–17.00

SATELLITE SYMPOSIUM

Interchangeability of drugs in cardiology: the possibilities of generics

(supported by Canonpharma production, CME points are not accrued)

Chairpersons: **Martsevich S.** (Moscow), **Reznik I.** (Ekaterinburg)

- **Martsevich S.** (Moscow). How safe are generics?
- **Reznik I.** (Ekaterinburg). Comorbid patient – therapy approaches.

HALL 3.9

15.30–17.00

SATELLITE SYMPOSIUM

Towards the main goal

(joint symposium of the Russian Society of Cardiology and Sanofi, CME points are not accrued)

Chairpersons: **Shlyakhto E.** (Saint-Petersburg), **Kobalava Zh.** (Moscow)

- **Shlyakhto E., Tanicheva A.** (Saint-Petersburg). Introduction: Sanofi and RSC together on the way to the main goal.
- **Kobalava Zh.** (Moscow). Monotherapy and combination therapy. Dot all the i's.
- **Gilyarevskiy S.** (Moscow). From doctor's prescription to cardiovascular risk decreasing: approaches to decrease the way.
- **Nedogoda S.** (Volgograd). Hypertensive patient: how to achieve several targets at the same time?

HALL 3.10

15.30–17.00

SYMPOSIUM

Familial hypercholesterolemia is a target for reducing cardiovascular mortality in the Russian Federation

Chairpersons: **Boytsov S.** (Moscow), **Shalnova S.** (Moscow)

- **Meshkov A.** (Moscow). The prevalence of familial hypercholesterolemia in the Russian Federation: a substudy of the ESSE-RF.
- **Ershova A.** (Moscow). Clinical features of patients with familial hypercholesterolemia in Russia.
- **Rotar O.** (Saint-Petersburg). Stiffness of the vascular wall in patients with familial hypercholesterolemia: results of the ESSE-RF in St. Petersburg.
- **Belova O.** (Ivanovo). Detection of patients with familial hypercholesterolemia in Ivanovo region.
- **Boytsov S.** (Moscow). Opportunities to improve diagnosis and treatment of familial hypercholesterolemia in Russia.

HALL 4.5

15.30–17.00

SATELLITE SYMPOSIUM

Ideal sponsor of the clinical trial vs ideal trial site

(supported by the Association of International Pharmaceutical Manufacturers, CME points are not accrued)

Chairpersons: **Konradi A.** (Saint-Petersburg), **Teplova-Bareisha K.** (Moscow)

- **Konradi A.** (Saint-Petersburg), **Teplova-Bareisha K.** (Moscow). Introduction.
- **Andreev A.** (Servier). Top 5 problems and top 5 advantages of the clinical center according to the sponsor company.
- **Discussion.** What is really important to the quality of the clinical study?
- **Vrubel M.** (Moscow, Federal Service for Surveillance in Healthcare). Guidelines of the Federal Service on clinical study in the trial center.
- Q&A session with Vrubel M. (Moscow).
- **Teplova-Bareisha K.** (Bayer). Top trends in clinical studies.
- **Discussion.** Drivers in the Russian clinical studies.

HALL 4.6

15.30–17.00

SYMPOSIUM

Typical errors in the diagnosis and treatment of cardiovascular diseases in multimorbid patients: 3D session

Chairperson **Arutyunov G.** (Moscow)

- **Orlova I.** (Moscow). Antihypertensive therapy errors.
- **Rebrov A.** (Saratov). Odds in treatment of chronic heart failure in multimorbid patient.
- **Arutyunov A.** (Moscow). Mistakes of diuretic therapy.
- **Fomin I.** (Nizhny Novgorod). Errors of antithrombotic therapy in atrial fibrillation.

- **Koziolova N.** (Perm). Mistakes of glucose-lowering therapy in diabetes mellitus and cardiovascular diseases.
- **Chesnikova A.** (Rostov-on-Don). Mistakes in the diagnosis and treatment of cardiovascular diseases in thyroid gland dysfunction.
- **Tarlovsckaya E.** (Nizhny Novgorod). Errors of antiarrhythmic therapy in a multimorbid patient.
- **Grigorieva N.** (Nizhny Novgorod). Odds of antianginal therapy in patients with a combination of COPD and CAD.
- **Petrova M.** (Krasnoyarsk). Errors in the rehabilitation of patients after coronary artery bypass surgery.

PLENARY HALL №1

17.15–19.00

PLENARY SESSION OPENING CEREMONY


On-line broadcasting / Simultaneous translation

- **Welcome greetings**

Shlyakhto E. (Saint-Petersburg). The role of the Russian Society of Cardiology in implementation of the national Healthcare project.

Casadei B. (UK). Using Big Data to understand cardiovascular disease.

- **Awarding Ceremony:
Young Scientists Awards
RSC Prize 2019**



Time	Plenary Hall №1	Plenary Hall №2 (3.2)	Hall 2.3	Hall 3.1	Hall 3.3	Hall 3.4	Hall 3.5	Hall 3.6	Hall 3.7	Hall 3.8	Hall 3.9	Hall 3.10	Hall 4.5	Hall 4.6
ONSITE REGISTRATION OF PARTICIPANTS OPENS AT 08.00 (MAIN ENTRANCE)														
09.00–10.30	Plenary Session Joint session of the Russian Society of Cardiology and European Society of Cardiology On-line broadcasting / Simultaneous translation	Plenary Session Hybrid surgery On-line broadcasting / Simultaneous translation	Symposium Population phenotypes of risk factors and outcomes of cardiovascular diseases among the population of the Siberian region	Symposium Myocardial infarction with non-obstructive coronary arteries: what's new?	Joint Russian-Turkish Symposium (together with Turkish Cardiovascular Academy Society) 10 Years of Anticoagulation with the NOACs On-line broadcasting / Simultaneous translation	Satellite symposium Simple diagnostic solutions for complex cardiology problems. Bloodless victory (supported by Roche, CME points are not accrued)	Symposium Focus on obesity: risk factor, pathogenesis mechanism, goal of therapy	Scientific session Modern heart science: from translational research to personalized cardiology. Part I	Scientific session Joint session of the Moscow Scientific Society of Cardiology and the Russian Society of Cardiology Treatment of complicated ST-elevation myocardial infarction	Educational workshop of the Council of Cardiology Journals «True» and «manipulative» statistics in modern cardiology	Symposium Management of patient with stroke. Role of the multidisciplinary team	Symposium Pericardial effusion in a multimorbid patient	Scientific session CAD, lipids and atherosclerosis	Symposium QT interval. What should cardiologist know?
10.30–11.00 BREAK														
11.00–12.30	Satellite symposium Open dialogue with experts Heading to life prolonging. Hot topics – correct solutions (supported by KRKA, CME points are not accrued)	Satellite symposium The third age: the efficacy and safety of elderly AF patients' therapy' (supported by Bayer, CME points are not accrued)	Symposium Burning questions of management of acute coronary syndrome	Satellite symposium Myocardial ischaemia: roadmap of cardiologist (supported by Servier, CME points are not accrued)	Satellite symposium Mixed dyslipidemia: The Phantom Menace (supported by Abbott Laboratories, CME points are not accrued)	Satellite symposium The best way to predict the future is to create it (supported by Novo Nordisk, CME points are not accrued)	Debates Dyspnea in comorbid patient – talking past each other?	Scientific session Modern heart science: from translational research to personalized cardiology. Part II	Satellite symposium Modern technologies in daily practice of cardiologist (supported by Cardiomedics, CME points are not accrued)	Symposium Secondary prevention in patients with cardiovascular diseases and history of stroke: evidence-based medicine and real practice	Satellite symposium «Pairs skating» as a key to successful treatment of patient with AF (supported by Boehringer Ingelheim, CME points are not accrued) On-line broadcasting	Symposium Cardiac rehabilitation: new approaches to increase the efficacy	Scientific session Cardiovascular and hybrid surgery	Session of the Council of Cardiology Journals
12.40–13.20	Plenary lecture Pinto F. (Portugal). Moderator: Nedoshivin A. (Санкт-Петербург)	Plenary lecture Ferrari R. (Italy). Moderator: Lopatin Yu. (Volgograd) On-line broadcasting / Simultaneous translation												
12.30–13.30 ПЕРЕРЫВ														

09.00–15.00 / Hall 4.4

Rapid Fire Abstracts

Time	Plenary Hall №1	Plenary Hall №2 (3.2)	Hall 2.3	Hall 3.1	Hall 3.3	Hall 3.4	Hall 3.5	Hall 3.6	Hall 3.7	Hall 3.8	Hall 3.9	Hall 3.10	Hall 4.5	Hall 4.6			
13.30–15.00	Plenary Session News of cardiology 2019 <small>On-line broadcasting / Simultaneous translation</small>	Satellite symposium Lowering the risk of death in patients with chronic CAD – new solution of the old problem <small>(supported by Bayer, CME points are not accrued)</small>	Satellite symposium Current therapy of arterial hypertension – the role of calcium channel blockers <small>(supported by Recordati, CME points are not accrued)</small>	Interactive satellite symposium Implementation of innovative drugs in real clinical practice of CHF patients management in out-patient and in-hospital conditions <small>(supported by Novartis Pharma, CME points are not accrued)</small>	Joint Russian-Turkish symposium (together with the Turkish Society of Cardiology) Patient with aortic stenosis. Answers to difficult questions <small>Simultaneous translation</small>	Satellite symposium Prescribe not cancel. Discussion club «Is there life with CHF?» <small>(supported by Gedeon Richter, CME points are not accrued)</small>	Satellite symposium in the form of clinical case discussion From hypertension to heart failure – life-long road <small>(supported by Werteks, CME points are not accrued)</small>	Symposium Cardiorespiratory continuum: myth or reality?	Symposium Multi-marker approach to early vascular aging syndrome	Symposium Complex and unresolved issues in the treatment of hypertension in the elderly and senile age	Satellite symposium Odyssey of innovative lipid-lowering treatment in patients after ACS: from research to implementation in clinical practice <small>(supported by Sanofi, CME points are not accrued)</small>	Satellite symposium Dyslipidemia 2019. Key events, challenges and perspectives <small>(supported by AstraZeneca, CME points are not accrued)</small>	Scientific session Managing patients with non-coronary pathologies	Conference Attraction of specialists of allied professions to preparing, reviewing and publishing of articles in the Russian Journal of Cardiology. Problem discussion and solution searching			
	12.30–13.30 BREAK							12.30–13.30 BREAK									
	15.30-17:00	Plenary Session From hypertension pathogenesis to the real clinical practice and Russian guidelines 2019 <small>On-line broadcasting / Simultaneous translation</small>	Satellite symposium SGLT2 inhibitors: a new era in the prevention and treatment of CHF <small>(supported by AstraZeneca, CME points are not accrued)</small>	Symposium Sleep-related heart rhythm disorders	Satellite symposium Direct oral anticoagulants in cardiology: innovation or standard of treatment? <small>(supported by Pfizer, CME points are not accrued)</small>	Symposium Modern genomics of cardiovascular diseases <small>Simultaneous translation</small>	Symposium Translational approach in aortic surgery	Symposium Cardiovascular disease prevention as a component of public health promotion	Symposium Cardiac amyloidosis	Symposium Cardiovascular diseases in elderly: navigating between Scylla and Charybdis	Satellite symposium Opportunities of clinical use of ezetimibe in patients with high and very high cardiovascular risk <small>(supported by Akrikhin, CME points are not accrued)</small>	Satellite symposium Cardio-diabetology or diabeto-cardiology in the modern physician's practice <small>(supported by Boehringer Ingelheim, CME points are not accrued)</small>	Satellite symposium Hot issues of using beta-blockers in clinical practice <small>(supported by Merck, CME points are not accrued)</small> <small>On-line broadcasting</small>	Scientific session Urgent cardiology	Battle of the Scholars 2019. Finale		
		17.00–17.30 BREAK							17.00–17.30 BREAK								
		17:30-19:00	Plenary Session Urgent cardiology – 2019 (in memoriam of Prof. Mikhail Ruda) <small>On-line broadcasting / Simultaneous translation</small>	Plenary Session Myocarditis: current state of the problem <small>On-line broadcasting / Simultaneous translation</small>	Satellite symposium From theory to practice in the treatment of arterial hypertension and chronic heart failure <small>(supported by Akrikhin, CME points are not accrued)</small>	Symposium Cardiorespiratory comorbidity	Symposium Management of patients with CHF in elderly and senile age: theory and practice	Symposium From hypertension to heart failure: the road of a lifetime	Roundtable together with the government of Sverdlovsk region Public Health 2020	Russian Journal of Cardiology Editorial Board meeting	Symposium Palliative medicine: problems of arrhythmological care	Symposium Psychosomatic disorders in cardiovascular diseases: diagnosis and correction by medical cardiologists	Training workshop Chest pain at a young age	Symposium Stable coronary heart disease: optimization of diagnostics, treatment and prognosis	Scientific session Fundamental studies	Battle of the Scholars 2019. Finale	
			19.00–19.15 BREAK							19.00–19.15 BREAK							
			19.15–20.30 GENERAL ASSEMBLY OF THE RUSSIAN SOCIETY OF CARDIOLOGY							19.15–20.30 GENERAL ASSEMBLY OF THE RUSSIAN SOCIETY OF CARDIOLOGY							

PLENARY HALL №1

09.00–10.30

PLENARY SESSION

Joint session of the Russian Society of Cardiology and European Society of Cardiology

On-line broadcasting / Simultaneous translation

Chairpersons: **Shlyakhto E.** (Saint-Petersburg), **Zamorano J.L.** (Spain)

- **Madonna R.** (Italy). Cellular senescence, adiposopathy and cardiometabolic disease: novel insights into cell-based rejuvenating therapies by genetic engineering.
- **Zateyschikov D.** (Moscow). Genomics of pulmonary hypertension — from decoding of development mechanisms to translation to clinical practice.
- **Joao Morais** (Portugal). Diabetes mellitus – a roadbook to vascular protection.
- **Kobalava Zh.** (Moscow). Diabetes mellitus and heart failure: cardiorenal axis.

PLENARY HALL №2 (3.2)

09.00–10.30

PLENARY SESSION

Hybrid surgery

On-line broadcasting / Simultaneous translation

Chairperson **Akchurin R.** (Moscow).

- **Akchurin R.** (Moscow). TAVI – state-of-the-art.
- **Gordeev M.** (Saint-Petersburg). Modern aspects of thoracic aorta hybrid surgery.
- **Imaev T.** (Moscow). Treatment tactics of patient with acute coronary syndrome.
- **Charchyan E.** (Moscow). Mega-aorta. Mega- and hybrid surgery.
- **Chernyavsky M.** (Saint-Petersburg). Hybrid surgery in aortic and peripheral arteries pathology.

HALL 2.3

09.00–10.30

SYMPOSIUM

Population phenotypes of risk factors and outcomes of cardiovascular diseases among the population of the Siberian region

Chairpersons: **Voevoda M.** (Novosibirsk), **Gafarov V.** (Novosibirsk), **Osipova I.** (Barnaul)

- **Maksimov V., Ivanova A., Orlov P., Ivanoshuk D., Voevoda M.** (Novosibirsk). Molecular genetic markers of sudden death in young and middle-aged people in the Siberian region.
- **Gromova E., Gagulin I., Panov D., Gafarova A., Krymov E., Gafarov V.** (Novosibirsk). 22-year tendencies of non-conventional risk factors for cardiovascular diseases psychosocial among young people in the conditions of a megapolis of Western Siberia WHO MONICA — psychosocial program.
- **Pyrikova N., Repkina T., Dekhar V., Borisova L., Osipova I.** (Barnaul). Ten-year dynamics of leading CVD risk factors among young and middle-aged people in an organized population of the Altai Region.
- **Akimova E., Gakova E., Kayumova M., Kuznetsov V.** (Tyumen). Psychosocial risk factors of cardiovascular diseases in men and young women according to a cross-sectional epidemiological study in a moderately urbanized city of Western Siberia.
- **Repin A., Okrugin S.** (Tomsk). WHO program «Register of acute myocardial infarction»: dynamics of complications over a decade of observation in a moderately urbanized city in Western Siberia.
- **Tsigankova O., Latyntseva L.** (Novosibirsk). Trends in the treatment of arterial hypertension in young population under the conditions of a megacity in Western Siberia.

HALL 3.1

09.00–10.30

SYMPOSIUM

Myocardial infarction with non-obstructive coronary arteries: what's new?

Chairpersons: **Boldueva S.** (Saint-Petersburg),
Kosmachova E. (Krasnodar)

Boldueva S. (Saint-Petersburg). Myocardial infarction with non-obstructive coronary arteries: clinical variants, diagnostic methods.

Kosmachova E., Kruchinova S. (Krasnodar). Analysis of the causes of myocardial infarction with non-obstructive coronary arteries: data of the ACS registry of the Krasnodar Region.

Galyavich A. (Kazan). Type 2 myocardial infarction: from theory to practice.

Oblavatsky D., Boldueva S. (Saint-Petersburg). Type 2 myocardial infarction: causes, features of diagnosis and treatment according to 10-year data from multidisciplinary hospital.

HALL 3.3

09.00-10.30

JOINT RUSSIAN-TURKISH SYMPOSIUM

(together with Turkish Cardiovascular Academy Society) 10 Years of Anticoagulation with the NOACs

On-line broadcasting / Simultaneous translation

Chairpersons: **Kozan Ö.** (Turkey), **Nedoshivin A.** (Saint-Petersburg)

Tülece S.Y. (Turkey). Stroke Prevention in Patients with NVAF.

Barbarash O. (Kemerovo). Patients with NVAF undergoing PCI.

Mikhailov E. (Saint-Petersburg). Patients with NVAF undergoing cardioversion or catheter ablation.

Karabay C.Y. (Turkey). How should anticoagulant therapy be applied in patients with Chads2-Vasc score 1?

HALL 3.4

09.00–10.30

SATELLITE SYMPOSIUM

Simple diagnostic solutions for complex cardiology problems. Bloodless victory

(supported by Roche, CME points are not accrued)

Chairpersons: **Fomin I.** (Nizhny Novgorod)

- **Fomin I.** (Nizhny Novgorod). At the intersection of diagnostics and cardiology. Diagnostic solutions in the hands of cardiologist.
- **Petrov A.** (Saint-Petersburg). Use of highly sensitive troponins in the practice of cardiologist.
- **Zotova I.** (Moscow). Outpatient management of patients with heart valve prosthesis.

HALL 3.5

09.00–10.30

SYMPOSIUM

Focus on obesity: risk factor, pathogenesis mechanism, goal of therapy

Chairpersons: **Drapkina O.** (Moscow), **Chumakova G.** (Barnaul), **Baranova E.** (Saint-Petersburg)

- **Drapkina O.** (Moscow). Obesity is a pandemic of the 21st century contributing to cardiovascular morbidity and mortality.
- **Chumakova G., Gritzenko O.** (Barnaul). The role of lipotoxicity in the pathogenesis of obesity complications.
- **Baranova E., Ionin V, Polyakova E.** (Saint-Petersburg). Epicardial adipose tissue and cardiovascular disease: two sides of the same problem?
- **Kuznetsova T., Druzhilov M.** (Petrozavodsk). Possibilities for improving prognosis in cardiovascular diseases by affecting visceral obesity.

HALL 3.6

09.00–10.30

SCIENTIFIC SESSION

Modern heart science: from translational research to personalized cardiology. Part I

Chairpersons: **Efimov I.** (USA), **Lebedev D.** (Saint-Petersburg), **Solovyova O.** (Ekaterinburg)

- **Dementieva E., Zakyan S.** (Novosibirsk). Developing a model of hypertrophic cardiomyopathy based on patient-specific induced pluripotent stem cells.
- **Agladze K.** (Moscow). Biopacemakers: from experiment to practice.
- **Vassilevskiy Y.** (Moscow). Methods of virtual evaluation of the fractional reserve of blood flow.
- **Reznik I., Grichuk E.** (Ekaterinburg). Interactions of antiarrhythmic and antithrombotic drugs.
- **Lebedeva V., Lyubimtseva T.** (Saint-Petersburg). Ways to optimize cardiac resynchronization therapy in CHF: from a mathematical model to clinical practice.

HALL 3.7

09.00–10.30

SCIENTIFIC SESSION

Joint session of the Moscow Scientific Society of Cardioangiology and the Russian Society of Cardiology Treatment of complicated ST-elevation myocardial infarction

Chairpersons: **Ioseliani D.** (Moscow), **Matskeplishvili S.** (Moscow)

- **Ioseliani D.** (Moscow). Modern trends in the management of STEMI in a megalopolis.
- **Semitko S.** (Moscow). Cardiogenic shock in acute myocardial infarction: the role of auxiliary circulation techniques in the management of this severe complication.

- **Azarov A.** (Moscow). Massive thrombosis of the infarct-related artery in STEMI: choice of the optimal treatment tactics.
- **Matskeplishvili S.** (Moscow). Patients with STEMI, diabetes and rheumatoid arthritis — how to treat this «diabolic combination»?

HALL 3.8

09.00–10.30

EDUCATIONAL WORKSHOP OF THE COUNCIL OF CARDIOLOGY JOURNALS

«True» and «manipulative» statistics in modern cardiology

Chairpersons: **Belenkov Yu.** (Moscow), **Boytsov S.** (Moscow),
Martsevich S. (Moscow)

- **Begrambekova Yu.** (Moscow). Reproducibility of clinical research as a paradigm of scientific ethics.
- **Gendlin G.** (Moscow). Why a small value of “p” does not always mean there is a clinically significant effect and why doctor should understand the risks ratio.
- **Mareev Yu.** (Moscow). How analysis of secondary points can lead to a false conclusion about the effects of the method under study.
- **Gilyarevsky S.** (Moscow). Why did the statistics come up with different types of endpoint analysis (intention to treat, per protocol, as treated) and why doctor needs to know it.
- **Martsevich S.** (Moscow). Why it is important to know the basic principles of the interpretation of clinical studies. Observational studies vs RCTs different principles of organization — different roles in evidence-based medicine.

HALL 3.9

09.00–10.30

SYMPOSIUM

Management of patient with stroke. Role of the multidisciplinary team

Chairpersons: **Konradi A.** (Saint-Petersburg), **Kislyak O.** (Moscow), **Ostroumova O.** (Moscow)

- **Nedogoda S.** (Volgograd). Modern tactics of managing patients in the acute period of stroke: are there target blood pressure levels?
- **Volkova L.** (Ekaterinburg). In-hospital strokes in patients with cardiovascular diseases.
- **Konradi A.** (Saint-Petersburg). Antihypertensive therapy in the prevention of recurrent stroke.
- **Kislyak O.** (Moscow). Statins in the secondary stroke prevention.
- **Ostroumova O.** (Moscow). Post-stroke cognitive impairment: prevention and treatment.

HALL 3.10

09.00–10.30

SYMPOSIUM

Pericardial effusion in a multimorbid patient

Chairperson **Arutyunov G.** (Moscow)

- **Moiseeva O.** (Saint-Petersburg). Modern differential diagnosis of pericardial effusion.
- **Arutunov A.** (Moscow). Treatment algorithm of acute and recurrent pericarditis in the guidelines.
- **Chapochnik I.** (Chelyabinsk). Differential diagnosis of myopericarditis with myocardial infarction.
- **Tarlovskaja E., Kamardina N., Mazalov K.** (Nizhny Novgorod). Differential diagnosis of pericardial effusion in heart failure and Demons-Meigs syndrome: a clinical review.

HALL 4.5

09.00–10.30

SCIENTIFIC SESSION

CAD, lipids and atherosclerosis

Chairpersons: **Karpov Yu.** (Moscow), **Yakushin S.** (Ryazan)

- **Korneva V., Kuznetsova T.** (Petrozavodsk). Cardiovascular events and causes of death in patients with familial hypercholesterolemia in real clinical practice.
- **Shakhtshneider E., Ivanoschuk D., Orlov P., Semaev S., Timoschenko O., Voevoda M.** (Novosibirsk). Target sequencing of the known and new genes in patients with family hypercholesterolemia.
- **Benimetskaya K., Yachmeneva M., Astrakov S., Scherbakova L., Denisova D., Ragino Yu., Voevoda M.** (Novosibirsk). Coherence of PCSK9 and cardiometabolic risk factors on a population level.
- **Shekhovtsova T., Arzhakova M., Mullova I., Duplyakov D.** (Samara). Features of ACS in HIV-patients.
- **Zubova E., Rogozhina A., Brazhnik V., Minushkina L., Chichkova M.** (Moscow), **Khasanov N.** (Kazan), **Kosmacheva E.** (Krasnodar), **Zateyschikov D.** (Moscow). Risk of bleeding and antithrombotic therapy safety in 75-year-old and older patients after ACS: data of the Oracle II observational study.
- **Trusov I., Nifontov E., Biryukov A., Ivanchenko R., Smirnov K.** (Saint-Petersburg). Factors impacting on neointimal vascular repair of coronary arteries after implantation of everolimus-eluting stents based on the optical coherent tomography.

HALL 4.6

09.00–10.30

SYMPOSIUM

QT interval. What should cardiologist know?

Chairpersons: **Makarov L.** (Moscow), **Balykova L.** (Saransk)

- **Makarov L.** (Moscow). Analysis of QT interval.
- **Komolyatova V.** (Moscow). Sport activity and QT interval.
- **Balykova L.** (Saransk). Drug induced prolongation of QT interval.
- **Zaklyazminskaya E.** (Moscow). Inconsistency of cardiographic and genetic data in LQTS: how to explain and what to do about it.

PLENARY HALL №1

11.00–12.30

SATELLITE SYMPOSIUM

Open dialogue with experts

Heading to life prolonging. Hot topics – correct solutions

(supported by KRKA, CME points are not accrued)

On-line broadcasting

Chairpersons: **Boytsov S.** (Moscow), **Shlyakhto E.** (Saint-Petersburg)

Moderator: **Drapkina O.** (Moscow)

- **Ageev F.** (Moscow). BP control for 24 hours to protect cardiovascular patient.
- **Kobalava Zh.** (Moscow). Influence on the risk factors to control the vascular age.

PLENARY HALL №2 (3.2)

11.00–12.30

SATELLITE SYMPOSIUM

The third age: the efficacy and safety of elderly AF patients' therapy'

(supported by Bayer, CME points are not accrued)

Chairperson **Belenkov Yu.** (Moscow)

Obrezan A. (Saint-Petersburg). How to maintain the risk/benefit balance when choosing anticoagulant therapy in elderly AF patient?

Vereina N. (Chelyabinsk). Hemostasiologist's point of view: the use of anticoagulants in cancer patients.

Koziolova N. (Perm). A simple solution to a 'difficult' problem: increasing therapy adherence in elderly AF patients

HALL 2.3

11.00–12.30

SYMPOSIUM

Burning questions of management of acute coronary syndrome

Chairpersons: **Tereschenko S.** (Moscow), **Duplyakov D.** (Samara)

- **Tereschenko S.** (Moscow). Pharmacoinvasive strategy in patients with ACS with ST elevation.
- **Duplyakov D.** (Samara). Is there a place for thrombolytic therapy in modern strategy of treatment of ACS with ST elevation?
- **Uskach T.** (Moscow). Close and late complications of the myocardial infarction.
- **Gaponova N.** (Moscow). A few important aspects of thrombolytic therapy.

HALL 3.1

11.00–12.30

SATELLITE SYMPOSIUM

Myocardial ischaemia: roadmap of cardiologist (supported by Servier, CME points are not accrued)

Chairperson **Glezer M.** (Moscow)

- **Nedoshivin A.** (Saint-Petersburg). Paradigm shift in CAD treatment: to treat the cause, not the outcome.
- **Perepech N.** (Saint-Petersburg). Personalized approach in the treatment of patients with CAD and CVD.
- **Averkov O.** (Moscow). Diagnostics and treatment features of ACS at prehospital and in-hospital stages.

HALL 3.3

11.00-12.30

SATELLITE SYMPOSIUM

Mixed dyslipidemia: The Phantom Menace

(supported by Abbott Laboratories, CME points are not accrued)

Chairpersons: **Nedogoda S.** (Volgograd), **Arutyunov G.** (Moscow)

- **Nedogoda S.** (Volgograd). Atherogenic dyslipidemia: it's time for a new reading of the Clinical Guidelines.
- **Sergienko I.** (Moscow). Two ways of atherogenesis — the choice of optimal therapy.
- **Arutyunov G.** (Moscow). New opportunities to prevent cardiovascular disasters.
- **Sitnikova M.** (Saint-Petersburg). Features of treatment in patients with CHF after myocardial infarction.

HALL 3.5

11.00–12.30

DEBATES

Dyspnea in comorbid patient — talking past each other?

Chairpersons: **Lopatin Yu.** (Volgograd), **Zykov K.** (Moscow), **Ratova L.** (Saint-Petersburg)

- **Lopatin Yu.** (Volgograd). Failure – heart.
- **Zykov K.** (Moscow). Insufficiency – respiratory.
- **Chernyak A.** (Moscow). Cardiorespiratory monitoring – simply about difficult.
- **Ratova L.** (Saint-Petersburg). Many-sided dyspnea.

HALL 3.6

11.00–12.30

SCIENTIFIC SESSION

Modern heart science: from translational research to personalized cardiology. Part II

Chairpersons: **Idov E.** (Ekaterinburg), **Kohl P.** (Germany), **Revishvili A.** (Moscow)

- **Roshchevskaya I.M.** (Moscow), **Smirnova S.L.** (Syktyvkar). Non-invasive electrocardiotopographic analysis of the atrial depolarization sequence.
- **Batalov R.** (Tomsk). Clinical and pathogenetic approaches in the interventional treatment of atrial fibrillation.
- **Miller O.** (Novosibirsk). Selection of antiarrhythmic drug for patient with atrial fibrillation based on its comorbid pathology.
- **Mikhailov E.** (Saint-Petersburg). Ventricular tachycardias in structural cardiac pathology: electrophysiology and neuromodulation.
- **Gurev V.** (USA). Towards personalized biophysical models of cardiovascular function for echocardiography analytics.

HALL 3.7

11.00–12.30

SATELLITE SYMPOSIUM

Modern technologies in daily practice of cardiologist (supported by Cardiomedics, CME points are not accrued)

Chairpersons: **Artyukhina E.** (Moscow), **Golitsyn S.** (Moscow), **Paleev F.** (Moscow)

- **Komlev A.** (Moscow). Patient with severe aortic stenosis: should we send him to open surgery or endovascular prosthetics? Recommendations for the TAVI patients selection and prospects for 2019.
- **Tereschenko A.** (Moscow). Endovascular methods for the ischemic strokes prevention. Left atrial appendage and patent foramen ovale closure. Indications, how to select patients and where to direct them.

- **Mikhailov E., Vander M.** (Saint-Petersburg). Which patients with chronic heart failure are advised to cardiac contractility modulation? Proper patient selection determines the outcome.
- **Golytsyn S.** (Moscow). Implantable cardioverter defibrillators are the basis of sudden cardiac death prevention in high-risk patients.
- **Artyukhina E.** (Moscow). Modern possibilities of increasing the effectiveness of catheter interventions in atrial fibrillation. Mapping with “Rhythmia” system for primary and redo procedures.

HALL 3.8

11.00–12.30

SYMPOSIUM

Secondary prevention in patients with cardiovascular diseases and history of stroke: evidence-based medicine and real practice

Chairpersons: **Martsevich S.** (Moscow), **Drapkina O.** (Moscow)

- **Martsevich S.** (Moscow). Principles of preventive pharmacotherapy of patients with cardiovascular diseases and history of stroke: evidence-based medicine and modern approaches to estimate treatment quality.
- **Alashev A., Prazdnichkova E.** (Ekaterinburg). Problems of dispensary observation and secondary prevention in patients after stroke.
- **Kutishenko N.** (Moscow). Quality of treatment and outcomes in patients after cerebral stroke: data of prospective hospital registry REGION.
- **Lukyanov M., Okshina E.** (Moscow). Patients with concomitant cardiovascular diseases and history of stroke: drug treatment and effectiveness of the secondary prevention.

HALL 3.9

11.00–12.30

SATELLITE SYMPOSIUM

«Pairs skating» as a key to successful treatment of patient with AF

(supported by Boehringer Ingelheim, CME points are not accrued)

On-line broadcasting

Chairpersons: **Baranova E.** (Saint-Petersburg), **Zamyatin M.** (Moscow)

- **Zotova I., Vinogradov O.** (Moscow). Cardioneurological cooperation for stroke prevention in atrial fibrillation.
- **Ostroumova O.** (Moscow), Yanishevskiy S. (Saint-Petersburg). Elderly ages and anticoagulation: what to consider when selecting NOAC?
- **Baranova E.** (Saint-Petersburg), **Zamyatin M.** (Moscow). Foresee a danger – to protect the patient.

HALL 3.10

11.00–12.30

SYMPOSIUM

Cardiac rehabilitation: new approaches to increase the efficacy

Chairpersons: **Aronov D.** (Moscow), **Bubnova M.** (Moscow)

- **Aronov D.** (Moscow). The effects of exercise training on telomere length of cardiac patients.
- **Barbarash O., Karetnikova V.** (Kemerovo). Improving the effectiveness of planned percutaneous coronary interventions: emphasis on active detection and modern methods of correction of carbohydrate metabolism disorders.
- **Simonenko M., Sitnikova M.** (Saint-Petersburg). Integrated approach to rehabilitation of patients after heart transplant.
- **Lyamina N.** (Moscow). Telemedicine technologies in rehabilitation of cardiosomatic patients.

HALL 4.5

11.00–12.30

SCIENTIFIC SESSION

Cardiovascular and hybrid surgery

Chairpersons: **Gordeev M.** (Saint-Petersburg), **Chernyavskiy A.** (Novosibirsk)

- Bezdenzhnykh A., Bezdenzhnykh N., Sumin A., Barbarash O.** (Kemerovo). Impact of prediabetes on frequency of late big cardiovascular events in patients after bypass surgery.
- Kudaev Yu., Chernyavskiy M., Chernov A., Chernova D., Zherdev N.** (Saint-Petersburg). Myocardial revascularization in high cardiovascular risk patients before surgical treatment of aorto-iliac segment occlusion.
- Kashtanov M., Rzhannikova A., Chernyshov S., Kardapoltsev L., Idov E., Berdnikov S., Reznik I., Kochmashova V.** (Ekaterinburg). Late results of alcohol septal ablation with the same dose of 150 consistent patients with hypertrophic obstructive cardiomyopathy.
- Mustafina I., Ishmetov V., Zagidullin N., Pavlov V.** (Ufa). Role of chronic coronary artery occlusion in stent endothelialization with drug cover.
- Mikhaylov K., Kuznetsov D., Khokhlunov S., Gevorgyan A., Novokshenov V., Polyeva M.** (Samara). Period of radial artery safe use in coronary surgery after its catheterization.
- Kuznetsov D., Gevorgyan A., Kislukhin T., Mikhaylov K., Khokhluniv S.** (Samara). Moderately urgent results of coronary bypass surgery in CAD patients with one or both internal thoracic arteries.
- Ognerubov D., Merkulov E., Pevzner D., Makeev M., Saidova M., Balakhonova T., Chechyotkin A., Dobrynina L., Schekochikhin D., Udovichenko A., Samko A.** (Moscow). Endovascular patent foramen ovale closure for secondary prevention of ischaemic stroke.

HALL 4.6

11.00–12.30

SESSION OF THE COUNCIL OF CARDIOLOGY JOURNALS

PLENARY HALL №1

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

- **Pinto F.** (Portugal). The global burden of cardiovascular disease in the 21st century.
Moderator: **Nedoshivin A.** (Saint-Petersburg)

PLENARY HALL №2 (3.2)

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

- **Ferrari R.** (Italy). Difficult questions in HF treatment: why do beta-blockers increase ejection fraction and why are ARNIs so successful?
Moderator: **Lopatin Yu.** (Volgograd)

PLENARY HALL №1

13.30–15.00

PLENARY SESSION News of cardiology 2019

On-line broadcasting / Simultaneous translation

Chairpersons: **Shlyakhto E.** (Saint-Petersburg), **Casadei B.** (UK)

- **Achenbach S.** (Germany). Chronic Coronary Syndromes – what is new in 2019?
- **Zamorano J.L.** (Spain). Tricuspid regurgitation. How to assess and why we need a new classification.
- **Arutyunov G.** (Moscow). Chronic heart failure: what is new?
- **Lee Goldberg** (USA). Novel treatment strategies for heart failure with preserved ejection fraction.

PLENARY HALL №2 (3.2)

13.30–15.00

SATELLITE SYMPOSIUM

Lowering the risk of death in patients with chronic CAD – new solution of the old problem

(supported by Bayer, CME points are not accrued)

Chairperson **Perepech N.** (Saint-Petersburg)

- **Andreev D.** (Moscow). Patient with multifocal atherosclerosis: how to proceed?
- **Koziolova N.** (Perm). CAD and Diabetes Mellitus – focusing on atherothrombotic events.
- **Averkov O.** (Moscow). Secondary prevention in patients with prior MI.

HALL 2.3

13.30–15.00

SATELLITE SYMPOSIUM

Current therapy of arterial hypertension – the role of calcium channel blockers

(supported by Recordati, CME points are not accrued)

Chairpersons: **Bubnova M.** (Moscow), **Karpov Yu.** (Moscow)

- **Karpov Yu.** (Moscow). Introduction.
- **Karpov Yu.** (Moscow). Current recommendations for the treatment of arterial hypertension: calcium channel blockers positions. What is new?
- **Gilyarevskiy S.** (Moscow). Calcium channel blockers of the first line therapy? Lercanidipine special role.
- **Bubnova M.** (Moscow). Arterial hypertension and comorbidities in clinical practice.
- **Discussion.**

HALL 3.1

13.30–15.00

INTERACTIVE SATELLITE SYMPOSIUM

Implementation of innovative drugs in real clinical practice of CHF patients management in outpatient and in-hospital conditions

(supported by Novartis Pharma, CME points are not accrued)

- **Ageev F.** (Moscow). Outpatient stage of managing CHF patient: how to find universal solution.
- **Zhirov I.** (Moscow). Hospitalization as a reason to optimize the baseline therapy for CHF patient.
- **Ageev F., Zhirov I.** (Moscow). Discussion.

HALL 3.3

13.30-15.00

JOINT RUSSIAN-TURKISH SYMPOSIUM

(together with the Turkish Society of Cardiology)

Patient with aortic stenosis. Answers to difficult questions

Simultaneous translation

Chairpersons: **Aytekin V.** (Turkey), **Belenkov Yu.** (Moscow)

- **Aytekin V.** (Turkey). Changing horizons in TAVR: Will low-risk patients change our expectations for the previously established complication rates.
- **Gordeev M.** (Saint-Petersburg). Modern aspects of open-chest aortic valve replacement.
- **Moiseeva O.** (Saint-Petersburg). Calcification of aortic valve: search for new diagnostic and treatment methods.
- **Boyaci A.** (Turkey). Low gradient low output aortic stenosis.

HALL 3.4

13.30–15.00

SATELLITE SYMPOSIUM

Prescribe not cancel. Discussion club «Is there life with CHF?»

(supported by Gedeon Richter, CME points are not accrued)

Chairpersons: **Mareev V.** (Moscow), **Ageev F.** (Moscow)

- **Mareev V.** (Moscow). Chronic heart failure — is everything as it seems?
- **Villevalde S.** (Saint-Petersburg). Strong pressure control is the key to effective treatment of CHF.
- **Ageev F.** (Moscow). CHF is not a sentence. What else can we do for a patient with CHF.

HALL 3.5

13.30–15.00

SATELLITE SYMPOSIUM IN THE FORM OF clinical case discussion

From hypertension to heart failure – life-long road

(supported by Werteks, CME points are not accrued)

Chairperson **Lopatin Yu.** (Volgograd)

- **Lopatin Yu., Nedogoda S.** (Volgograd).

HALL 3.6

13.30–15.00

SYMPOSIUM

Cardiorespiratory continuum: myth or reality?

Chairpersons: **Fomin I.** (Nizhny Novgorod), **Zykov K.** (Moscow)

- **Fomin I.** (Nizhny Novgorod). CHF and COPD: what is similar?
- **Zykov K.** (Moscow). CHF and COPD: what are the differences?
- **Grigoreva N.** (Nizhny Novgorod). Acute coronary syndrome in patients with COPD: are there any features?
- **Ratova L.** (Saint-Petersburg). Interventional cardiology in patients with COPD: are there any features?

HALL 3.7

13.30–15.00

SYMPOSIUM

Multi-marker approach to early vascular aging syndrome

Chairpersons: **Boytsov S.** (Moscow), **Vasyuk Yu.** (Moscow),
Oleynikov V. (Penza)

- **Rogoza A., Zairova A., Zheleznova E.** (Moscow). Vascular paradox of overweight patients.
- **Orlova Ya., Plisyuk A., Stragesko I.** (Moscow). Hormones and vascular aging.
- **Ivanova S., Yushchuk E., Melekhina I., Vasyuk Yu.** (Moscow). Markers of biological aging in patients with arterial hypertension and type 2 diabetes mellitus.
- **Alieva A., Rotar O., Konradi A.** (Saint-Petersburg). Predictors of early vascular aging syndrome in St. Petersburg population (results of a 5-year observation in the framework of ESSE-RF).
- **Salyamova L., Khromova A., Burko N., Oleynikov V.** (Penza). Features of early and physiological vascular aging in patients with coronary artery disease.

HALL 3.8

13.30–15.00

SYMPOSIUM

Complex and unresolved issues in the treatment of hypertension in the elderly and senile age

Chairpersons: **Tkacheva O.** (Moscow), **Kotoskaya Yu.** (Moscow)

- **Tkacheva O.** (Moscow). Arterial hypertension in the elderly and senile age: new goals of antihypertensive therapy.
- **Kotoskaya Yu.** (Moscow). Orthostatic hypotension: diagnosis and treatment.
- **Konradi A.** (Saint-Petersburg). Approaches to the treatment of hypertension in elderly and senile patients in conditions of comorbidity: focus on rarely discussed comorbidities.
- **Ostroumova O.** (Moscow). Polypragmasia in the treatment of hypertension in geriatric patients. Methods of dealing with excessive drug treatment.

HALL 3.9

13.30–15.00

SATELLITE SYMPOSIUM

Odyssey of innovative lipid-lowering treatment in patients after ACS: from research to implementation in clinical practice

(supported by Sanofi, CME points are not accrued)

Chairperson: **Barbarash O.** (Kemerovo)

- **Ezhov M.** (Moscow). Evolution of approaches to lipid-lowering treatment in patients after ACS, what is next?
- **Barbarash O.** (Kemerovo). PCSK9 inhibitors in patients with diabetes mellitus and atherosclerosis –maximal potential for improving the prognosis.
- **Duplyakov D.** (Samara), **Kashtalap V.** (Kemerovo). How to bring innovations closer to the patient? Experience in providing medical care for patients with atherogenic lipid metabolism disorders.
- **Discussion.**

HALL 3.10

13.30–15.00

SATELLITE SYMPOSIUM

Dyslipidemia 2019. Key events, challenges and perspectives

(supported by AstraZeneca, CME points are not accrued)

Chairperson: **Kobalava Zh.** (Moscow)

- **Kobalava Zh.** (Moscow). Key events in the world of dyslipidemia in 2019.
- **Khasanov N.** (Kazan). Problems that we solve every day.
- **Susekov A.** (Moscow). Statin therapy in Russia, where are we going or where are we standing?

HALL 4.5

13.30–15.00

SCIENTIFIC SESSION

Managing patients with non-coronary pathologies

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Pavlyukova E.** (Tomsk)

- **Goncharova N., Simakova M., Moiseeva O.** (Saint-Petersburg). Comparative analysis of patients with idiopathic pulmonary artery hypertension and pulmonary artery hypertension associated with HIV.
- **Gorbunova E., Ponasenko A., Rozhnev V., Barbarash O.** (Kemerovo). Pharmacogenetic approach to increasing of efficacy and safety of anticoagulant therapy in patients with prosthetic cardiac valve.
- **Tokareva E., Kamenschikov N., Baev A., Varvarenko V., Bykova N.** (Tomsk). Endovascular correction of congenital heart defects in patients with venous bed bottom pathology using alternative approach — internal jugular vein.
- **Komissarova S., Rineyskaya N., Chakova N., Niyazova S.** (Belarus). Unfortunate outcomes and events in patients with hypertrophic cardiomyopathy and mutations of ionic currents genes.
- **Krylova N., Kovalevskaya E., Poteshkina N., Maslova M.** (Moscow). Role of stress echo in managing patients with hypertrophic cardiomyopathy.

- **Taran I., Belevskaya A., Sharf T., Masenko V., Saidova M., Martynyuk T.** (Moscow). Role of new biomarkers – ST2 and osteopontin in degree assessment of heart remodeling and severity of condition of patient with idiopathic pulmonary hypertension and chronic thromboembolic pulmonary hypertension.

HALL 4.6

13.30–15.00

CONFERENCE

Attraction of specialists of allied professions to preparing, reviewing and publishing of articles in the Russian Journal of Cardiology. Problem discussion and solution searching

PLENARY HALL №1

15.30–17.00

PLENARY SESSION

From hypertension pathogenesis to the real clinical practice and Russian guidelines 2019

On-line broadcasting / Simultaneous translation

Chairpersons: **Konradi A.** (Saint-Petersburg), **Nedogoda S.** (Volgograd)

- **Konradi A.** (Saint-Petersburg). Sympathetic nervous system and hypertension.
- **Nedogoda S.** (Volgograd). Assessment criteria of efficacy and quality of hypertension treatment in the light of the national clinical guidelines.
- **Chazova I.** (Moscow). Modern view on diagnostics and treatment of arterial hypertension.

PLENARY HALL №2 (3.2)

15.30–17.00

SATELLITE SYMPOSIUM

SGLT2 inhibitors: a new era in the prevention and treatment of CHF

(supported by AstraZeneca, CME points are not accrued)

Chairpersons: **Tereschenko S.** (Moscow), **Galyavich A.** (Kazan)

- **Lopatin Yu.** (Volgograd). Type 2 diabetes mellitus as a risk factor for CHF and the role of iSGLT2 in the prevention of heart failure.
- **Zhirov I.** (Moscow). iSGLT2: new approach affecting the prognosis for patients with CHF.
- **Kobalava Zh.** (Moscow). iSGLT2: diuretic with hypoglycemic effect or hypoglycemic drug with a unique cardioprotective mechanism?

HALL 2.3

15.30–17.00

SYMPOSIUM

Sleep-related heart rhythm disorders

Chairpersons: **Belkin A.** (Ekaterinburg), **Mikhailov E.** (Saint-Petersburg), **Sviryaev Yu.** (Saint-Petersburg)

- **Garkina S.** (Saint-Petersburg). Heart rhythm disorders associated with the obstructive sleep apnea syndrome: the view of the arrhythmologist.
- **Medvedeva E., Korostovtseva L., Sazonova Yu., Simonenko M., Sviryaev Yu.** (Saint-Petersburg). Sleep-disordered breathing in severe heart failure: prognostic role and management approaches.
- **Ionin V.** (Saint-Petersburg). Atrial fibrillation in patients with metabolic syndrome and obstructive sleep apnea.
- **Korostovtseva L., Alieva A., Rotar O.** (Saint-Petersburg). Insomnia and the risk of fatal cardiovascular events: data of the ESSE-RF study.
- **Bochkarev M.** (Saint-Petersburg). Nocturnal bradyarrhythmias and sleep disorders.
- **Belkin A.** (Ekaterinburg). Sleep structure and heart rhythm disturbances in unresponsive patients.

HALL 3.1

15.30–17.00

SATELLITE SYMPOSIUM

Direct oral anticoagulants in cardiology: innovation or standard of treatment?

(supported by Pfizer, CME points are not accrued)

Chairperson **Averkov O.** (Moscow)

- **Vinogradov O.** (Moscow). Dispelling the myths of anticoagulants usage for the prevention of cardioembolic stroke.
- **Andreev D.** (Moscow). Features of DOAC therapy in patients with AF and CKD.
- **Averkov O.** (Moscow). What questions about the patients with AF and ACS usage of anticoagulants were answered by the AUGUSTUS study?

HALL 3.3

15.30-17.00

SYMPOSIUM

Modern genomics of cardiovascular diseases

Simultaneous translation

Chairpersons: **Giustiniani G.D.** (La Coruna), **Zateyshchikov D.** (Moscow)

- **Garcia Giustiniani D.** (Spain). Premature atherosclerosis: the role of genetics.
- **Sonicheva N.** (Moscow). Genetic aspects of conduction disorders.
- **Dankovtseva E., Zateyshchikov D., Osipova N., Speshilov G.** (Moscow). Pulmonary hypertension of various pathogenesis: targeted sequencing.
- **Kosinova A., Grinstein Y., Mongush T., Goncharov M., Subbotina T., Semashchenko K., Kochmareva G.** (Krasnoyarsk). Genetic Aspects of Acetylsalicylic Acid Resistance. The role of polymorphisms in the P-selectin gene.
- **Minushkina L., Brazhnik V., Zubova E., Rogozhina A., Speshilov G., Zateyshchikov D.** (Moscow). ANXA gene polymorphism is associated with the effectiveness of statins. Data of ORACLE II study.

- **Nikulina S., Shulman V., Chernova A., Shihkova K.** (Krasnoyarsk). Associations rs1082402 in the development of atrial fibrillation.

HALL 3.4

15.30–17.00

SYMPOSIUM

Translational approach in aortic surgery

Chairpersons: **Gordeev M.** (Saint-Petersburg), **Chernyavskiy A.** (Novosibirsk), **Benetis B.** (Lithuania)

- **Benetis B.** (Lithuania). Reconstructive surgery of aortic root and arch.
- **Chernyavskiy A.** (Novosibirsk). Hybrid techniques in treatment of thoracic aortic diseases.
- **Uspenskiy V.** (Saint-Petersburg). Choosing surgery tactics in aortic dissection type A spreading to brachiocephalic arteries.
- **Bazylev V.** (Penza). Physiological cerebral perfusion in aortic arch surgery.
- **Skvortsov A.** (Moscow). Mini-access in the treatment of aortic pathology.
- **Chernyavskiy M.** (Saint-Petersburg). Hybrid surgery of aortic arch.

HALL 3.5

15.30–17.00

SYMPOSIUM

Cardiovascular disease prevention as a component of public health promotion

Chairpersons: **Kontsevaya A.** (Moscow), **Drapkina O.** (Moscow)

- **Kontsevaya A.** (Moscow). Federal project «Strengthening public health» in the prevention of cardiovascular diseases at the Federal, regional and municipal levels.
- **Duplyakov D.** (Samara). Regional educational program to improve the literacy of medical personnel and patients with atrial fibrillation in the Samara region: first results.

- **Maksimova Zh.** (Ekaterinburg). Prevention of cardiovascular disease at the municipal level: the experience of Ekaterinburg.
- **Tokarev S.** (Nadym, Tyumen region). Implementation of cardiovascular disease prevention programs in the region with low population density.
- **Popovich M.** (Moscow). Prevention of cardiovascular diseases at the workplace.

HALL 3.6

15.30–17.00

SYMPOSIUM

Cardiac amyloidosis

Chairpersons: **Reznik E.** (Moscow), **Nikitin I.** (Moscow)

- **Reznik E.** (Moscow). Heart disease in patients with amyloidosis.
- **Stepanova E.** (Moscow). Some diagnostic pitfalls in the diagnosis of amyloidosis.
- **Nikitin I.** (Moscow). Clinical cases of systemic amyloidosis.

HALL 3.7

15.30–17.00

SYMPOSIUM

Cardiovascular diseases in elderly: navigating between Scylla and Charybdis

Chairperson **Tkacheva O.** (Moscow)

- **Kotovskaya Yu.** (Moscow). Lipidlowering therapy in older adults: yes or no?
- **Tkacheva O.** (Moscow). Aticoagulation treatment in older adults: how to avoid bleeding nightmare?
- **Naumov A.** (Moscow). Increase of cardiovascular risk related to chronic pain treatment: what can we do?
- **Runikhina N.** (Moscow). Antihypertensive treatment in the very elderly: balancing benefits and risks.

HALL 3.8

15.30–17.00

SATELLITE SYMPOSIUM

Opportunities of clinical use of ezetimibe in patients with high and very high cardiovascular risk

(supported by Akrikhin, CME points are not accrued)

Chairpersons: **Susekov A.** (Moscow), **Galyavich A.** (Kazan),
Shaposhnik I. (Chelyabinsk)

- **Susekov A.** (Moscow). Rationale for the rationality of the combination of statins with ezetimibe (mechanism of action and effect on endpoints).
- **Galyavich A.** (Kazan). Complex issues of lipid-lowering therapy.
- **Shaposhnik I., Genkel V.** (Chelyabinsk). Pleiotropic effects of ezetimibe.

HALL 3.9

15.30-17.00

SATELLITE SYMPOSIUM

Cardio-diabetology or diabeto-cardiology in the modern physician's practice

(supported by Boehringer Ingelheim, CME points are not accrued)

Chairperson **Boytsov S.** (Moscow)

- **Arutyunov G.** (Moscow). Heart failure: important and serious cardiovascular complication in type 2 diabetes mellitus.
- **Khalimov Yu.** (Saint-Petersburg). Modern management of type 2 diabetes mellitus: from glucocentric model to concept of total cardiovascular protection.

HALL 3.10

15.30–17.00

SATELLITE SYMPOSIUM**Hot issues of using beta-blockers in clinical practice**

(supported by Merck, CME points are not accrued)

*On-line broadcasting*Chairpersons: **Arutyunov G.** (Moscow), **Koziolova N.** (Perm)

- **Lopatin Yu.** (Volgograd). Heart rate as a prognostic cardiovascular risk factor and marker of hypersympathicotonia.
- **Ostroumova O.** (Moscow). Hypersympathicotonia in peculiar patients: metabolic disorders, CKD, left ventricular hypertrophy.
- **Arutyunov G.** (Moscow). Impact of beta-blockers on cardiovascular death rate: real clinical practice.
- **Koziolova N.** (Perm). Clinical case report: patient with comorbidity.

HALL 4.5

15.30–17.00

SCIENTIFIC SESSION**Urgent cardiology**Chairpersons: **Kosmacheva E.** (Krasnodar), **Yavelov I.** (Moscow)

- **Mullova I., Cherepanova N., Pavlova T., Khokhlunov S., Gnilomedova D., Leksina A., Duplyakov D.** (Samara). Scale GRACE in hospital outcomes risks assessment in patients PATE.
- **Botova S., Pochinka I., Rostova L.** (Nizhny Novgorod). Providing continuation of antithrombotic therapy in STEMI on different stages of medical care.
- **Kozlov S., Dmitriev V., Borodenko E., Molodykh S.** (Ekaterinburg). Application of temporary electrocardiostimulation with coronary guidewire in MI patients undergoing PCI.
- **Konovaltsev E., Lipchenko A.** (Ekaterinburg). Acute thrombotic coronary occlusion in patients with primary NSTEMI at the ECG: prevalence, localization, outcomes.
- **Levedeva O., Kukharchik G.** (Saint-Petersburg). Lymphocytes and NK-cells subpopulations as predictors of development of acute heart failure in patients with acute myocardial infarction.
- **Vyshlov E., Alekseeva Ya., Usov V., Mochula O., Markov V.** (Tomsk). Does thrombolysis increase the frequency of myocardial hemorrhage.

- **Solovyova M., Boldueva S., Leonova I.** (Saint-Petersburg). Embologenic MI and AF.

HALL 4.6

15.30–17.00

BATTLE OF THE SCHOLARS 2019. FINALE

Moderator **Matskeplishvili S.** (Moscow)

Jury: **Garkina S.** (Saint-Petersburg), **Drapkina O.** (Moscow), **Drozdova L.** (Moscow), **Irtyuga O.** (Saint-Petersburg), **Kontsevaya A.** (Moscow), **Lebedev D.** (Tomsk), **Mareev Yu.** (Moscow), **Moiseeva O.** (Saint-Petersburg), **Nikulina S.** (Krasnoyarsk), **Tatarskiy R.** (Saint-Petersburg)

Finalists:

- **Tourette syndrome (Moscow).** Orlov D. (captain), Dadashova E., Angarskiy R., Egorov P., Rogozhkina E.
- **Hearts of Samara (Samara).** Davydova N. (captain), Mullova I., Duplyakova P., Gubareva E., Svechkov N.
- **Core-dinators (Krasnoyarsk).** Maltseva A. (captain), Fedorova T., Adamyan R., Tretyakov K., Shut E.

PLENARY HALL №1

17.30–19.00

PLENARY SESSION

Urgent cardiology – 2019

(in memoriam of Prof. Mikhail Ruda)

On-line broadcasting / Simultaneous translation

Chairpersons: **Goudevenos I.** (Greece), **Tereschenko S.** (Moscow)

- **Goudevenos I.** (Greece). STEMI Interpretation of guideline recommendations. New evidence that has emerged since the guidelines were published.
- **Averkov O.** (Moscow). Myocardial infarction– 2019.
- **Zhirov I.** (Moscow). Acute heart failure – 2019.
- **Golitsyn S.** (Moscow). Arrhythmias – 2019.
- **Yavelov I.** (Moscow). PATE – 2019.

PLENARY HALL №2 (3.2)

17.30–19.00

PLENARY SESSION

Myocarditis: current state of the problem

On-line broadcasting / Simultaneous translation

Chairpersons: **Boytsov S.** (Moscow), **Paleev P.** (Moscow), **Sinisalo J.** (Finland)

- **Sinisalo J.** (Finland). Adult congenital heart disease patient surveillance in Finland.
- **Paleev P.** (Moscow). Project of the Russian guidelines on the diagnosis and treatment of myocarditis.
- **Moiseeva O.** (Saint-Petersburg). Invasive diagnosis of myocarditis: clinical importance for choosing management tactics.
- **Sinitsyn V.** (Moscow). Opportunities and role of MRI in myocarditis diagnosis.
- **Blagova O.** (Moscow). Eosinophile heart diseases.

HALL 2.3

17.30–19.00

SATELLITE SYMPOSIUM

From theory to practice in the treatment of arterial hypertension and chronic heart failure

(supported by Akrikhin, CME points are not accrued)

Chairpersons: **Ageev F.** (Moscow), **Arutyunov G.** (Moscow), **Kobalava Zh.** (Moscow)

- **Ageev F.** (Moscow). Additional clinical effects of sartans in the treatment of patients with cardiovascular disease.
- **Kobalava Zh.** (Moscow). Difficulties and errors in the appointment of diuretics in the treatment of CHF.
- **Arutyunov G.** (Moscow). Role of mineralcorticoid receptor antagonists in the treatment of heart failure.

HALL 3.1

17.30–19.00

SYMPOSIUM

Cardiorespiratory comorbidity

Chairperson **Martynov A.** (Moscow)

- **Martynov A.** (Moscow). Cardiorespiratory comorbidity: traditions of the Russian therapeutic school.
- **Adasheva T.** (Moscow). Heart failure and COPD. Difficulties of diagnosis and features of therapy.
- **Malyavin A.** (Moscow). Hypertension and COPD. Risk management strategies in comorbid patient.
- **Gorbunova M., Adasheva T.** (Moscow). Diagnosis and management of patient with resistant hypertension and obstructive apnea.

HALL 3.3

17.30-19.00

SYMPOSIUM

Management of patients with CHF in elderly and senile age: theory and practice

Chairperson **Belenkov Yu.** (Moscow)

- **Orlova Ya.** (Moscow). Features of management of patients with CHF in elderly and senile age.
- **Tkacheva O.** (Moscow). Role of the geriatrician in a multidisciplinary team in the treatment of heart failure.
- **Kotovskaya Yu.** (Moscow). Drug therapy of heart failure in patients of older age group.
- **Mareev Yu.** (Moscow). Surgical and electrophysiological treatment in elderly patients with CHF.
- **Begrambekova Yu.** (Moscow). Physical rehabilitation of patients with CHF: theory and practice.

HALL 3.4

17.30–19.00

SYMPOSIUM

From hypertension to heart failure: the road of a lifetime

Chairpersons: **Arutyunov G.** (Moscow), **Lopatin Yu.** (Volgograd)

- **Arutyunov G.** (Moscow). How to extend the distance?
- **Lopatin Yu.** (Volgograd). How to «support» the traveler?
- **Nedogoda S.** (Volgograd). How to avoid dangerous turns?

HALL 3.5

17.30–19.00

ROUNDTABLE TOGETHER WITH THE GOVERNMENT OF SVERDLOVSK REGION

Public Health 2020

Chairpersons: **Krekov P.** (Ekaterinburg), **Drapkina O.** (Moscow),
Kontsevaya A. (Moscow)

- **Kontsevaya A.** (Moscow). Promotion of public health in Russia: time for changes.
- **Kozlovskikh D.** (Ekaterinburg). Impact of environment on public health in Sverdlovsk region.
- **Popovich M.** (Moscow). Corporate programmes of health promotion as part of the Public Health Federal Project realization strategy.
- **Bazite I.** (Ekaterinburg). Measures on tobacco consumption control. Experience of Sverdlovsk region.
- **Gurvich V.** (Ekaterinburg). Health of the working population.
- **Runikhina N.** (Moscow). Healthy aging: contribution of geriatrics.
- **Bachinin I.** (Ekaterinburg). Spiritual and ethic education and public health.

HALL 3.6

17.30–19.00

RUSSIAN JOURNAL OF CARDIOLOGY EDITORIAL BOARD MEETING

HALL 3.7

17.30–19.00

SYMPOSIUM

Palliative medicine: problems of arrhythmological care

Chairpersons: **Lebedev D.** (Saint-Petersburg), **Matskeplishvili S.** (Moscow), **Popov S.** (Tomsk), **Sitnikova M.** (Saint-Petersburg)

- **Lebedev D., Lebedeva V.** (Saint-Petersburg). ICD deactivation in patients with terminal heart failure: decision making.
- **Matskeplishvili S.** (Moscow). ICD deactivation in patients with terminal oncological disease: decision making.
- **Sitnikova M.** (Saint-Petersburg). Terminal heart failure. Prognosis and palliative care principles.
- **Lubertseva N.** (Ekaterinburg). Legal aspects of medical care for patients with terminal conditions.

HALL 3.8

17.30–19.00

SYMPOSIUM

Psychosomatic disorders in cardiovascular diseases: diagnosis and correction by medical cardiologists

Chairpersons: **Repin A.** (Tomsk), **Barbarash O.** (Kemerovo)

- **Repin A., Lebedeva E.** (Tomsk). Coronary artery disease patients with depression: Diagnostics, correction and impact on survival. The results of 7 years of observation by a multidisciplinary team of specialists.

- **Pomeshkina S., Lebedeva N., Solodukhin A.** (Kemerovo). Modification of stress reactions in patients before coronary artery bypass grafting.
- **Poponina T., Poponina Yu., Gunderina K.** (Tomsk). Current aspects of the use of antidepressants in patients with acute coronary syndrome.
- **Gorbunova E., Sedykh D.** (Kemerovo). Psychosocial factors of formation of treatment adherence in patients with repeated myocardial infarction.

HALL 3.9

17.30–19.00

TRAINING WORKSHOP

Chest pain at a young age

Chairpersons: **Yakushin S.** (Ryazan), **Shostak N.** (Moscow)

- **Yakushin S.** (Ryazan). Acute stress reactions and MINOCA.
- **Shostak N., Klimenko A.** (Moscow). Vasculitis as a cause of acute coronary syndrome.
- **Filippov E.** (Ryazan). Chest pain, as a manifestation of Fabry disease.
- **Rudoi A.** (Belarus). Acute aortic dissection in patients with connective tissue dysplasia.

HALL 3.10

17.30–19.00

SYMPOSIUM

Stable coronary heart disease: optimization of diagnostics, treatment and prognosis

Chairpersons: **Karpov Yu.** (Moscow), **Panov A.** (Saint-Petersburg)

- **Soboleva G., Gaman S., Ternovoy S., Shariya M., Minasyan A., Karpov Yu.** (Moscow). Volume cardiac CT in combination with pharmacological test of ATP: the place among noninvasive and invasive diagnostic methods of an ischemic heart disease.
- **Kuleshova E., Panov A.** (Saint-Petersburg). Ratio of invasive and conservative methods of treatment of stable coronary artery disease. Selection of patients on a surgical myocardial revascularization according to the Registry of three regions of the Russian Federation.

- **Gostishev R., Soboleva G., Samko A.** (Moscow). Prevention of intraoperative injury of a myocardium in transdermal coronary interventions with stenting of coronary arteries and impact on the long-term forecast in patients with stable coronary artery disease: Nicorandil in focus.
- **Gurevich V.** (Saint-Petersburg). Place of statin and fibrat in correction of residual risks in patients with coronary artery disease and mixed dyslipidemia.

HALL 4.5

17.30–19.00

SCIENTIFIC SESSION Fundamental studies

Chairpersons: **Nikulina S.** (Krasnoyarsk), **Minushkina L.** (Moscow)

- **Mukhomedzyanov A., Tsubulnikov S.** (Tomsk). Role of KATP channels in realization of cardioprotective effect of $\Delta 2$ -opioid receptors agonists.
- **Siverina A., Skorodumova E., Kostenko V., Pivovarova L., Ariskina O., Fedorov A., Skorodumova E., Rysev A.** (Saint-Petersburg). Lethality risk assessment in close and late period in patients with MI and cardiorenal syndrome based on NOS3 and APOE genes polymorphism.
- **Shakhtshneider E., Ivanoschuk D., Kashtanova E., Ragino Yu., Polonskaya Ya., Chernyavskiy A., Voevoda M.** (Novosibirsk). Data analysis of full-genome sequencing of plaques RNA of coronary arteries.
- **Vasilevskiy Yu., Simakov S., Gamilov T., Pryamonosov R.** (Moscow). Method of virtual assessment of fractional flow reserve.
- **Berg V., Nabiev S., Koscheeva O., Nikitina L., Bershitskiy S., Schepkin D., Kopylova G.** (Ekaterinburg). Impact of cardiac myosin activator CK-1827452 on its interaction with thin filomen.
- **Nazarenko M., Markov A., Sleptsov A., Koroleva Yu., Zarubin A., Sharysh D., Valiakhmetov N., Salakhov R., Kucher A.** (Tomsk), **Kazantsev A., Burkov N., Tarasov R., Barbarash O.** (Kemerovo), **Puzyrev V.** (Tomsk). Identification of molecular targets of complicated atherosclerosis.
- **Dementieva E., Kovalenko V., Vyatkin Yu., Kretov E.** (Novosibirsk), **Slotvitskiy M.** (Dolgoprudniy), **Medvedev S., Shtokalo D., Pokushalov E., Zakiyan S.** (Novosibirsk). Creation of hypertrophic cardiomyopathy model based on patient-specific induced pluripotent stem cells.

HALL 4.6

17.30-19.00

BATTLE OF THE SCHOLARS 2019. FINALE

Moderator **Matskeplishvili S.** (Moscow)

Jury: **Garkina S.** (Saint-Petersburg), **Drapkina O.** (Moscow),

Drozdova L. (Moscow), **Irtyuga O.** (Saint-Petersburg),

Kontsevaya A. (Moscow), **Lebedev D.** (Tomsk), **Mareev Yu.** (Moscow),

Moiseeva O. (Saint-Petersburg), **Nikulina S.** (Krasnoyarsk), **Tatarskiy R.** (Saint-Petersburg)

Finalists:

- **Tourette syndrome (Moscow).** Orlov D. (captain), Dadashova E., Angarskiy R., Egorov P., Rogozhkina E.
- **Hearts of Samara (Samara).** Davydova N. (captain), Mullova I., Duplyakova P., Gubareva E., Svechkov N.
- **Core-dinators (Krasnoyarsk).** Maltseva A. (captain), Fedorova T., Adamyan R., Tretyakov K., Shut E.



Time	Plenary Hall №1	Plenary Hall №2 (3.2)	Hall 2.3	Hall 3.1	Hall 3.3	Hall 3.4	Hall 3.5	Hall 3.6	Hall 3.7	Hall 3.8	Hall 3.9	Hall 3.10	Hall 4.5	Hall 4.6
ONSITE REGISTRATION OF PARTICIPANTS OPENS AT 08.00 (MAIN ENTRANCE)														
09.00–10.30	Plenary Session Fundamental cardiology <small>On-line broadcasting / Simultaneous translation</small>	Plenary Session Heart failure 2019: HF patients care in the world and in the Russian Federation <small>On-line broadcasting / Simultaneous translation</small>	Training seminar Nursing in Cardiology	Symposium Atrial fibrillation and age	Russian-Belarusian symposium Interdisciplinary problems in cardiology	Symposium Evidence-based medicine and real practice	Round table Integration of professional medical communities and associated RSC societies for clinical guidelines development	Symposium Modern technologies of echocardiography for a practicing cardiologist	Symposium Nutrition in management of patients with cardiovascular diseases	Symposium Cognitive status in patients with cardiovascular diseases: a cardiologist's opinion	Symposium Myocarditis and cardiomyopathy with DCM phenotype	Symposium Iatrogenic cardiomyopathy and nephropathy in a polymorbid patient with cardiovascular diseases	Scientific session Arrhythmology, stimulation, resynchronization	Symposium Genetic studies: does a cardiologist need them?
10.30–11.00 BREAK														
11.00–12.30	Plenary Session Epidemiology as the basis of prevention <small>On-line broadcasting / Simultaneous translation</small>	Satellite symposium OAC in thrombosis associated diseases as an extension of treatment options <small>(supported by Pfizer, CME points are not accrued)</small>	Training seminar The role of nurse practitioners in improving accessibility, quality and safety of cardiological care: the experience of Russian regions	Satellite symposium Secrets of the female planet. What to consider when managing a female AF patient <small>(supported by Bayer, CME points are not accrued)</small>	Scientific Session Modern heart science: from translational research to personalized cardiology. Part 3 <small>Simultaneous translation</small>	Symposium Primary cardiomyopathies: rare forms and combinations	Symposium Patient with heart failure at a doctor's office: solving problems, correcting mistakes	Symposium Actual issues of cardioreumatology	Satellite symposium Court session: modern medicine against arterial hypertension <small>(supported by Berlin Chemie, CME points are not accrued)</small>	Symposium Patient with pulmonary hypertension, a comprehensive view	Symposium Aspects of acute coronary syndrome treatment in 80+ age	Master class Expanding the horizons of clinical echocardiography	Scientific session Arterial hypertension, metabolic syndrome, diabetes	Symposium Remote monitoring in cardiology
12.40–13.20	Plenary lecture Djordjevic-Dikic A. (Sebia). Moderator: Galyavich A. (Kazan) <small>On-line broadcasting / Simultaneous translation</small>	Plenary lecture Moutiris J. (Cyprus). Moderator: Yakushin S. (Ryazan) <small>On-line broadcasting / Simultaneous translation</small>												
12.30–13.30 BREAK														

09.00–15.00 / Hall 4.4

Rapid Fire Abstracts

Time	Plenary Hall №1	Plenary Hall №2 (3.2)	Hall 2.3	Hall 3.1	Hall 3.3	Hall 3.4	Hall 3.5	Hall 3.6	Hall 3.7	Hall 3.8	Hall 3.9	Hall 3.10	Hall 4.5	Hall 4.6
13.30–15.00	<p>Plenary Session Challenges of modern arrhythmology</p> <p>On-line broadcasting / Simultaneous translation</p>	<p>Symposium Mortality reduction technology in patients with arterial hypertension depending on the comorbid pathology. Patient with hypertension and diabetes mellitus, CHF, AF and COPD at a doctor</p>	<p>Symposium SCD prevention in daily cardiological practice. Experts dialogue</p>	<p>Satellite symposium Do we use all opportunities for reducing CVD risk in patients after myocardial infarction?</p> <p>(supported by Amgen, CME points are not accrued)</p> <p>On-line broadcasting</p>	<p>Symposium Cardiovascular disease in Russia: risk factors and treatment in international perspective</p> <p>Simultaneous translation</p>	<p>Symposium Registries in acute cardiac care</p>	<p>Working meeting</p>	<p>Symposium Adult congenital heart diseases – multidisciplinary approach</p>	<p>Symposium Non-drug management of heart failure – a mandatory option</p>	<p>Symposium From dawn to flowering: new opportunities in the diagnosis and management of patients with familial hypercholesterolemia</p>	<p>Symposium Sarcopenia and myopenia as a new syndrome in the clinic of internal diseases: the impact on the CVD course</p>	<p>Symposium Pitfalls in diagnostics and treatment methods in patients with hypertrophic cardiomyopathy – part I</p>	<p>Session of the Society of Heart Failure Specialists</p>	<p>Symposium Indications and control of the primary prevention effectiveness in atherosclerosis: «target» values or vascular imaging?</p>
15.00–15.30 BREAK							15.00–15.30 BREAK							
15.30–17.00	<p>Plenary Session Cardiological patient through the prism of polymorbidity: insufficiently studied and difficult issues</p> <p>On-line broadcasting / Simultaneous translation</p>	<p>Symposium Complex and unresolved issues of antithrombotic therapy</p>	<p>Symposium The long-term prognosis in patients with coronary heart disease after the coronary flow recovery</p>	<p>Symposium of the ESC Heart Failure Specialists of Tomorrow (HOT) Heart failure clinics – current condition in the Russian Federation and the world and things to expect in the future</p>	<p>Symposium Classics and innovations in modern vascular surgery</p> <p>Simultaneous translation</p>	<p>Symposium Controversial and unresolved issues of hypertension treatment: new guidelines perspective</p>	<p>Symposium Rare causes of chronic heart failure at a young age</p>	<p>Symposium Cardiogenic shock. Unresolved problems and possible solutions</p>	<p>Symposium Cardiovascular risks in professional sport</p>	<p>Symposium Sudden death: from cardiomyopathies to channelopathies</p>	<p>Symposium Work of multidisciplinary team in the perioperative management of cardiac surgery patients</p>	<p>Symposium Pitfalls in diagnostics and treatment decision-making in patients with hypertrophic cardiomyopathy. Part 2</p>	<p>Scientific session Imaging in cardiology, ultrasound and tomography</p>	<p>Symposium Current questions of psychocardiology</p>
17.00–17.15 BREAK							17.00–17.15 BREAK							
17.15–19:00	<p>Plenary Session Innovations in cardiology2019</p> <p>On-line broadcasting / Simultaneous translation</p>													

PLENARY HALL №1

09.00–10.30

PLENARY SESSION Fundamental cardiology

On-line broadcasting / Simultaneous translation

Chairpersons: **Zateyschikov D.A.** (Moscow), **Galagudza M.M.** (Saint-Petersburg)

- **Kohl P.** (Germany). The mechano-sensitive heart: mechanisms of cardiac mechano-electric coupling.
- **Efimov I.** (USA). Bioinformatics of heart diseases.
- **Parfenova E.V.** (Moscow). Epicardium as a target for affecting regenerative heart processes.
- **Kostareva A.A.** (Saint-Petersburg). Molecular mechanisms of cardiomyopathies.

PLENARY HALL №2 (3.2)

09.00–10.30

PLENARY SESSION Heart failure 2019: HF patients care in the world and in the Russian Federation

On-line broadcasting / Simultaneous translation

Chairpersons: **Belenkov Yu.N.** (Moscow), **Lopatin Yu.M.** (Volgograd)

- **Tereshchenko S.N.** (Moscow). The problem of heart failure in the world and the Russian Federation.
- **Lopatin Yu.M.** (Volgograd). Optimization of HF patients' management.
- **Sitnikova M.Yu.** (Saint-Petersburg). Experience of the federal HF clinic.
- **Fomin I.V.** (Nizhny Novgorod). Experience of the regional HF clinic.
- **Mirrahimov E.M.** (Kyrgyzstan). Specific management aspects for HF patients with obstructive pulmonary disease.

HALL 2.3

09.00–10.30

TRAINING SEMINAR Nursing in Cardiology

Chairpersons: **Levina I.A.** (Ekaterinburg), **Dvonikov S.I.** (Samara)

- **Levina I.A.** (Ekaterinburg). The social campaign #Dobrovselo (Kindness to the countryside) as a real resource for CVD prevention in the population of rural areas.
- **Ivanov V.M.** (Chelyabinsk). Compliance difficulties in cardiac patients.
- **Dmitrievyh T.G.** (St. Petersburg). Nurse's participation role in the organization of the Health School for patients with CVD.
- **Ryabova N.A.** (Tyumen). Responsibility of a nurse in CVD prevention (results of the Presidential grant "STOP Hypertension").
- **Vapzhenina E.I.** (Novosibirsk). Early activation of patients with coronary heart disease after CABG in early postoperative period.
- **Kuznetsova N.A.** (Krasnodar). Rehabilitation of patients after CABG in Research Institute — Regional Clinical Hospital №1 named after Professor S.V. Ochapovsky

HALL 3.1

09.00–10.30

SYMPOSIUM Atrial fibrillation and age

Chairpersons: **Lebedev D.S.** (Saint-Petersburg), **Shkolnikova M.A.** (Moscow), **Tkacheva O.N.** (Moscow)

- **Solovieva O.E.** (Ekaterinburg), **Lebedev D.S.** (Saint-Petersburg). Mechanisms of atrial fibrillation and age: from molecule and cell to patient and population.
- **Shkolnikova M.A.** (Moscow). Atrial fibrillation in children: clinical problems and evidence-based medicine.
- **Termosesov S.A.** (Moscow). Approaches to interventional treatment of atrial fibrillation in children.
- **Vavilova T.V.** (Saint-Petersburg). Anticoagulation treatment in atrial fibrillation: from pediatrician to gerontologist.

- **Vorobieva N.M.** (Moscow). Fragile patient with atrial fibrillation: which anticoagulant for stroke prevention?
- **Mikhaylov E.N.** (Saint-Petersburg). Rhythm control in elderly patients with atrial fibrillation: focus on interventional treatment.

HALL 3.3

09.00-10.30

RUSSIAN-BELARUSIAN SYMPOSIUM Interdisciplinary problems in cardiology

Chairpersons: **Arutyunov G.P.** (Moscow), **Mitkovskaya N.P.** (Belarus)

- **Arutyunov G.P.** (Moscow). Fibrillation of auricles in patients with comorbid pathology.
- **Mitkovskaya N.P.** (Belarus). Rethromboses after the reperfusion of the infarct related artery in comorbid patients.
- **Koziołova N.A.** (Perm). Stable ischemic heart disease in conditions of comorbid pathology. Time to change recommendations?
- **Grigorenko E.A.** (Belarus). Hepatocardial continuum: from the liver dysfunction to heart failure.

HALL 3.4

09.00–10.30

SYMPOSIUM Evidence-based medicine and real practice

Chairpersons: **Martsevich S.Yu.** (Moscow), **Galyavich A.S.** (Kazan)

- **Martsevich S.Yu.** (Moscow). Evidence-based medicine about modern evidence in treatment.
- **Yakusevich V.V.** (Yaroslavl). Evidence-based medicine — dogma or guide to action?
- **Galyavich A.S.** (Kazan). Statins in the first day of a myocardial infarction — as soon as possible?

HALL 3.5

09.00–10.30

ROUND TABLE

Integration of professional medical communities and associated RSC societies for clinical guidelines development

Chairpersons: **Shlyakhto E.V.** (Saint-Petersburg),
Nedogoda S.V. (Volgograd)

HALL 3.6

09.00–10.30

SYMPOSIUM

Modern technologies of echocardiography for a practicing cardiologist

Chairpersons: **Saidova M.A.** (Moscow), **Oleynikov V.E.** (Penza),
Vasyuk Y.A. (Moscow)

- **Saidova M.A.** (Moscow), **Avalyan A.A.** (Moscow), **Oshepkova E.V.** (Moscow). Comparative evaluation of left ventricular myocardial deformation according to 2D and 3D Speckle-Tracking Echo as a marker of subclinical cardiotoxicity.
- **Pavlyukova E.N.** (Tomsk), **Evtushenko A.V.** (Tomsk). Clinical significance of the volumetric anatomy of the mitral valve in patients with mitral regurgitation.
- **Galimskaya V.A.** (Penza), **Golubeva A.V.** (Penza), **Oleynikov V.E.** (Penza). New approaches in assessing left ventricular contractility using 3D speckle echocardiography.
- **Skidan V.I.** (Khabarovsk), **Pavlyukova E.N.** (Tomsk), **Narcissova G.** (Novosibirsk). The right ventricle contractility dysfunction in prognosis assessing in HF patients with a reduced ejection fraction and implanted devices.
- **Stepanova A.I.** (Moscow), **Radova N.F.** (Moscow), **Alekhin M.N.** (Moscow). Opportunities and limitations of speckle tracking stress echocardiography.

- **Guseva O.A.** (Saint-Petersburg), **Mamaeva O.P.** (Saint-Petersburg), **Pavlova N.E.** (Saint-Petersburg), **Lebedeva S.V.** (Saint-Petersburg), **Scherbak S.G.** (Saint-Petersburg). Modern diagnostic technology in dynamic observation of patients with acute coronary syndrome after percutaneous coronary intervention.

HALL 3.7

09.00–10.30

SYMPOSIUM

Nutrition in management of patients with cardiovascular diseases

Chairpersons: **Starodubova A.** (Moscow),
Konradi A. (Saint-Petersburg), **Shalnova S.** (Moscow)

- **Starodubova A.** (Moscow). Recommendations for therapeutic and preventive nutrition in cardiovascular diseases: realities and prospects.
- **Orlov A.** (Saint-Petersburg), **Rotar O.** (Saint-Petersburg), **Konradi A.** (Saint-Petersburg). The results of different methodological approaches to studying the nutrition profile in the Russian population in connection with risk factors for cardiovascular disease.
- **Karamnova N.** (Moscow), **Shalnova S.** (Moscow). Individual and population eating habits associated with arterial hypertension.
- **Ostroumova O.** (Moscow). Drugs-food interaction.
- **Leiderman I.** (Ekaterinburg). Nutritive support in cardiology – for whom and for what?

HALL 3.8

09.00–10.30

SYMPOSIUM

Cognitive status in patients with cardiovascular diseases: a cardiologist's opinion

Chairpersons: **Barbarash O.** (Kemerovo), **Davidivich I.** (Khabarovsk),
Garganeeva N. (Tomsk)

- **Barbarash O.** (Kemerovo), **Trubnikova O.** (Kemerovo). Effects of physical training in prevention of cognitive dysfunction in patients with coronary heart disease.
- **Davidivich I.** (Khabarovsk). Cognitive functions in patients with atrial fibrillation and constant pacemaker: anticoagulant therapy effect.
- **Petrova M.** (Krasnoyarsk), **Kaskaeva D.** (Krasnoyarsk). The variety of clinical situations and therapy of cognitive disorders after coronary artery bypass surgery.
- **Chumakova G.** (Barnaul), **Demenko T.** (Barnaul). The risk and mechanisms of development of cognitive functions in various forms of atrial fibrillation.

HALL 3.9

09.00–10.30

SYMPOSIUM

Myocarditis and cardiomyopathy with DCM phenotype

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Blagova O.** (Moscow)

- **Titov V.** (Saint-Petersburg), **Runov A.** (Saint-Petersburg), **Vonsky M.** (Saint-Petersburg), **Moiseeva O.** (Saint-Petersburg). The clinical significance of the study of gene expressions in myocardial biopsy specimens in patients with myocarditis.
- **Lutokhina Y.** (Moscow), **Blagova O.** (Moscow). The value of myocarditis in ARVD clinical forms and approaches to its treatment.
- **Blagova O.** (Moscow), **Solovieva E.** (Moscow). Course, outcomes and predictors of negative events in DCM syndrome depending on its etiology.
- **Miasnikov R.** (Moscow), **Kulikova O.** (Moscow), **Kharlap M.** (Moscow), **Meshkov A.** (Moscow), **Mershina E.** (Moscow). Noncompact myocardium of the left ventricle. Clinical and genetic data of a multicenter register.
- **Polyak M.** (Moscow), **Zakliazminskaya E.** (Moscow). The mutations spectrum in the left ventricular noncompaction syndrome and various remodeling options.

HALL 3.10

09.00–10.30

SYMPOSIUM**Iatrogenic cardiomyopathy and nephropathy
in a polymorbid patient with cardiovascular diseases**

Chairpersons: **Tarlovskaya E.** (Nizhny Novgorod), **Petrova M.** (Krasnoyarsk)

- **Koziolova N.** (Perm). Diabetic cardiomyopathy: what is the role of glucose-lowering therapy?
- **Rebrov A.** (Saratov). Non-steroidal anti-inflammatory drugs and cardiovascular diseases — is long-term therapy possible?
- **Chesnikova A.** (Rostov-on-Don). Complications of lipid-lowering therapy for hypothyroidism.
- **Arutunov A.** (Moscow). Long-term treatment of PPI in a cardiac patient, potential and supposed risks.

HALL 4.5

09.00–10.30

SCIENTIFIC SESSION**Arrhythmology, stimulation, resynchronization**

Chairpersons: **Popov S.V.** (Tomsk), **Duplyakov D.V.** (Samara)

- **Lebedev D.I., Mishkina A.I., Lebedeva M.V., Popov S.V.** (Tomsk). Cardiac resynchronization therapy in patients with non-ischemic cardiomyopathy and severe heart failure can affect on the paroxysms of unstable ventricular tachycardia.
- **Chichkova T.Yu., Mamchur S.E., Romanova M.P.** (Kemerovo). Clinical efficacy of cryoballoon and radiofrequency isolation of pulmonary veins in atrial fibrillation treatment.
- **Kirgizova M.A., Dedkova A.A., Kisteneva I.V., Krivolapov S.N., Popov S.V.** (Tomsk). Efficacy and safety of interventional treatment of cardiac arrhythmias in pregnant women.
- **Loginova A.I., Kropacheva E.S., Maykov E.B., Balakhonova T.V.** (Moscow). Venous thrombosis in patients after intracardiac catheter interventions. Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy.

- **Utsumueva M.D., Mironova N.A., Stukalova O.V., Kashtanova S.Yu., Tarasovsky G.S., Butorova E.A., Gaman S.A., Ternova S.K., Golitsyn S.P.** (Moscow). Electrophysiological and structural features of heart in patients with chronic HF and various efficacy of cardiac resynchronization therapy.
- **Mironova E.S., Mironova N.A., Sharf T.V., Mironov N.Yu., Lajovich L.Yu., Sokolov S.F., Zykov K.A., Golitsyn S.P.** (Moscow). Autoantibodies to M2-cholinergic receptors as a potential factor in the development of arrhythmias in patients with paroxysmal atrial fibrillation.

HALL 4.6

09.00–10.30

SYMPOSIUM

Genetic studies: does a cardiologist need them?

Chairpersons: **Aksyutina N.** (Krasnoyarsk), **Minushkina L.** (Moscow), **Nikulina S.** (Krasnoyarsk)

- **Shulman V.** (Krasnoyarsk), **Aksyutina N.** (Krasnoyarsk), **Aldanova E.** (Krasnoyarsk), **Nikulina S.** (Krasnoyarsk), **Maksimov V.** (Novosibirsk). New genetic predictors of atrial fibrillation: chromosome 4q2 polymorphism rs2200733.
- **Minushkina L.** (Moscow), **Brazhnik V.** (Moscow), **Zubova E.** (Moscow), **Rogozhina A.** (Moscow), **Zateyshchikov D.** (Moscow). Do genetic factors matter in assessing atherothrombotic risk in acute coronary syndrome? Data of the ORAKUL registry.
- **Aksyutina N.** (Krasnoyarsk), **Shulman V.** (Krasnoyarsk), **Aldanova E.** (Krasnoyarsk), **Nikulina S.** (Krasnoyarsk), **Maksimov V.** (Novosibirsk). Genetic markers of effective catheter ablation of the mouths of pulmonary veins in atrial fibrillation.
- **Chumakova O.** (Moscow). Sarcomeric hypertrophic cardiomyopathy or transthyretin amyloidosis of heart: clinical and genetic keys to the diagnosis.
- **Fedorova A.** (Chita), **Serebryakova O.** (Chita). Prediction of atrial fibrillation risk in women with coronary heart disease and comorbid endocrine pathology.
- **Kozik V.** (Novosibirsk), **Lozhkina N.** (Novosibirsk), **Tolmacheva A.** (Novosibirsk). Acute myocardial infarction: the role of genetic polymorphisms.
- **Lifshitz G.** (Novosibirsk), **Koch N.** (Novosibirsk), **Kovaleva A.** (Novosibirsk), **Donirova O.** (Ulan-Ude), **Protasov K.** (Irkutsk). The link between genetic factors and hypertension severity and complications including ethnic factor.

PLENARY HALL №1

11.00–12.30

PLENARY SESSION

Epidemiology as the basis of prevention

On-line broadcasting / Simultaneous translation

Chairpersons: **Drapkina O.M.** (Moscow), **Shalnova S.A.** (Moscow)

- **Martsevich S.S.** (Moscow). CVD registers in Russia. Yesterday, Today, Tomorrow.
- **Shkolnikova M.A.** (Moscow). Population aspects of ventricular arrhythmias in Russia.
- **Smolensky A.V.** (Moscow). Cardiovascular risks in professional sports.
- **Leon D.** (the UK). Opportunities for reducing CVD damage in the Russian Federation: results of a 5-year randomized international study.

PLENARY HALL №2 (3.2)

11.00–12.30

SATELLITE SYMPOSIUM

OAC in thrombosis associated diseases as an extension of treatment options

(supported by Pfizer, CME points are not accrued)

Chairperson: **Panchenko E.P.** (Moscow)

- **Duplyakov D.V.** (Samara). Confirmation or addition: study of real practice and clinical research.
- **Panchenko E.P.** (Moscow). Special groups of patients with VTE: what can OAC offer?
- **Yavelov I.S.** (Moscow). Apixaban: safety in different patients' categories.

HALL 2.3

11.00–12.30

TRAINING SEMINAR

The role of nurse practitioners in improving accessibility, quality and safety of cardiological care: the experience of Russian regions

Chairpersons: **Levina I.A.** (Ekaterinburg), **Dvoynikov S.I.** (Samara)

- **Storozhenko A.V.** (Ekaterinburg). ACS in the practice of nurse practitioner of the emergency ambulance service. Experience of the Sverdlovsk region.
- **Elizarova Z.S.** (Cheboksary). The role of nursing staff in patients' preparation for coronary angiography in acute coronary syndrome.
- **Badretdinova M.A.** (Ufa). The participation of nursing staff in specialized care for patients with ACS in the Republic of Bashkortostan.
- **Mysina S.A.** (Ryazan). Organization of the nursing staff work in high-tech medical care to patients with ACS in the Ryazan Region "Regional Clinical Cardiology Dispensary".
- **Pyryeva E.V., Nesterova S.E.** (Nizhny Novgorod). Aspects of assisting cardiological patients in the Clinical Diagnostic Centre.
- **Shakhvorstova O.P.** (Surgut). Nurses in the cardiac surgery department. New logistic approaches to the treatment process.
- **Kokareva I.A.** (Penza) Safe environment as a factor of improving nursing care quality at the cardiology department of a multidisciplinary medical organization.

HALL 3.1

11.00–12.30

SATELLITE SYMPOSIUM**Secrets of the female planet. What to consider when managing a female AF patient**

(supported by Bayer, CME points are not accrued)

Chairperson: **Glezer M.G.** (Moscow)

- **Tapilskaya N.I.** (Saint-Petersburg). Life is wonderful: Anticoagulant therapy at different stages of a woman's reproductive cycle.
- **Gilyarevsky S.R.** (Moscow). The Invisible Side: How does patient weight affect medical tactics?
- **Glezer M.G.** (Moscow). The Dark Knight: A patient with AF and diabetes at a doctor. What to consider when choosing anticoagulant therapy?
- **Grachev V.G.** (Ekaterinburg). Elderly patient with AF: let's show everything that is hidden.

HALL 3.3

11.00-12.30

SCIENTIFIC SESSION**Modern heart science: from translational research to personalized cardiology. Part 3***Simultaneous translation*Chairpersons: **Shlyakhto E.** (Saint-Petersburg), **Popov S.** (Tomsk)

- **Kohl P.** (Germany). Imaging of cardiac structure and function: from nanometre dynamics to whole heart behaviour
- **Efimov I.** (USA). Digital cardiology
- **Panfilov A.** (Belgium). Combination of in-silico and in-vitro approaches to the study of the mechanisms of cardiac arrhythmia.
- **Lebedev D.** (Saint-Petersburg), **Zubarev S.** (Saint-Petersburg). Integral imaging and mathematical modeling — the fundamental basis of the arrhythmology of the future
- **Solovyova O.** (Ekaterinburg), **Idov E.** (Ekaterinburg), **Mikhaylov S.** (Ekaterinburg), **Chumarnaya T.** (Ekaterinburg). Functional geometry of the left ventricle for evaluation of its dysfunction.

HALL 3.4

11.00–12.30

SYMPOSIUM

Primary cardiomyopathies: rare forms and combinations

Chairpersons: **Zaklyazminskaya E.** (Moscow), **Zateyshchikov D.** (Moscow)

- **Zaklyazminskaya E.** (Moscow). «One patient — one genetic diagnosis» — outgoing concept?
- **Blagova O.** (Moscow), **Sedov V.** (Moscow), **Dashinemaeva L.** (Moscow), **Kogan E.** (Moscow). Cardiomyopathy with restrictive-hypertrophic phenotype and initial morphological diagnosis amyloidosis in women with Danone disease.
- **Vasichkina E.** (Saint-Petersburg), **Vershinina T.** (Saint-Petersburg), **Zaklyazminskaya E.** (Moscow), **Kostareva A.** (Saint-Petersburg), **Pervunina T.** (Saint-Petersburg). Restrictive cardiomyopathy and congenital heart disease in pediatric patient with new mutation in the FLNC gene.
- **Makarov L.** (Moscow). Atrial standstill in children.
- **Komolyatova V.** (Moscow). Familial case of A-V block in twins.
- **Rumyantseva V.** (Moscow). Dilated cardiomyopathy in patients with systemic connective tissue disorders.

HALL 3.5

11.00–12.30

SYMPOSIUM

Patient with heart failure at a doctor's office: solving problems, correcting mistakes

Chairpersons: **Skibitskiy V.** (Krasnodar), **Chesnikova A.** (Rostov-on-Don)

- **Skibitskiy V.** (Krasnodar). Patients with various forms of CHF: therapy problems or how to avoid mistakes?
- **Chesnikova A.** (Rostov-on-Don). Patient with CHF and ventricular arrhythmia at a doctor's office: how to avoid mistakes and improve the prognosis?

- **Fendrikova A.** (Krasnodar). Patient with CHF and obesity at the doctor's office: are there any particular treatment options?
- **Statsenko M.** (Volgograd). Patient with CHF and kidney dysfunction at the doctor's office: drugs choice.

HALL 3.6

11.00–12.30

Symposium

Actual issues of cardiorheumatology

Chairpersons: **Shostak N.** (Moscow), **Karpova N.** (Moscow), **Klimenko A.** (Moscow)

- **Shostak N.** (Moscow), **Karpova N.** (Moscow), **Rashid M.** (Moscow). Calcific aortic stenosis. Real clinical practice and modern recommendations.
- **Klimenko A.** (Moscow), **Aksyonova A.** (Moscow). Chronic rheumatic heart disease — problems of stratification of severity and clinical outcomes.
- **Anichkov D.** (Moscow), **Muradyants A.** (Moscow), **Timofeev V.** (Moscow). Rheumatoid arthritis and arterial hypertension.
- **Demidova N.** (Москва), **Klimenko A.** (Moscow). Autoimmune chronic thromboembolic pulmonary hypertension as a subtype of the disease, diagnostic algorithm.
- **Kondrashov A.** (Moscow), **Loginova T.** (Moscow). Gout and cardiovascular events.
- **Chipigina N.** (Moscow), **Pravdyuk N.** (Moscow), **Andriyashkina D.** (Moscow). Infectious endocarditis and spondylodiscitis: clinical observation.

HALL 3.7

11.00–12.30

SATELLITE SYMPOSIUM

Court session: modern medicine against arterial hypertension

(supported by Berlin Chemie, CME points are not accrued)

Chairperson (judge): **Lopatin Yu.M.** (Volgograd)

- **Arutyunov G.P.** (Moscow). Prosecution witness: kidneys. Is there any chance to prevent the crime?
- **Nedogoda S.V.** (Volgograd). Prosecution witness: metabolic syndrome. Is there any chance to prevent the crime?
- **Ratova L.G.** (Saint-Petersburg). Prosecution witness: endothelium. Is there any chance to prevent the crime?

HALL 3.8

11.00–12.30

SYMPOSIUM

Patient with pulmonary hypertension, a comprehensive view

Chairpersons: **Martynyuk T.V.** (Moscow),
Moiseeva O.M. (Saint-Petersburg)

- **Martynyuk T.V.** (Moscow). Pulmonary hypertension — from recommendations to clinical practice.
- **Moiseeva O.M.** (Saint-Petersburg). Patient pathway from acute pulmonary embolism to CTEH.

HALL 3.9

11.00–12.30

SYMPOSIUM

Aspects of acute coronary syndrome treatment in 80+ age

Chairpersons: **Kosmacheva E.** (Krasnodar), **Erlikh A.** (Moscow),
Khripun A. (Rostov-on-Don)

- **Namitkov A.** (Krasnodar), **Enaldieva D.** (Krasnodar), **Kruchinova S.** (Krasnodar), **Raff S.** (Krasnodar), **Kosmacheva E.** (Krasnodar). The results of treatment of ACS in patients «80 +» in the conditions of the PCI-center 24/7.
- **Erlikh A.** (Moscow). The combination of ACS and atrial fibrillation in an elderly patient.

- **Kashtalap V.** (Kemerovo), **Zykov M.** (Kemerovo). Multimorbidity in patients with ACS older than 80 years. Own register research data.
- **Khripun A.** (Rostov-on-Don). Specifics of an elderly patient with ACS and dementia. Differential diagnosis, treatment and prognosis.
- **Namitokov A.** (Krasnodar), **Fetisova V.** (Krasnodar), **Kruchinova S.** (Krasnodar), **Raff S.** (Krasnodar), **Kosmacheva E.** (Krasnodar). The use of prognostic scales in real clinical practice in patient 80+ age. Expectations and reality.

HALL 3.10

11.00–12.30

MASTER CLASS

Expanding the horizons of clinical echocardiography

Chairpersons: **Pavlyukova E.** (Tomsk), **Saidova M.A.** (Moscow)

- **Saidova M.A.** (Moscow). Contrast echocardiography: all secrets becomes clear.
- **Pavlyukova E.** (Tomsk). Echocardiography role in evaluation of surgical treatment in patients with HCM.
- **Skidan V.** (Khabarovsk). Rare inborn cardiomyopathy: isolated left ventricular apical hypoplasia.

HALL 4.5


11.00–12.30

SCIENTIFIC SESSION

Arterial hypertension, metabolic syndrome, diabetes

Chairpersons: **Konradi A.O.** (Saint-Petersburg), **Chumakova G.A.** (Barnaul)

- **Kovalev D.V., Skibitsky V.V., Kurzanov A.N., Ponomareva A.I.** (Krasnodar). Data of the BP daily profile in patients with AH and comorbid depression on the background of antihypertensive therapy with antidepressants.



- **Ionin V.A., Zaslavskaya E.L., Ma I., Skuridin D.S., Filatova A.G., Ivanova A.A., Bliznyuk O.I., Petrishcheva E.Yu., Baranova E.I., Shlyakhto E.V.** (Saint-Petersburg). Clinical aspects of the atrial fibrillation course in patients with metabolic syndrome: what is the role of galectin-3?
- **Tkachenko K.G., Erlikh A.D., Kislyak O.A.** (Moscow). The role of behavioral CVD risk factors in public health care professionals.
- **Ionov M.V., Dubinina E.A., Tregubenko I.A., Khromov-Borisov N.N., Zvartau N.E., Konradi A.O.** (St. Petersburg). Creation and validation of a disease-specific questionnaire for patients with arterial hypertension.
- **Falkovskaya A.Yu., Mordovin V.F., Pekarsky S.E., Baev A.E., Ripp T.M., Lichikaki V.A., Sitkova E.S., Zyubanova I.V., Gusakova A.M., Manukyan M.A.** (Tomsk). Resistant arterial hypertension and diabetes mellitus: possibilities of distal renal denervation in renal risk management.
- **Falkovskaya A.Yu., Mordovin V.F., Ryumshina N.I., Pekarsky S.E., Ripp T.M., Lichikaki V.A., Sitkova E.S., Zyubanova I.V., Gusakova A.M., Manukyan M.A., Bayev A.E.** (Tomsk). Renal denervation can reduce the severity of MRI signs of vascular wall damage in patients with resistant arterial hypertension associated with type 2 diabetes mellitus.
- **Mamontov O.V.** (St. Petersburg). Efficiency and safety of BP daily profile correction using the apparatus for electrical stimulation ABP-051.

HALL 4.6

11.00–12.30

SYMPOSIUM

Remote monitoring in cardiology

Chairpersons: **Kopylov Ph.** (Moscow), **Pogosova N.** (Moscow)

- **Pogosova N.** (Moscow). Telemedicine technologies in secondary prevention of CAD.
- **Chomakhidze P.** (Moscow). Telerehabilitation: is it already a reality?
- **Kopylov Ph.** (Moscow). Remote monitoring in cardiology.

PLENARY HALL №1

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

- **Ana Djordjevic Dikic** (Serbia). Noninvasive functional and prognostic estimation of CAD in challenging pathological scenarios.
Moderator: **Galyavich A.S.** (Kazan)

PLENARY HALL №2 (3.2)

12.40–13.20

PLENARY LECTURE

On-line broadcasting / Simultaneous translation

- **Moutiris J.** (Cyprus). Secondary prevention of coronary artery disease in Cyprus.
Moderator: **Yakushin S.S.** (Ryazan)

PLENARY HALL №1

13.30–15.00


PLENARY SESSION

Challenges of modern arrhythmology

On-line broadcasting / Simultaneous translation

Chairpersons: **Revishvili A.Sh.** (Moscow), **Popov S.V.** (Tomsk), **Golitsyn S.P.** (Moscow), **Lebedev D.S.** (Saint-Petersburg), **Rolf S.** (Germany)

- **Mikhailov E.N.** (Saint-Petersburg). Translational approaches in the diagnosis and treatment of arrhythmias, heart failure and syncope.
- **Artyukhina E.A.** (Moscow). Hybrid approach to atrial fibrillation treatment.



- **Batalov R.E.** (Tomsk). Etiopathogenetic aspects of atrial fibrillation treatment.
- **Rolf S.** (Germany). Impact of new tools and technologies on catheter ablation efficacy and safety.
- **Pevzner A.V.** (Moscow). Conduction and heart rhythm disorders in patients with obstructive sleep apnea syndrome. Clinical significance. Conjugation concepts and treatment methods.

PLENARY HALL №2 (3.2)

13.30–15.00

SYMPOSIUM

Mortality reduction technology in patients with arterial hypertension depending on the comorbid pathology. Patient with hypertension and diabetes mellitus, CHF, AF and COPD at a doctor

Chairpersons: **Arutyunov G.** (Moscow), **Nedogoda S.** (Volgograd)

- **Arutyunov G.** (Moscow). Therapeutic point of view.
- **Lopatin Y.** (Volgograd). Cardiological point of view.
- **Nedogoda S.** (Volgograd). Endocrinological point of view.

HALL 2.3

13.30–15.00

SYMPOSIUM

SCD prevention in daily cardiological practice. Experts dialogue

Chairpersons: **Ardashev A.** (Moscow), **Zotova I.** (Moscow), **Karpenko Y.** (Ukraine)

- **Ardashev A.** (Moscow). SCD prevention: pharmacological, surgical, interventional approach. To whom and how?
- **Zotova I.** (Moscow). Pharmacological approach for SCD prevention in AF patients according to the modern Russian recommendations.

- **Knigin A.** (Moscow). S-ICD in SCD prevention. What a cardiologist should know?
- **Babokin V.** (Moscow). Surgical approach to SCD prevention. «Heart team» can't function without a cardiologist.
- **Karpenko Y.** (Ukraine). Urgent aspects in SCD prevention in patients with bradyarrhythmias.
- **Zheliakov E.** (Moscow). EPS is a key instrument to SCD risks stratification in cardiology practice.

HALL 3.1

13.30–15.00

SATELLITE SYMPOSIUM

Do we use all opportunities for reducing CVD risk in patients after myocardial infarction?

(supported by Amgen, CME points are not accrued)

On-line broadcasting

Chairperson: **Shlyakhto E.V.** (Saint-Petersburg)

- **Villevalde S.V.** (Saint-Petersburg). LDL-C control in patients after MI: guidelines and clinical practice.
- **Matskeplishvili S.T.** (Moscow). What is the cost of our inertness for patient?
- **Lopatin Yu.M.** (Volgograd). The target level of LDL-C in most patients can be achieved!


HALL 3.3

13.30-15.00

SYMPOSIUM

Cardiovascular disease in Russia: risk factors and treatment in international perspective

Simultaneous translation



Chairpersons: **Leon D.** (UK), **Kontsevaya A.** (Moscow)

- **Yakunchikova O., Averina M., Wilsgaard T.** (Norway), **Malyutina S.** (Novosibirsk), **Kudryavtsev A.** (Arkhangelsk), **Leon D.** (UK). New glance at comparative figures of CVD risks and cardiac damage blood biomarkers in Russia and Norway.
- **Churilova E.** (Moscow), **Leon D.** (UK), **Shkolnikova V.** (Moscow). Blood pressure and hypertension in Russia: synthesis of available data in international perspective.
- **Malyutina S.** (Novosibirsk), **Ryabikov A.** (Novosibirsk), **Cook S.** (UK), **Kudryavtsev A.** (Arkhangelsk), **Leon D.** (London). Echocardiographic parameters in connection to alcohol intake patterns.
- **Cook S.** (UK), **Hopstock L., Eggen A.** (Norway), **Malyutina S.** (Novosibirsk), **Kudryavtsev A.** (Arkhangelsk). Pharmacological treatment and BP and lipids control after diagnosis of MI, stroke or diabetes in Russia and Norway: a population-based comparison.
- **Kontsevaya A.** (Moscow), **Bates K.** (UK), **McKee M.** (UK). Medical care and treatment in 12 months' period after MI.

HALL 3.4

13.30–15.00

SYMPOSIUM

Registries in acute cardiac care

Chairpersons: **Duplyakov D.** (Samara), **Martsevich S.** (Moscow), **Barbarash O.** (Kemerovo)

- **Duplyakov D.** (Samara), **Zolotovskaya I.** (Samara), **Davydkin I.** (Samara), **Kokorin V.** (Moscow). Atrial fibrillation markers after STEMI – FAKEL clinical trial.
- **Erikh A.** (Moscow). SIRENA registry on PATE.
- **Martsevich S.** (Moscow). Hospital registry for patients with stroke – REGION trial.
- **Kosmatcheva E.** (Krasnodar), **Namitokov A.** (Krasnodar). Acute Coronary Syndrome registry for patients 80+.

HALL 3.5

13.30–15.00

WORKING MEETING

HALL 3.6

13.30–15.00

SYMPOSIUM

Adult congenital heart diseases – multidisciplinary approach

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Avraamenko A.** (Samara), **Bautin A.** (Saint-Petersburg)

- **Verbilo S.** (Saint-Petersburg), **Karev E.** (Saint-Petersburg). Possible diagnostic approach in adult congenital heart diseases – current state.
- **Avraamenko A.** (Samara). Heart team approach in follow up of adult patients with congenital heart diseases.
- **Irtyuga O.** (Saint-Petersburg), **Gabrelyan A.** (Saint-Petersburg), **Karelkina E.** (Saint-Petersburg), **Bautin A.** (Saint-Petersburg), **Moiseeva O.** (Saint-Petersburg). Eisenmenger syndrome and pregnancy – is it possible?
- **Dzhioeva O.** (Moscow), **Egorov P.** (Moscow), **Orlov D.** (Moscow). Comorbidity in adult patients with congenital heart diseases.


HALL 3.7

13.30–15.00

SYMPOSIUM

Non-drug management of heart failure – a mandatory option

Chairpersons: **Tarlovskaya E.** (Nizhny Novgorod), **Sitnikova M.** (Saint-Petersburg)



- **Begrambekova Y.** (Moscow). Standards of non-drug management of patients with CHF.
- **Lyasnikova E.** (Saint-Petersburg). Different models of CHF patients' management and outcomes.
- **Shindrikov R.** (Saint-Petersburg). Psychological care practice for patients with severe CHF.
- **Lelyavina T.** (Saint-Petersburg). Pathogenetic aspects of physical rehabilitation of patients with heart failure.

HALL 3.8

13.30–15.00

SYMPOSIUM

From dawn to flowering: new opportunities in the diagnosis and management of patients with familial hypercholesterolemia

Chairpersons: **Zateyshchikov D.** (Moscow), **Konstantinov V.** (Saint-Petersburg), **Kuznetsova T.** (Petrozavodsk)

- **Zateyshchikov D.** (Moscow). Identification of the hereditary causes of early atherosclerosis in clinical practice.
- **Konstantinov V.** (Saint-Petersburg). Modern portrait of a patient with familial hypercholesterolemia.
- **Korneva V.** (Petrozavodsk). Modern tactics of managing a patient with familial hypercholesterolemia: new opportunities for improving the prognosis.
- **Sonicheva N.** (Moscow). Patients with familial hypercholesterolemia: why do we need genetics?

HALL 3.9

13.30–15.00

SYMPOSIUM

Sarcopenia and myopenia as a new syndrome in the clinic of internal diseases: the impact on the CVD course

Chairpersons: **Rebrov A.** (Saratov)

- **Orlova I.** (Moscow). Age sarcopenia: norm or pathology?
- **Fomin I.** (Nizhny Novgorod). Differential diagnosis of myopenia and its contribution to the CVD continuum.
- **Arutunov G.** (Moscow). Possibilities of correction of sarcopenia in patients with cardiovascular system pathology.
- **Grigorieva N.** (Nizhny Novgorod). A patient with COPD, CHF and myopenia: a clinical review.

HALL 3.10

13.30–15.00

SYMPOSIUM

Pitfalls in diagnostics and treatment methods in patients with hypertrophic cardiomyopathy – part I

Chairpersons: **Dzemeshevich S.** (Moscow), **Krylova N.** (Moscow)

- **Motreva A.** (Moscow), **Zaklyazminskaya E.** (Moscow), **Kalmykova O.** (Astrakhan), **Nechepurenko A.** (Astrakhan), **Radghabova G.** (Moscow), **Nikituk T.** (Moscow), **Frolova Y.** (Moscow), **Dzemeshevich S.** (Moscow). Early manifestation of the HCM: features, causes, and natural course.
- **Korzh D.** (Astrakhan), **Motreva A.** (Astrakhan), **Kalmykova O.** (Astrakhan), **Nikolaeva E.** (Astrakhan). Clinical phenotypes of HCM, selection criteria and the possibility of alcoholic ablation.
- **Merzhina E.** (Moscow), **Sinitsyn V.** (Moscow). Contrasting MRI in the SCD risk stratification in patients with HCM.
- **Komissarove S.** (Belarus), **Rineyskaya N.** (Belarus), **Chakova N.** (Belarus), **Niyazova S.** (Belarus). Mixed phenotype: HCM and non compaction cardiomyopathy in the patients from Belarus.
- **Golubenko M.** (Tomsk), **Salakhov R.** (Tomsk), **Glotov O.** (Saint-Petersburg), **Pavlukova E.** (Tomsk). DNA diagnostics of HCM: spectrum of genetic variants and relationship with genotype.

HALL 4.5

13.30–15.00

SESSION OF THE SOCIETY OF HEART FAILURE SPECIALISTS

HALL 4.6

13.30–15.00

SYMPOSIUM

Indications and control of the primary prevention effectiveness in atherosclerosis: «target» values or vascular imaging?

Chairpersons: **Sergienko I.** (Moscow)

- **Sergienko I.** (Moscow). Peripheral arterial diseases and cholesterol. Where is the truth?
- **Bershtein L.** (Saint-Petersburg). Quantitative analysis of coronary and carotid atherosclerosis: a key step in cardiovascular risk assessment.
- **Obrezan A.** (Saint-Petersburg). Primary cardiovascular prevention: philosophy, goal setting, tools.

PLENARY HALL №1

15.30–17.00

PLENARY SESSION

Cardiological patient through the prism of polymorbidity: insufficiently studied and difficult issues

On-line broadcasting / Simultaneous translation

Chairpersons: **Arutyunov G.P.** (Moscow)

- **Tarlovskaya E.I.** (Nizhny Novgorod). Current aspects of the polymorbidity of a cardiological patient: a view of 2019.
- **Fomin I.V.** (Nizhny Novgorod). Cardiological pathology in patients with chronic anemia: diagnostics and treatment aspects.
- **Arutyunov A.G.** (Moscow). Strategy and tactics of drug selection and dose calculation in cardiological polymorbid patients with liver and kidney diseases.
- **Koziołova N.A.** (Perm). Delicate cardiological patient: clinical features and treatment tactics.

PLENARY HALL №2 (3.2)

15.30–17.00

SYMPOSIUM

Complex and unresolved issues of antithrombotic therapy

Chairpersons: **Yavelov I.** (Moscow), **Panchenko E.** (Moscow)

- **Yavelov I.** (Moscow). Triple antithrombotic therapy after percutaneous coronary interventions in patients with atrial fibrillation: news and contradictions.
- **Komarov A.** (Moscow). Bleeding as a complication of antithrombotic therapy: causes, treatment and prevention (case report).
- **Panchenko E.** (Moscow). Deep venous thrombosis and pulmonary embolism: resources of antithrombotic therapy and real clinical practice (case report).

HALL 2.3

15.30–17.00

SYMPOSIUM

The long-term prognosis in patients with coronary heart disease after the coronary flow recovery

Chairpersons: **Shiriayev A.** (Moscow), **Provatorov S.** (Moscow)

- **Kurbanov S.** (Moscow), **Shiriayev A.** (Moscow), **Vasilyev V.** (Moscow), **Galiautdinov D.** (Moscow), **Latipov R.** (Moscow), **Mayorov G.** (Moscow). Coronary artery bypass grafting in patients with diffuse coronary artery disease: the game is worth the effort.
- **Gazizova V.** (Moscow), **Vlasova R.** (Moscow), **Ilyina L.** (Moscow), **Dzibinskaya Y.** (Moscow), **Koroliov S.** (Moscow), **Gramovich V.** (Moscow), **Akchurin R.** (Moscow). A patient with CHD and HF is prepared for coronary artery bypass grafting and successfully operated. What is the next step?
- **Mironov V.** (Moscow), **Arutiunian G.** (Moscow), **Merkulov E.** (Moscow). Complex coronary stenting. What to expect afterwards?
- **Potekhina A.** (Moscow), **Filatova A.** (Moscow), **Schinova A.** (Moscow), **Arefieva T.** (Moscow). Long-term prognosis after coronary stenting: what predictors should we to focus on?
- **Osokina A.** (Moscow), **Provatorov S.** (Moscow), **Filippov E.** (Ryazan). Remote monitoring of a patient after coronary stenting.
- **Sapelnikov O.** (Moscow), **Nikolayeva O.** (Moscow). Interventional treatment of cardiac arrhythmias in IHD patients: does the prognosis change?

HALL 3.1

15.30–17.00

SYMPOSIUM OF THE ESC HEART FAILURE SPECIALISTS OF TOMORROW (HOT)

Heart failure clinics – current condition in the Russian Federation and the world and things to expect in the future

Chairpersons: **Drapkina O.** (Moscow), **Kobalava Zh.** (Moscow), **Fomin I.** (Nizhny Novgorod)

- **Mareev Y.** (Moscow). The English model of heart failure clinics.
- **Kashtalap V.** (Kemerovo). Modern concepts of HF management optimization. European initiative.
- **Vinogradova N.** (Nizhny Novgorod). Experience of the City Center for HF Treatment in real clinical practice.
- **Soloveva A.** (Moscow), **Galochkin S.** (Moscow). Key role of the in-hospital stage in HF patient logistics model.
- **Myasnikov R.** (Moscow). The future that is coming: Translational medicine in a HF clinic.

HALL 3.3

15.30-17.00

SYMPOSIUM

Classics and innovations in modern vascular surgery

Simultaneous translation

Chairpersons: **Kavteladze Z.** (Moscow), **Chernyavsky M.** (Saint-Petersburg)

- **Kavteladze Z.** (Moscow). “Splendour and misery” of endovascular surgery in lesions of the lower limbs arteries.
- **Karpenko A.** (Novosibirsk). Hybrid technology for peripheral arteries disease.
- **Langhoff R.** (Germany). The role of PTA and stenting in the treatment of femoropopliteal disease today.

- **Chernyavskiy M.** (Saint-Petersburg). Occlusion of the terminal aorta in high-risk patients: own observations.
- **Bylov K.** (Moscow). Non-standard approaches for treatment of lower limbs artery disease.
- **Kolegaev A.** (Moscow). Experience of critical lower limb ischemia treatment.

HALL 3.4

15.30–17.00

SYMPOSIUM

Controversial and unresolved issues of hypertension treatment: new guidelines perspective

Chairpersons: **Nedogoda S.** (Volgograd), **Arhipov M.** (Ekaterinburg)

- **Nedogoda S.** (Volgograd). Approaches to the management of arterial hypertension patients of young and middle age. Are there any special tactics?
- **Ostroumova O.** (Moscow). Controversial and unresolved issues in patients with arterial hypertension and cerebrovascular diseases in European recommendations for hypertension diagnostics and treatment 2018.
- **Kislyak O.** (Moscow). Arterial hypertension and peripheral arterial atherosclerosis. Is there any link?
- **Arhipov M.** (Ekaterinburg). Arterial hypertension, coronary heart disease and chronic heart failure. Together or apart? Approaches to the optimal pharmacotherapy scheme.

HALL 3.5

15.30–17.00

SYMPOSIUM

Rare causes of chronic heart failure at a young age

Chairpersons: **Blagova O.** (Moscow), **Filippov E.** (Ryazan)

- **Yakushin S.** (Ryazan), **Pereverzeva K.** (Ryazan). Coronary chronic heart failure at a young age.
- **Tereschenko S.** (Moscow), **Zhirov I.** (Moscow). Heart amyloidosis — chronic HF clinical course and possibilities of its medical correction.
- **Blagova O.** (Moscow). Myocarditis as a cause of chronic HF in real clinical practice.
- **Filippov E.** (Ryazan), **Moseichuk K.** (Ryazan). Causes of right ventricular failure at a young age.

HALL 3.6

15.30–17.00

SYMPOSIUM

Cardiogenic shock. Unresolved problems and possible solutions

Chairperson **Pevsner D.** (Moscow)

- **Shakhnovich R.** (Moscow). Prevention of cardiogenic shock in patients with acute myocardial infarction.
- **Arutunyan G.** (Moscow). Endovascular methods of treatment of cardiogenic shock.
- **Razumov A.** (Saint-Petersburg). Using of extracorporeal assistant device Cardiohelp in patients with cardiogenic shock.
- **Pevsner D.** (Moscow). Creation of Shock centers — new step in the treatment of cardiogenic shock.

HALL 3.7


15.30–17.00

SYMPOSIUM

Cardiovascular risks in professional sport

Chairpersons: **Smolensky A.** (Moscow), **Balykova L.** (Saransk), **Mikhailova A.** (Moscow)

- **Smolensky A.** (Moscow). Cardiovascular risks in professional sport: pro and contro.



- **Badtieva V.** (Moscow). Actual issues of cardiac screening of athletes: successes and failures.
- **Balykova L.** (Saransk). Remodeling of cardiovascular system in young athletes: what is the norm.
- **Mikhailova A.** (Moscow). Risk factors of cardiovascular over-training syndrome.
- **Bondarev S., Shloydo E.** (Saint-Petersburg). The possibilities of interventional cardiology in the treatment of cardiac pathology in athletes.

HALL 3.8

15.30–17.00

SYMPOSIUM

Sudden death: from cardiomyopathies to channelopathies

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Abdullaev A.** (Makhachkala)

- **Arad M.** (Israel). Implication of genetic testing in dilated cardiomyopathy.
- **Zateyschikov D.** (Moscow). Channelopathies is not as rare as previously thought.
- **Sonicheva N.** (Moscow). Risk stratification in channelopathies.
- **Duplyakov D.** (Samara). Brugada syndrome and its masks.

HALL 3.9

15.30–17.00

SYMPOSIUM

Work of multidisciplinary team in the perioperative management of cardiac surgery patients

Chairpersons: **Sumin A.** (Kemerovo), **Kosmacheva E.** (Krasnodar), **Garganeeva N.** (Tomsk)

- **Namitokov A., Kosmacheva E., Kruchinova S., Fetisova V., Raff S.** (Krasnodar). Role of the multidisciplinary team in examining patients before emergency CABG.

- **Bezdenzhnykh N., Bezdenzhnykh A., Sumin A.** (Kemerovo). Perioperative management of patients with diabetes undergoing coronary bypass.
- **Skaletskiy K., Zafiraki V., Kosmacheva E.** (Krasnodar). Perioperative management of patients with COPD during coronary artery bypass surgery.
- **Pomeshkina S.** (Kemerovo). Perioperative management of the cardiac surgery patient from the point of view of the rehabilitation specialist.
- **Belyalov F.** (Irkutsk). Psychosomatic aspects of the perioperative period.
- **Trubnikova O., Syrova I., Maleva O., Barbarash O.** (Kemerovo). The problem of cognitive dysfunction after direct myocardial revascularization and strategies to cope with it — the cardiologist's view.

HALL 3.10

15.30–17.00

SYMPOSIUM

Pitfalls in diagnostics and treatment decision-making in patients with hypertrophic cardiomyopathy. Part 2

Chairpersons: **Kotlukova N.** (Moscow), **Komissarova S.** (Belarus)

- **Kotlukova N.** (Moscow). Differential diagnostics of the early left ventricular hypertrophy: transitory phenomenon or implicit threat?
- **Zaklyazminskaya E.** (Moscow). Sporadic HCM: the role of de novo mutations.
- **Savchenko A., Rineyskaya N., Komissarova S., Chakova N., Niyazova S., Mazur O.** (Belarus). Life-threatening events in HCM patients with mutations in the genes encoding cardiac ion channels.
- **Dankovtseva E.** (Moscow). Combination of HCM, familial hypercholesterolemia and deficiency of the lipoprotein lipase.
- **Radzhabova G.** (Moscow), **Kalmykova O.** (Astrakhan), **Motreva A.** (Astrakhan), **Dzemeshevich S.** (Moscow), **Shchagina O.** (Moscow). Unusually high rate of inherited thrombophilia in Dagestani patients.

HALL 4.5

15.30–17.00

SCIENTIFIC SESSION

Imaging in cardiology, ultrasound and tomography

Chairpersons: **Saidova M.** (Moscow), **Matskeplishvili S.** (Moscow)

- **Dzhioeva O.** (Moscow). Echocardiographic predictors of cardiac complications risk in extracardiac interventions.
- **Usov V., Mochula O., Maksimova A., Alekseeva Ya., Ryabov V., Turbocheva I., Bobrikova E.** (Tomsk). Paramagnetic contrast MRI of aortic wall and large arteries in prognosis of advanced atherosclerosis complications.
- **Ryumshina N., Falkovskaya A., Gusakova A., Usov V.** (Tomsk). Features of vascular wall imaging in resistant hypertension combined with type 2 diabetes mellitus.
- **Kulagina T., Sandrikov V., Van E., Khadzhieva D., Zyabirova R.** (Moscow). Measurements dynamics of left heart biomechanics in patients with mitral insufficiency before and after surgery.
- **Mochula O., Alekseeva Ya., Vyshlov E., Ryabov V., Markov V., Usov V.** (Tomsk). Contrast MRI as objectification method of reperfusion therapy efficacy.
- **Voronin E., Ryabikov A., Shakhmatov S., Guseva V., Malyutina S.** (Novosibirsk). Echocardiographic changes due to alcohol intake in population.
- **Boschenko A., Vrublevskiy A., Zorkaltseva M.** (Tomsk). B-lines, contractile reserve and coronary reserve in anterior descending artery as addition to standard stress echo in diagnosis of coronary stenosis >50%.

HALL 4.6

15.30–17.00

SYMPOSIUM

Current questions of psychocardiology

Chairpersons: **Syrkin A.** (Moscow), **Smulevich A.** (Moscow)

- **Vasyuk Yu., Dovzhenko T., Nesterova E., Dubrovskaya T.** (Moscow). Can comorbid anxiety-depression disorders, obesity and arterial hypertension be effectively controlled?
- **Volel B.** (Moscow). Mental disorders in cardiological practice.
- **Ivanov S.** (Moscow). Psychopharmacotherapy of mental disorders in cardiology.
- **Kopylov P., Syrkina E.** (Moscow). Atrial fibrillation and mental disorders: first results of an interdisciplinary research.
- **Repin A., Lebedeva E.** (Tomsk). Prevention and treatment of cognitive disorders during coronary artery bypass surgery in patients with CAD.

PLENARY HALL №1

17.30–19.00

PLENARY SESSION

INNOVATIONS IN CARDIOLOGY2019

On-line broadcasting / Simultaneous translation

Chairperson **Shlyakhto E.** (Saint-Petersburg)

- **Nedogoda S.** (Volgograd). New European clinical guidelines on Diabetes, Pre-diabetes & Cardiovascular Diseases.
- **Galyavich A.** (Kazan). New European clinical guidelines on Chronic Coronary Syndromes.



GENERAL PARTNERS



PRINCIPAL PARTNERS



PARTNERS



ГЕДЕОН РИХТЕР



КАНОНФАРМА
продакш



GENERAL INFORMATION PARTNER




INFORMATION PARTNERS



EXHIBITORS





Ксарелто®: снижение риска смерти у пациентов с хронической ИБС*¹

Зарегистрировано новое показание для пациентов с ИБС
и/или заболеваниями периферических артерий

По данным исследования COMPASS:

↓ 26% снижение риска сердечно-сосудистой смерти, инфаркта миокарда и инсульта*¹

↓ 23% снижение риска смерти от всех причин у пациентов с хронической ИБС*¹

↓ 44% снижение риска инсульта*¹



Благоприятный профиль безопасности без статистически значимого повышения частоты наиболее тяжелых кровотечений*¹

КСАРЕЛТО®. Международное непатентованное или группировочное наименование: ривароксабан. Лекарственная форма: таблетки покрытые пленочной оболочкой. 1 таблетка покрытая пленочной оболочкой содержит 2,50 мг ривароксабана микроинкапсулированного. **ПОКАЗАНИЯ К ПРИМЕНЕНИЮ.** Профилактика смерти вследствие сердечно-сосудистых причин, инфаркта миокарда и тромбоза стенки у пациентов после острого коронарного синдрома (ОКС), протекавшего с повышением кардиоспецифических биомаркеров, в комбинационной терапии с ацетилсалициловой кислотой или с ацетилсалициловой кислотой и тенололидом или клопидогрелем или тиклопидином. Профилактика инсульта, инфаркта миокарда и смерти вследствие сердечно-сосудистых причин, а также профилактика острой ишемии конечностей и общей смертности у пациентов с системной粥硬化症 сердца (ИБС) или заболеванием периферических артерий (ПА) в комбинационной терапии с ацетилсалициловой кислотой. **ПРОТИВОПОКАЗАНИЯ.** Повышенная чувствительность к ривароксабану или любому вспомогательному веществу, входящему в состав препарата; клинически значимые кровотечения (например, внутричерепное кровоизлияние, желудочно-кишечное кровотечение), заболевания печени, протекающие с коагулопатией, ведущей к клинически значимому риску кровотечения, в том числе цирроз печени и нарушения функции печени класса B и C по классификации Чайлд-Пью; беременность и период грудного вскармливания; детский и подростковый возраст до 18 лет (эффективность и безопасность для пациентов данной возрастной группы не установлены); тяжелая степень нарушения функции почек (КЛРП < 15 мл/мин). Клинические данные о применении ривароксабана у данной категории пациентов отсутствуют; лечение ОКС при помощи антиагрегантов у пациентов, перенесших инсульт или транзиторную ишемическую атаку, сопутствующая терапия камилиптоби другими антикоагулянтами, например, нефракционированным гепарином, низкомолекулярными гепаринами, ратипарани и др.; производными гепарина (фундапаринус и др.), пероральными антикоагулянтами (варфарин, апикасан, дабигатран и др.), кроме случаев перехода или на ривароксабан или при применении нефракционированного гепарина в дозах, необходимых для обеспечения функционирования центрального венозного или артериального катетера; наследственная непереносимость лактозы или галактозы (например, врожденный дефицит лактазы или глюкозо-галактозная мальабсорбция), поскольку в состав данного лекарственного препарата входит лактоза. **С ОСТОРОЖНОСТЬЮ:** При лечении пациентов с повышенным риском кровотечения (в том числе при врожденной или приобретенной склонности к кровотечениям, неконтролируемой тяжелой артериальной гипертонии, язвенной болезни желудка и 12-перстной кишки в стадии обострения, недавно перенесенной острой язве желудка и 12-перстной кишки, судорожной ретинопатии, недавно перенесенной операции на желудке и в области кровотока, при наличии вострой или хронической патологии сосудов спинного или головного мозга, после недавно перенесенной операции на головном, спинном мозге или глазод, при наличии бронхоэктазов или легочной гематомы в анамнезе). При лечении пациентов со средней степенью нарушения функции почек (КЛРП 3-49 мл/мин), получающих одновременно препараты, повышающие концентрацию ривароксабана в плазме крови. При лечении пациентов с тяжелой степенью нарушения функции почек (КЛРП 15-29 мл/мин). У пациентов, получающих одновременно лекарственные

препараты, влияющие на гемостаз, например, нестероидные противовоспалительные препараты (НПВП), антиагреганты, другие антикоагулянтные средства или селективные ингибиторы обратного захвата серотонина (СИОЗС). Ривароксабан не рекомендуется к применению у пациентов, получающих системное лечение противогрибковыми препаратами азоловой группы (например, кетоконазол, итраконазол, вориконазол, вориконазол и позконазол) или ингибиторами протазы ВЧН (например, ритонавиром). Пациенты с тяжелой степенью нарушения функции почек (КЛРП 30-45 мл/мин) или повышенным риском кровотечения и пациенты, получающие сопутствующее системное лечение противогрибковыми препаратами азоловой группы или ингибиторами протазы ВЧН, после начала лечения должны находиться под пристальным контролем для своевременного обнаружения осложнений в форме кровотечения. **ПОБОЧНОЕ ДЕЙСТВИЕ.** Учитывая механизм действия, применение препарата Ксарелто® может быть связано с повышенным риском сырых или явных кровотечений из любых тканей и органов, которые могут привести к развитию постгеморрагической анемии. Риск развития кровотечения может увеличиваться у пациентов с тяжелой неконтролируемой артериальной гипертонией и/или при совместном применении с препаратами, влияющими на гемостаз. Признаки симптома и тяжесть (включая возможный летальный исход) будут варьировать в зависимости от источника и степени или выраженности кровотечения и/или анемии; геморрагические осложнения могут проявляться в виде обморока, бледности, головокружения, головной боли или несоблюдения отечков, слабости или шока, развитие которого нельзя объяснить другими причинами. В некоторых случаях, как следствие анемии, наблюдаются симптомы ишемии миокарда, такие как боль в грудной клетке или стенокардия. Наиболее частыми НРП у пациентов, применявших препарат, являлись кровотечения. Также часто отмечаются анемия (включая соответствующие лабораторные показатели), головокружение, головная боль, кровоизлияние в глаз (включая кровоизлияние в конъюнктиву), снижение артериального давления (гематома, носовое кровотечение, кровоизлияние в ротовую полость, желудочно-кишечное кровотечение (включая ректальное кровотечение), боли в области желудочно-кишечного тракта и в области диспепсии, тошнота, запор*, диарея, рвота*, кожный зуд (включая нечастые случаи генерализованного зуда), кожная сыпь, экхимоз, кожные и подкожные кровоизлияния, боль в конечностях*, кровоизлияние из ретроинтентального тракта (включая гематурию и меноррагию)*, нарушение функции почек (включая повышение концентрации креатинина крови, повышение концентрации мочевины крови)*, лихорадка*, периферический отек, снижение общей мышечной силы и тонуса (включая слабость и астению), повышение активности печеночных трансаминаз, кровотечение после медицинской манипуляции (включая послеоперационную анемию и кровотечения из ран), диарея, *Наблюдались преимущественно после наиболее ортопедических операций на нижних конечностях. **Наблюдались при лечении ВТЗ как очень частые у женщин и в возрасте < 55 лет. Регистрационный номер: ПЛ-002118. Актуальная версия инструкции от 30.01.2019. Производитель: Байер АГ, Германия, отпускаяется по рецепту врача. Подробная информация содержится в инструкции по применению.

*По данным субанализа исследования COMPASS у пациентов со стабильным течением ИБС в сравнении с монотерапией ацетилсалициловой кислотой. *Фатальные, внутричерепные, кровотечения в клинически важные органы, ИБС – ишемическая болезнь сердца. 1. Connolly SJ, Ezekowitz JMW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; doi: 10.1016/S0140-6736(17)32458-3

Уважаемый коллега!

Приглашаем Вас на симпозиум компании «Берингер Ингельхайм» с международным участием и междисциплинарным подходом*

24 сентября

11:00-12:30

Зал пленарных
заседаний, 1 этаж

ПОАК в профилактике инсульта: рациональные решения для сложных пациентов

Председатели: Шляхто Е.В., Дан Атар, Кобалава Ж.Д., Хасанова Д.Р., Замятин М.Н.

ПОАК как инструмент снижения сердечно-сосудистой смертности

Шляхто Евгений Владимирович

Академик РАН, заслуженный деятель науки РФ, генеральный директор ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России, президент Российского кардиологического общества, главный внештатный специалист-кардиолог Минздрава России по СЗФО, ЮФО, СКФО, ПФО, главный внештатный специалист-кардиолог Комитета по здравоохранению Правительства Санкт-Петербурга

ПОАК у пациента с ФП: новые решения в ведении пациентов высокого риска

Дан Атар

Профессор кардиологии, руководитель научно-исследовательского отдела медицинского факультета Университета Осло, ученый секретарь управляющего комитета Европейского кардиологического общества, главный редактор журнала *Cardiology*, Норвегия

Что должен знать кардиолог о неотложных ситуациях пациента, получающего антикоагулянтную терапию

Замятин Михаил Николаевич

Д.м.н., профессор, заведующий кафедрой анестезиологии и реаниматологии Института усовершенствования врачей ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России, Москва

Ишемический инсульт и ПОАК: что изменилось в лечении и вторичной профилактике?

Хасанова Дина Рустемовна

Д.м.н., профессор кафедры неврологии и нейрохирургии факультета повышения квалификации и профессиональной переподготовки специалистов, ФГБОУ ВО «Казанский ГМУ» Минздрава России, главный внештатный ангионевролог МЗ Республики Татарстан, Казань

Индивидуальный подход к антикоагулянтной терапии у пациента с ФП

Кобалава Жанна Давидовна

Д.м.н., профессор, заведующая кафедрой внутренних болезней, кардиологии и клинической фармакологии ФНМО Медицинского института Российского университета дружбы народов, Москва

Дискуссия, ответы на вопросы

* не аккредитован НМО



ООО «Берингер Ингельхайм»
125171, г. Москва, Ленинградское шоссе, 16А, стр. 3
Телефон: +7 (495) 544-50-44 Факс: +7 (495) 544-56-20

СПАСИ ЖИЗНЬ



Доверие препаратам KRKA – это доверие передовым технологиям и высокому Европейскому качеству (1)



ДАЛЬНЕВА®

амлодипин и периндоприл
таблетки

5 мг/4 мг 10 мг/4 мг
5 мг/8 мг 10 мг/8 мг

КО-ДАЛЬНЕВА®

амлодипин, индапамид, периндоприл
таблетки

5 мг/0,625 мг/2 мг 5 мг/1,25 мг/4 мг
5 мг/2,5 мг/8 мг 10 мг/2,5 мг/8 мг

Сила в синергии!

Дальнева®:

Показания к применению: артериальная гипертензия и/или ишемическая болезнь сердца: стабильная стенокардия напряжения у пациентов, которым требуется терапия периндоприлом и амлодипином. **Способ применения и дозы:** внутрь, по одной таблетке 1 раз в день, предпочтительно утром перед приемом пищи. Доза препарата Дальнева® подбирается после ранее проведенного титрования доз отдельных компонентов препарата: периндоприла и амлодипина у пациентов с артериальной гипертензией и стабильной стенокардией. Максимальная суточная доза: амлодипин 10 мг + периндоприл 8 мг. **Условия отпуска из аптек:** по рецепту. **Форма выпуска:** таблетки 5 мг + 4 мг; 5 мг + 8 мг; 10 мг + 8 мг по 30 и 90 таблеток и 10 мг + 4 мг по 30 таб.

Ко-Дальнева®:

Показания к применению: артериальная гипертензия (при необходимости одновременной терапии амлодипином, индапамидом и периндоприлом в дозах, применяемых в монотерапии отдельных компонентов). **Способ применения и дозы:** внутрь, по одной таблетке 1 раз в день, предпочтительно утром перед приемом пищи. Доза препарата Ко-Дальнева® подбирается после ранее проведенного титрования доз отдельных активных компонентов препарата. Максимальная суточная доза препарата Ко-Дальнева® составляет 10 мг амлодипина + 2,5 мг индапамида + 8 мг периндоприла. **Условия отпуска из аптек:** по рецепту. **Форма выпуска:** таблетки 5 мг + 1,25 мг + 4 мг; 5 мг + 2,5 мг + 8 мг; 10 мг + 2,5 мг + 8 мг по 30 и 90 таблеток и 5 мг + 0,625 мг + 2 мг по 30 таблеток

1. Собственные данные компании KRKA, д. Ново Место, Словения, 2018 г.

Информация предназначена для медицинских
и фармацевтических работников.

Заказчик размещения рекламы ООО «KRKA ФАРМА»

125212, г. Москва, Головинское шоссе, д. 5, корп. 1

Тел.: (495) 981-10-95, факс: (495) 981-10-91. e-mail: info.ru@krka.biz, www.krka.ru




ЭЛИКВИС®
апиксабан

AUGUSTUS

Крупнейшее исследование
у пациентов с сочетанием неклапанной фибрилляции предсердий и острым
коронарным синдромом и/или чрескожным коронарным вмешательством¹⁻³

4614 пациентов • 33 страны



СНИЖЕНИЕ РИСКА
КРОВОТЕЧЕНИЙ¹

-31%

Частота
кровоотечений, %

14,7

10,5

Варфарин

Эликвис®

СНИЖЕНИЕ РИСКА
СМЕРТИ/ГОСПИТАЛИЗАЦИЙ¹

-17%

Частота
смерти/госпитализаций, %

27,4

23,5

Варфарин

Эликвис®

Доказанное
превосходство
в безопасности
и эффективности*

БОЛЬШИНСТВУ ТАКИХ ПАЦИЕНТОВ ЭЛИКВИС® ПОКАЗАН В ПОЛНОЙ ДОЗЕ** 5 МГ 2 РАЗА В ДЕНЬ***,4

Краткая инструкция по медицинскому применению препарата ЭЛИКВИС®

Торговое название: Эликвис®. **МНН:** апиксабан. **Лекарственная форма:** таблетки, покрытые пленочной оболочкой. Состав: одна таблетка содержит 2,5 мг и 5 мг апиксабана.
Показания к применению: • Профилактика венозной тромбоэмболии у пациентов после планового эндопротезирования тазобедренного или коленного суставов. • Профилактика инсульта и системной тромбоэмболии у взрослых пациентов с неклапанной фибрилляцией предсердий, имеющих один или несколько факторов риска (таких как инсульт или транзиторная ишемическая атака в анамнезе, возраст 75 лет и старше, артериальная гипертензия, сахарный диабет), сопровождающихся симптомами хронической сердечной недостаточности функционального класса II в стадии по классификации NYHA. Основное назначение пациентов с тромбозом и умеренно выраженными мигральными стенозами или искусственными митральными клапанами.
Лечение тромбоза глубоких вен (ТГВ), тромбоэмболии легочной артерии (ТЭЛА), а также профилактики рецидивов ТГВ и ТЭЛА.
Противопоказания: Повышенная чувствительность к апиксабану или любому другому компоненту препарата. Активная клинически значимая респираторная, желудочно-кишечная или почечная недостаточность в системе свертывания крови и клинически значимая респираторная, желудочно-кишечная или почечная недостаточность, характеризующаяся значимым риском большого кровотечения, существующее в настоящее время или недавнее обострение язвенной болезни желудочно-кишечного тракта, наличие значительного новообразования с высоким риском кровотечения, недавнее повреждение головного или спинного мозга, недавнее перенесенное оперативное вмешательство на головном или спинном мозге, а также на органе зрения, недавно перенесенный геморрагический инсульт, установленное или подозреваемое артериальное расширение вен пищевода, артериальная мальформация, аневризма сосуда или выходящая интраспинальная или внутримозговая аневризма сосуда. Нарушение функции почек с клиренсом креатинина менее 15 мл/мин, а также применение у пациентов, находящихся на диализе. Возраст до 18 лет (данные о применении препарата отсутствуют), беременность (данные о применении препарата отсутствуют), период грудного вскармливания (данные о применении препарата отсутствуют). Одновременное применение с любыми другими антикоагулянтными препаратами, включая нефармакологический гепарин (НМФ), низкомолекулярный гепарин (НМГ) (бюксидан, даптарин и др.), производные гепарина (фондапаринукс и др.), пероральные антикоагулянты (варфарин, ривароксабан, дабигатран и др.), за исключением тех ситуаций, когда пациент переводится на гепарин или с гепарина апиксабаном или если нефармакологический гепарин назначается в дозах, необходимых для поддержания проницаемости центрального венозного или артериального катетера. Врожденный дефицит лактазы, непереносимость лактозы, глюкозо-галактозная мальабсорбция. **Важное предупреждение:** Симптомы нежелательных реакции были кровотечения (носовые,

желудочно-кишечное, ректальное, кровоотечение из десен, гематурия, кровоизлияния в ткани глазного яблока), кровопоток, гематома ангина, зияющая рана, кошачья. **Примечание:** Все побочные эффекты представлены в полной версии инструкции по медицинскому применению. **Способ применения и дозы:** Препарат Эликвис® принимают внутрь, независимо от приема пищи. Для пациентов, которые не могут проглотить таблетку целиком, ее можно измельчить и развести (в воде, водной дисперсии, жидком супе или пюре) и незамедлительно принять внутрь. В качестве альтернативы, таблетку можно измельчить и развести в воде или 5% водном растворе декстрозы и незамедлительно ввести полученную суспензию через назоглоточный зонд. Лекарственное вещество в измельченной таблетке сохраняет стабильность в воде, водной дисперсии, жидком супе или пюре до 4 часов. У пациентов с фибрилляцией предсердий по 5 мг два раза в сутки. У пациентов с фибрилляцией предсердий дозу препарата снижают до 2,5 мг два раза в сутки при наличии сочетания двух или более из следующих характеристик – возраст 80 лет и старше, масса тела 60 кг и менее или концентрация креатинина в плазме крови $\geq 1,5$ мг/дл (133 мкмоль/л). У пациентов с нарушением функции почек тяжелой степени (с клиренсом креатинина 15–29 мл/мин) и фибрилляцией предсердий следует применять дозу апиксабана 10 мг по крайней мере за 2 часа до проведения процедуры с последующим приемом 5 мг два раза в сутки (2,5 мг в сутки, если пациент проходит под критериями снижения дозы). У пациентов после планового эндопротезирования тазобедренного или коленного суставов: 2,5 мг 2 раза в сутки (первый прием через 12–24 ч после оперативного вмешательства). У пациентов, перенесших эндопротезирование тазобедренного сустава, эндопротезирование тазобедренного сустава составляет от 32 до 38 дней, коленного сустава – от 10 до 14 дней. **Лечение тромбоза глубоких вен, тромбоэмболии легочной артерии (ТЭЛА):** По 10 мг два раза в сутки в течение 7 дней, затем 5 мг 2 раза в сутки. Продолжительность лечения определяется индивидуально с учетом состояния гемодинамической пользы и риска возникновения клинически значимых кровотечений. **Профилактика рецидивов тромбоза глубоких вен, тромбоэмболии легочной артерии (ТЭЛА):** По 2,5 мг два раза в сутки после как минимум 6 недель лечения тромбоза глубоких вен или ТЭЛА. Относится по рецепту врача. Срок лечения: 3 года. Регистрационное удостоверение: ЛП-002007, ЛП-001145. Подробная информация содержится в Инструкции по медицинскому применению лекарственного препарата, перво-наперво необходимо ознакомиться с полным текстом Инструкции. Дата версии: 31.05.2019

* У пациентов с НФП с повышенными ОКС и/или ЧМБ по сравнению с варфарином.

** Доза, зарегистрированная у пациентов с фибрилляцией предсердий.

*** 2,5 мг 2 раза в день при наличии сочетания двух или более из следующих характеристик – возраст 80 лет и старше, масса тела 60 кг и менее или концентрация креатинина в плазме крови $\geq 1,5$ мг/дл (133 мкмоль/л) или при клиренсе креатинина 15–29 мл/мин.

1. Lopez RD et al. *N Engl J Med.* 2019; 380: 1509–1524. 2. Cannon CP et al. *N Engl J Med.* 2017; 377: 1513–1524.

3. Gibson SR et al. *N Engl J Med.* 2016; 375: 2423–2434. 4. Инструкция по применению лекарственного препарата для медицинского применения ЭЛИКВИС®.



ООО «Пфайзер Инновации»

Россия, 123112, Москва, Пресненская наб., д. 10, БЦ «Башня на Набережной» (блок О).
Тел.: +7 495 287 5000; факс: +7 495 287 5300. www.pfizer.com

Реклама

PP-ELI-RUS-0706 19.06.2019

ЖИЗНЬ ПАЦИЕНТА — ЦЕННОСТЬ¹⁻³



ТЕЛЗАП® AM — КОНТРОЛЬ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ*4

3 степени артериальной гипертензии⁴

2 взаимодополняющих компонента —
амлодипин и телмисартан⁴

1 таблетка в день
для комбинированной терапии⁴

СТАРТ лечения артериальной
гипертензии с фиксированной комбинации^{5,6}



Реклама.

Краткая инструкция по медицинскому применению лекарственного препарата Телзап® AM
Регистрационный номер: ЛП-005472.

Международное непатентованное или группировочное наименование: амлодипин + телмисартан.

Лекарственная форма: таблетки.

Фармакотерапевтическая группа: гипотензивное средство комбинированное (блокатор «медленных» кальциевых каналов + ангиотензин II рецепторов антагонист).

Код АТХ: C09BD04. Показания к применению: артериальная гипертензия (у пациентов, у которых АД недостаточно контролируется телмисартаном или амлодипином, в качестве средств монотерапии); артериальная гипертензия (у пациентов, которым показана комбинированная терапия); артериальная гипертензия у пациентов, получающих телмисартан и амлодипин в виде отдельных монопрепаратов, в качестве замены данной терапии.

Противопоказания: повышенная чувствительность к действующим вспомогательным веществам и другим производным дигидропиридина; беременность; период грудного вскармливания; обструктивные заболевания желчевыводящих путей; тяжелая артериальная гипотензия; обструкция выходящего тракта левого желудочка (в том числе высокая степень аортального стеноза); гемодинамически нестабильная сердечная недостаточность после перенесенного острого инфаркта миокарда; тяжелое нарушение функции печени; шок (в том числе кардиогенный); одновременное применение с алискиреном или препаратам, содержащим алискирен, у пациентов с сахарным диабетом или/или средними или тяжелыми нарушениями функции почек (скорость клубочковой фильтрации (СКФ) менее 60 мл/мин/1,73 м² площади поверхности тела); одновременное применение с ингибиторами АПФ у пациентов с диабетической нефропатией; переносимость фруктозы и синдром нарушения всасывания глюкозы/галактозы или дефицит сахарозы/изомальтазы; возраст до 18 лет (эффективность и безопасность не установлены). **С осторожностью:** двусторонний стеноз почечных артерий или стеноз артерии единственной функционирующей почки; нестабильная стенокардия; острый инфаркт миокарда (нет данных о применении в остром периоде и в течение одного месяца после инфаркта миокарда); нарушение функции почек и состояние после трансплантации почки; нарушение функции печени; рекомендации в отношении режима дозирования у пациентов с нарушением функции печени не разработаны, поэтому в таких клинических случаях следует соблюдать осторожность, нужно с осторожностью принимать препарат на фоне снижения объема циркулирующей крови (ОЦК), возникающего в результате ограничения потребления поваренной соли, диуретики или рвоты, сахарный диабет; гипонатриемия; гиперкалиемия; стеноз аортального или митрального клапана; первичный гиперпаратиреоз (эффективность и безопасность не установлены); возраст старше 70 лет; ишемическая болезнь сердца и/или клинически значимый атеросклероз сосудов головного мозга (при чрезмерном снижении АД имеется риск усиления ишемического расстройства, вплоть до развития острого инфаркта миокарда или инсульта); синдром слабости синусового узла (выраженная брадикардия, тахикардия); хроническая сердечная недостаточность (ХСН) ишемической этиологии III-IV функционального класса по классификации NYHA; гипертрофическая обструктивная кардиомиопатия. **Способ применения и дозы:** внутрь один раз в сутки вне зависимости от приема пищи, запивая небольшим количеством жидкости. Пациенты, получающие терапию амлодипином и телмисартаном в виде отдельных таблеток, могут быть переведены на терапию препаратом Телзап® AM, содержащим те же дозы действующих веществ. Препарат Телзап® AM может применяться у пациентов, у которых применение одного амлодипина или одного телмисартана не приводит к адекватному контролю АД. Пациенты, принимающие амлодипин в дозе 10 мг, у которых отмечаются побочные эффекты, ограничивающие прием препарата, например, периферические отеки, могут перейти на прием препарата Телзап® AM в дозе 5 мг + 40 мг один раз в день, что позволит уменьшить дозу амлодипина, но не снизит общее ожидаемое гипотензивное действие. Лечение артериальной гипертензии у пациента может начинаться с применения препарата Телзап® AM в том случае, когда предполагается, что достижение контроля АД с помощью какого-либо одного препарата маловероятно. Начальная доза препарата Телзап® AM: 5 мг + 40 мг один раз в день. Пациенты, которым необходимо более значительное снижение артериального давления, могут начать прием препарата Телзап® AM в дозе 5 мг + 80 мг один раз в день. Если требуется дополнительное снижение АД, доза препарата может быть постепенно увеличена до максимальной 10 мг + 80 мг не ранее чем через 2 недели после начала терапии. Максимальная суточная доза: 10 мг амлодипина + 80 мг телмисартана. **Побочное действие:** потенциальные нежелательные реакции на фоне лечения препаратом Телзап® AM включают все нежелательные реакции, которые ранее были зарегистрированы на фоне применения отдельных компонентов препарата. Сх, полную инструкцию по применению. Приведены некоторые нежелательные реакции, ожидающиеся на основании опыта применения амлодипина и телмисартана: сонливость, мигрень, головная боль, парестезия, вертуго, брадикардия, ощущение сердцебиения, гипотензия, ортостатическая гипотензия, «приливы», кожный зуд, повышение концентрации «печеночных» трансаминаз и др. **Форма выпуска:** таблетки 5 мг + 40 мг; 10 мг + 40 мг; 5 мг + 80 мг; 10 мг + 80 мг. По 10 или 14 таблеток в блистере из ОПА/Ал/ПВХ/Алю. По 1, 2, 4 или 7 блистеров (14 таблеток), по 3 или 3 блистеров (10 таблеток) вместе с инструкцией по применению в картонной упаковке. Условия хранения: при температуре не выше 25 °С в оригинальной упаковке (блистер в картонной упаковке). Хранить в недоступной для детей месте. **Срок годности:** 2 года. Не применять по истечении срока годности. **Условия отпуска:** отпускают по рецепту.

Перед назначением ознакомьтесь с полной инструкцией по медицинскому применению лекарственного препарата.
*Препарат Телзап® AM имеет в своем составе два гипотензивных вещества с взаимодополняющими механизмами действия, которые обеспечивают контроль показателей артериального давления (АД) у пациентов с эссенциальной артериальной гипертензией.
1. Под ценностью жизни подразумевается снижение смертности и частоты сердечно-сосудистых заболеваний у взрослых пациентов с сердечно-сосудистыми заболеваниями атеросклеротического генеза (ишемическая болезнь сердца, инсульт или поражение периферических артерий в анамнезе). Инструкция по медицинскому применению препарата Телзап® ЛП-005545, 09.08.2017. 2. ONTARGET Investigators. N. Engl. J. Med. 2008; 358: 1547-59. (исследование ONTARGET, N. Engl. J. Med. 2008; 358: 1547-59). 3. TRANSCEND Investigators. Lancet. 2008; 372: 1174-83. (исследование TRANSCEND, Lancet. 2008; 372: 1174-83). 4. Инструкция по медицинскому применению препарата Телзап® AM ЛП-005472, 17.04.2019. 5. И. Е. Чацова, Ю. В. Жернакова от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертензии. Системные гипертензии, 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179. 6. Williams, G. Manca et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European HeartJournal (2018) 39, 3021-3104. doi: 10.1093/eurheartj/ehy339 (Б. Вильямс, Г. Манчиа et al. Европейское общество кардиологии, Европейское общество гипертонии, Европейский журнал сердца, (2018) 39: 3021-3104, doi: 10.1093/eurheartj/ehy339).

Информация предназначена для специалистов здравоохранения.
Представительство АО «Санofi-авентис груп» (Франция): 125009, Москва, ул. Тверская, д. 22.
Тел.: (495) 721-14-00, факс: (495) 721-14-11, www.sanofi.ru
SARU.GTEL.MIZ.19.07.1376

АПБРАВИ –

первый и единственный пероральный селективный агонист IP-рецепторов простаглицлина¹

БУДЬ ВПЕРЕДИ

На **64%** снижает риск прогрессирования заболевания/смерти у пациентов с ЛАГ на ранней стадии в тройной комбинированной терапии³

На **40%** снижает риск прогрессирования заболевания/смерти у всех пациентов с ЛАГ независимо от линии терапии²

Апбрави
селексипаг

КРАТКАЯ ИНФОРМАЦИЯ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ АПБРАВИ⁴

Регистрационный номер: ЛП-005577. Торговое наименование: Апбрави. Международное непатентованное наименование: селексипаг. Лекарственная форма: таблетки, покрытые плёночной оболочкой. Показания: Апбрави показан для длительного лечения лёгочной артериальной гипертензии у взрослых пациентов (ЛАГ, группа I по классификации ВОЗ) II-IV ФК по классификации ВОЗ, с целью предотвращения прогрессирования заболевания. Апбрави эффективен в комбинации с АРЭ и/или иФДЭ-5, или в составе тройной терапии с АРЭ и иФДЭ-5, или в монотерапии. Эффективность Апбрави доказана в отношении идиопатической и наследственной ЛАГ, ЛАГ, ассоциированной с заболеваниями соединительной ткани, ЛАГ, ассоциированной с компенсированным простым врождённым пороком сердца. Противопоказания: повышенная чувствительность к действующему и вспомогательным веществам; тяжёлая ишемическая болезнь сердца или нестабильная стенокардия; инфаркт миокарда, перенесённый в течение предшествующих 6 месяцев; декомпенсированная сердечная недостаточность при отсутствии пристального наблюдения врача; тяжёлые нарушения сердечного ритма; цереброваскулярные заболевания (например, преходящие нарушения мозгового кровообращения, инсульт), перенесённые в течение предшествующих 3 месяцев; врождённые или приобретённые пороки сердца с клинически значимыми нарушениями функции миокарда, не связанными с ЛАГ; совместное применение с мощными ингибиторами СYP2C8 (например, гемфиброзилом); беременность и период грудного вскармливания; детский возраст до 18 лет (эффективность и безопасность не изучены). С осторожностью: у пациентов с артериальной гипотензией, у пациентов с веноокклюзионной болезнью лёгких, при совместном применении с умеренными ингибиторами изофермента СYP2C8 (например, клопидогрелом, деферазироксом, терифлуномидом), у пациентов старше 75 лет (ограниченный опыт применения), у пациентов с нарушением функции печени тяжёлой степени (класс С по классификации Чайлд-Пью), у пациентов с нарушением функции почек тяжёлой степени (рСКФ < 30 мл/мин/1,73 м²), у пациентов с гипертиреозом и у женщин детородного возраста. Способ применения и дозы: Апбрави применяют внутрь два раза в сутки (утром и вечером), запивая необходимым количеством воды. Титрование дозы. Для каждого пациента с помощью титрования дозы должна быть подобрана индивидуальная максимальная переносимая доза, в диапазоне от 200 мг два раза в день до 1600 мг два раза в день (индивидуальная поддерживающая доза). Рекомендуемая начальная доза – 200 мг два раза в день с интервалом примерно 12 ч между приёмами. Дозу увеличивают с шагом 200 мг два раза в день, обычно с периодичностью 1 раз в неделю. В начале терапии и в начале каждого этапа повышения дозы рекомендуется принимать первую дозу вечером. Побочное действие: наиболее часто отмечавшимися нежелательными реакциями являются головная боль, диарея, тошнота, рвота, боль в челюсти, боль в конечностях, артралгия, приливы крови к лицу и верхней половине тела. Данные реакции наиболее часто наблюдаются во время титрования дозы. ПОЖАЛУЙСТА, ОЗНАКОМЬТЕСЬ С ПОЛНОЙ ИНСТРУКЦИЕЙ ПО МЕДИЦИНСКОМУ ПРИМЕНЕНИЮ ПЕРЕД НАЗНАЧЕНИЕМ ПРЕПАРАТА. ПРЕДНАЗНАЧЕНО ДЛЯ СПЕЦИАЛИСТОВ СФЕРЫ ЗДРАВООХРАНЕНИЯ.

1. Noel ZR et al. Selexipag for the treatment of pulmonary arterial hypertension. Am J Health-Syst Pharm. 2017; 74:1135-41. 2. Sitbon O, Channick R, Chin K, et al. Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study. Am J Cardiovasc Drugs. 2018; 18(1):37-47. 4. Инструкция по медицинскому применению лекарственного препарата Апбрави. Регистрационный номер ЛП-005577.



A JOHNSON PHARMACEUTICALS COMPANY
OF Johnson & Johnson

ООО «Актелион Фармасьютикалз РУС», Россия
127055, г. Москва, ул. Новослободская, д. 23
Тел. +7 495 258 3594 Эл. почта: drugsafetyru@actelion.com

CP-103162



ОТДЕЛЕНИЕ



РЕАНИМАЦИЯ



ОПЕРАЦИОННАЯ

НЕОТОН

И операция переносится легче.

- Достоверно уменьшает общую летальность по данным мета-анализа [1]
- Предупреждает кардиальные осложнения в периоперационном периоде [2, 3]



Информация о препарате НЕОТОН®

Регистрационный номер: П N0140030101. **Международное непатентованное название (МНН):** фосфоркреатин. **Лекарственная форма:** порошок для приготовления раствора для инфузий. **Фармакокинетика.** После однократной внутривенной инфузии максимальная концентрация фосфоркреатина в плазме крови определяется на 1-3 мин. Наибольшее количество фосфоркреатина накапливается в скелетных мышцах, миокарде и головном мозге. **Показания к применению.** Неотон применяется в составе комбинированной терапии следующих заболеваний: острого инфаркта миокарда; хронической сердечной недостаточности; интраоперационной ишемии миокарда; интраоперационной ишемии нижних конечностей, а также в спортивной медицине для профилактики развития синдрома острого и хронического физического перенапряжения и улучшения адаптации спортсменов к экстремальным физическим нагрузкам. **Противопоказания:** повышенная чувствительность к препарату; хроническая почечная недостаточность (при применении препарата в дозах 5 – 10 г/день); возраст до 18 лет (эффективность и безопасность не установлены). **Способ применения и дозы. ТОЛЬКО ВНУТРИВЕННО (капельно или в виде быстрой инфузии).** **Побочное действие.** Повышенная чувствительность к препарату, снижение артериального давления (при быстром внутривенном введении). **Передозировка.** В настоящее время о случаях передозировки препарата Неотон не сообщалось. **Условия хранения.** Хранить при температуре не выше 30°С. Хранить в недоступном для детей месте. **Срок годности.** 3 года. Не использовать после истечения срока годности, указанного на упаковке. **Условия отпуска из аптек.** По рецепту. **Производитель.** Альфасигма С.П.А., Виа Э. Ферми 1, 65020 Аланьо (Пескара), Италия Alfasigma S.p.A., Via E. Fermi 1, 65020 Alano (Pescara), Italy. *Более подробную информацию смотрите в инструкции по медицинскому применению или обращайтесь в ООО Альфасигма Рус, Россия, 125009, г. Москва, Тверская улица, 22/2, корпус 1, 4 этаж, пом. VII, комн. 1. Тел.: +7 (495) 225-3626, эл. адрес: info.rus@alfasigma.com

1. Landoni Giovanni, Zangillo Alberto, Lomivorotov Vladimir V., Likhvantsev Valery, Ma Jun, De Simone Francesco and Fominskiy Evgeny. Cardiac protection with phosphocreatine: a meta-analysis. *Interactive CardioVascular and Thoracic Surgery*. 2016; 1:10. Advance Access published June 17, 2016.
 2. Barasz O. B. и др. Результаты применения экзогенного фосфоркреатина при операциях аортокоронарного шунтирования у пациентов со сниженными резервами миокарда. Вестник НМХЦ им. Н. И. Пирогова, 2012; т. 7, № 4.
 3. Mingozzi F. et al (2018). Phosphocreatine in cardiac surgery patients: a meta-analysis of randomized controlled trials. <http://dx.doi.org/10.1053/j.vca.2017.07.024>

Take the next step



Become an ESC Professional Member for:

- Great savings on ESC Congress registration
- ESC 365 – access congress slides, abstracts, videos – all year long
- Three online ESC journals
- ESC CardioMed – ESC online encyclopaedia
- Networking & grants opportunities
- Webinars & online courses

Meet us on the ESC Stand

www.escardio.org/Membership

 **ESC**
European Society
of Cardiology



RUSSIAN
SOCIETY
OF CARDIOLOGY

www.scardio.ru • facebook.com/scardio.ru

VIII GLOBAL EDUCATIONAL FORUM «RUSSIAN CARDIOVASCULAR DAYS»

APRIL 23–25, 2020 | SAINT-PETERSBURG, RUSSIA

- European Speakers present the latest ESC Clinical Guidelines
- Forum will be accredited in UEMS-EACCME®
- Russian-English translation will be provided
- Early-Bird Registration Fee: 75€ (before March 1, 2020)
- Special offer for group registration

Contact rsc@scardio.ru to learn more!



**RUSSIAN
SOCIETY
OF CARDIOLOGY**

RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY 2020

WWW.SCARDIO.RU



SEPTEMBER 29 — OCTOBER 1, 2020 | KAZAN